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A B S T R A C T
Background
Uptake of human papillomavirus (HPV) vaccine remains low in many countries, although the bivalent and quadrivalent HPV vaccines given
as a three-dose schedule are effective in the prevention of precancerous lesions of the cervix in women. Simpler immunisation schedules,
such as those with fewer doses, might reduce barriers to vaccination, as may programmes that include males.
Objectives
To evaluate the efficacy, immunogenicity, and harms of different dose schedules and different types of HPV vaccines in females and males.
Search methods
We conducted electronic searches on 27 September 2018 in Ovid MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL) (in
the Cochrane Library), and Ovid Embase. We also searched the WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov
(both 27 September 2018), vaccine manufacturer websites, and checked reference lists from an index of HPV studies and other relevant
systematic reviews.
Selection criteria
We included randomised controlled trials (RCTs) with no language restriction. We considered studies if they enrolled HIV-negative males
or females aged 9 to 26 years, or HIV-positive males or females of any age.
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Data collection and analysis
We used methods recommended by Cochrane. We use the term 'control' to refer to comparator products containing an adjuvant or active
vaccine and 'placebo' to refer to products that contain no adjuvant or active vaccine. Most primary outcomes in this review were clinical
outcomes. However, for comparisons comparing dose schedules, the included RCTs were designed to measure antibody responses (i.e.
immunogenicity) as the primary outcome, rather than clinical outcomes, since it is unethical to collect cervical samples from girls under
16 years of age. We analysed immunogenicity outcomes (i.e. geometric mean titres) with ratios of means, clinical outcomes (e.g. cancer
and intraepithelial neoplasia) with risk ratios or rate ratios and, for serious adverse events and deaths, we calculated odds ratios. We rated
the certainty of evidence with GRADE.
Main results
We included 20 RCTs with 31,940 participants. The length of follow-up in the included studies ranged from seven months to five years.
Two doses versus three doses of HPV vaccine in 9- to 15-year-old females
Antibody responses after two-dose and three-dose HPV vaccine schedules were similar after up to five years of follow-up (4 RCTs, moder-
ate- to high-certainty evidence). No RCTs collected clinical outcome data. Evidence about serious adverse events in studies comparing
dose schedules was of very low-certainty owing to imprecision and indirectness (three doses 35/1159; two doses 36/1158; 4 RCTs). One
death was reported in the three-dose group (1/898) and none in the two-dose group (0/899) (low-certainty evidence).
Interval between doses of HPV vaccine in 9- to 14-year-old females and males
Antibody responses were stronger with a longer interval (6 or 12 months) between the first two doses of HPV vaccine than a shorter interval
(2 or 6 months) at up to three years of follow-up (4 RCTs, moderate- to high-certainty evidence). No RCTs collected data about clinical
outcomes. Evidence about serious adverse events in studies comparing intervals was of very low-certainty, owing to imprecision and
indirectness. No deaths were reported in any of the studies (0/1898, 3 RCTs, low-certainty evidence).
HPV vaccination of 10- to 26-year-old males
In one RCT there was moderate-certainty evidence that quadrivalent HPV vaccine, compared with control, reduced the incidence of ex-
ternal genital lesions (control 36 per 3081 person-years; quadrivalent 6 per 3173 person-years; rate ratio 0.16, 95% CI 0.07 to 0.38; 6254
person-years) and anogenital warts (control 28 per 2814 person-years; quadrivalent 3 per 2831 person-years; rate ratio 0.11, 95% CI 0.03
to 0.38; 5645 person-years). The quadrivalent vaccine resulted in more injection-site adverse events, such as pain or redness, than control
(537 versus 601 per 1000; risk ratio (RR) 1.12, 95% CI 1.06 to 1.18, 3895 participants, high-certainty evidence). There was very low-certainty
evidence from two RCTs about serious adverse events with quadrivalent vaccine (control 12/2588; quadrivalent 8/2574), and about deaths
(control 11/2591; quadrivalent 3/2582), owing to imprecision and indirectness.
Nonavalent versus quadrivalent vaccine in 9- to 26-year-old females and males
Three RCTs were included; one in females aged 9- to 15-years (n = 600), one in females aged 16- to 26-years (n = 14,215), and one in males
aged 16- to 26-years (n = 500). The RCT in 16- to 26-year-old females reported clinical outcomes. There was little to no difference in the
incidence of the combined outcome of high-grade cervical epithelial neoplasia, adenocarcinoma in situ, or cervical cancer between the
HPV vaccines (quadrivalent 325/6882, nonavalent 326/6871; OR 1.00, 95% CI 0.85 to 1.16; 13,753 participants; high-certainty evidence). The
other two RCTs did not collect data about clinical outcomes. There were slightly more local adverse events with the nonavalent vaccine (905
per 1000) than the quadrivalent vaccine (846 per 1000) (RR 1.07, 95% CI 1.05 to 1.08; 3 RCTs, 15,863 participants; high-certainty evidence).
Comparative evidence about serious adverse events in the three RCTs (nonavalent 243/8234, quadrivalent 192/7629; OR 0.60, 95% CI 0.14
to 2.61) was of low certainty, owing to imprecision and indirectness.
HPV vaccination for people living with HIV
Seven RCTs reported on HPV vaccines in people with HIV, with two small trials that collected data about clinical outcomes. Antibody
responses were higher following vaccination with either bivalent or quadrivalent HPV vaccine than with control, and these responses
could be demonstrated to have been maintained for up to 24 months in children living with HIV (low-certainty evidence). The evidence
about clinical outcomes and harms for HPV vaccines in people with HIV is very uncertain (low- to very low-certainty evidence), owing to
imprecision and indirectness.
Authors' conclusions
The immunogenicity of two-dose and three-dose HPV vaccine schedules, measured using antibody responses in young females, is compa-
rable. The quadrivalent vaccine probably reduces external genital lesions and anogenital warts in males compared with control. The non-
avalent and quadrivalent vaccines offer similar protection against a combined outcome of cervical, vaginal, and vulval precancer lesions
or cancer. In people living with HIV, both the bivalent and quadrivalent HPV vaccines result in high antibody responses. For all comparisons
of alternative HPV vaccine schedules, the certainty of the body of evidence about serious adverse events reported during the study periods
was low or very low, either because the number of events was low, or the evidence was indirect, or both. Post-marketing surveillance is
needed to continue monitoring harms that might be associated with HPV vaccines in the population, and this evidence will be incorporat-
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ed in future updates of this review. Long-term observational studies are needed to determine the effectiveness of reduced-dose schedules
against HPV-related cancer endpoints, and whether adopting these schedules improves vaccine coverage rates.
P L A I N   L A N G U A G E   S U M M A R Y
Comparison of different human papillomavirus (HPV) vaccines and the number of doses administered to prevent HPV-related dis-
ease in females and males
Human papillomaviruses (HPV) are a group of viruses that infect the skin and mucous membranes. Some types of HPV are sexually trans-
mitted and are common in young people. Most infections will be cleared by the immune system, but some people will experience persis-
tent infection with certain HPV types that go on to cause abnormalities in infected cells. These changes are called 'precancerous' because
they can develop into cancers of the cervix, vagina, vulva, anal canal, penis, and head and neck. Infection with other HPV types causes
warts in the genital area or around the anus.
Vaccination aims to prevent future HPV infections. Three HPV vaccines are in use – a bivalent one (protects against two HPV types), a
quadrivalent one (protects against four HPV types), and a nonavalent one (protects against nine HPV types). In women, three doses of
the bivalent or the quadrivalent HPV vaccines protect against precancer of the cervix caused by the HPV types contained in the vaccine.
Evidence about the nonavalent vaccine, about the effects of the quadrivalent vaccine in males, and about the effects of HPV vaccines in
people with HIV infection, has not yet been reviewed thoroughly. Uptake of HPV vaccines remains low in many countries. Simpler vaccine
schedules, or giving the vaccine to both girls and boys, could increase the number of people being vaccinated.
Trials of HPV vaccines are not always designed to collect data about precancer and cancer, for several reasons. Firstly, HPV vaccine is
routinely given before girls become sexually active, and it is not ethical to take specimens from the cervix of girls who have not had sex.
Secondly, HPV-related precancer and cancer are rare and do not develop until years after HPV infection has occurred. Thirdly, participants
in a trial will be offered treatment if precancer develops, so progression to cervical cancer would be even rarer, even without vaccination.
An international committee of experts states that, in some circumstances, antibody levels (i.e. showing a strong immune system response),
can be used to demonstrate protection against cervical and anal cancer. The antibody levels following vaccination in a trial should not
be lower than those found in other studies on adults in whom the vaccine has been shown to protect against severe HPV-related cervical
or anal disease.
Review question(s)
How effective or harmful are different HPV vaccine schedules (i.e. number and timing of doses) and different HPV vaccines in females and
males?
Main results
These results are based on research evidence to 27 September 2018. We analysed 20 studies involving 31,940 people.
Studies comparing two doses of HPV vaccine to three doses, or comparing the time interval between doses, focus on immune system
responses rather than infection or disease outcomes. Two doses of HPV vaccine result in similar immune system responses to three doses,
and a longer interval (up to 12 months) between doses gives a stronger immune system response than a shorter interval. There is insuffi-
cient evidence to determine whether there was a difference between the vaccine schedules for serious adverse events and death.
In 16- to 26-year-old men, one study showed evidence of moderate certainty that a quadrivalent HPV vaccine provides better protection
against external genital lesions and genital warts than a dummy treatment (control). In 16- to 26-year-old women, one study showed that
the nonavalent and quadrivalent vaccines provide the same levels of protection against cervical, vaginal, and vulval precancer lesions and
cancer (high-certainty evidence).
There was evidence that the quadrivalent vaccine resulted in more local adverse events (such as pain, swelling, and redness at the injection
site) than a control treatment in males, and that the nonavalent vaccine resulted in more local adverse events than the quadrivalent
vaccine in males and females. Evidence about serious adverse events and deaths from studies comparing different HPV vaccine types or
dose schedules was of low or very low-certainty.
In people living with HIV, HPV vaccines result in reasonable levels of immune system response, but evidence about their effects on persis-
tent HPV infection or HPV-related disease outcomes and harms is limited.
Certainty of the evidence
No major issues were identified with the methodological quality of the studies for the measurements of infection and disease outcomes, or
for immune system responses. Our certainty in the evidence about serious harms and deaths across all the studies comparing different HPV
vaccines and vaccine schedules is low, either because of their low frequency, or because the evidence is indirect, or both. Evidence graded
as high certainty means that we were confident that further research is unlikely to change our findings. Moderate-certainty evidence means
that there is a possibility that further research may have an important effect on our findings, whilst low-certainty evidence means that our
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confidence was limited and further research may have an important impact on our findings. Very low-certainty evidence means that we
were uncertain about the result.
Conclusion
A two-dose schedule of HPV vaccines in young females results in immune system responses that are comparable with a three-dose sched-
ule. In males, the quadrivalent HPV vaccine appears to be effective in the prevention of external genital lesions and genital warts. Quadri-
valent and nonavalent HPV vaccines in young women result in similar levels of protection against cervical, vaginal, and vulval precancer
lesions and cancer. Evidence about the efficacy and harms in people living with HIV is limited. Further long-term population-level stud-
ies are needed to continue monitoring safety of these vaccines, to determine for how long two doses of vaccine can provide protection
against HPV-related disease, the effect against HPV-related cancer, and whether a two-dose immunisation schedule will increase vaccine
coverage.
Comparison of dierent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females
and males (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
4
Com
parison of dierent hum
an papillom
avirus (H
PV) vaccine types and dose schedules for prevention of H
PV-related disease in fem
ales
and m
ales (Review
)
Copyright ©
 2019 The Authors. Cochrane Database of System
atic Review
s published by John W
iley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
5
S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Two doses of HPV vaccine compared with three doses of HPV vaccine in 9- to 15-year-old females
Two doses of HPV vaccine compared with three doses of HPV vaccine in 9- to 15-year-old females
Patient or population: 9- to 15-year-old females
Setting: community health centres in Africa, Asia Pacific, Europe, Latin America, North America
Intervention: two doses of HPV vaccine (bivalent, quadrivalent, or nonavalent) administered in months 0 and 2, 0 and 6, or 0 and 12
Comparison: three doses of HPV vaccine (bivalent, quadrivalent, or nonavalent) administered in months 0, 2, and 6, or 0, 1, and 6
Anticipated absolute effects** (95% CI)Clinical and harms out-
comes*
Risk with three doses of
HPV vaccine
Risk with two dos-
es of HPV vaccine
Relative effect
(95% CI)
№ of participants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Two doses were non-inferior to, or had higher GMTs than, three doses for all HPV vaccine genotypes (biva-
lent, quadrivalent, and nonavalent vaccines), except HPV 45 (where non-inferiority was inconclusive), at
short-term follow-up (4 studies, number of participants ranged from 132 to 1833 depending on HPV type
and vaccine; see Appendix 5).
MODERATE/
HIGH*
Short-term re-
sults (follow-up 1
month after final
dose)
Two doses of bivalent vaccine had inconclusive non-inferiority for GMTs of HPV 16 and HPV 18 compared
with three doses at 60-month follow-up (1 study, 93 participants; see Appendix 5).
LOW*
Two doses of quadrivalent vaccine resulted in non-inferior GMTs for HPV 6, HPV 11 and HPV 16 compared
with three doses, while results were inconclusive for HPV 18 at 60-month follow-up (1 study, 101 partici-
pants; see Appendix 5).
LOW*
Antibody response (im-
munogenicity)
Two doses of nonavalent vaccine resulted in non-inferior GMTs for all HPV genotypes measured except
HPV 45 and HPV 52 where non-inferiority was inconclusive, compared with three doses, at 36-month fol-
low-up (1 study, 476 to 511 participants depending on HPV type; see Appendix 5).
HIGH*
Long-term results
(follow-up 36 to
60 months)
High-grade cervical in-
traepithelial neoplasia,
adenocarcinoma in situ,
and cervical cancer
No studies were identified that reported on this outcome.
High-grade cervical, vul-
val, and vaginal disease
No studies were identified that reported on this outcome.
Overall local/injection
site adverse events
No studies were identified that reported on this outcome. Data for specific local adverse events (pain/swelling/redness at injection site) are pre-
sented in the analysis section.
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Overall systemic events
and general symptoms
No studies were identified that reported on this outcome.
Serious adverse events
at up to 5-year follow-up
30 per 1000 31 per 1000
(20 to 49)
OR 1.03
(0.64 to 1.66)
2317
(4 RCTs)
⊕⊝⊝⊝
VERY LOW 1,2
Please see Ta-
ble 2 for a list of
events in each
RCT.
Mortality
at up to 5-year follow-up
1 per 1000 0 per 1000 (0 to 9) OR 0.33 (0.01 to 8.19) 1797
(3 RCTs)
⊕⊕⊝⊝
LOW 1
One death was
reported in the
three-dose group
(nonavalent vac-
cine).
*Certainty of the evidence (GRADE) for immunogenicity outcomes are presented in detail in Appendix 5.
**The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention
(and its 95% CI).
CI: confidence interval; GMT: geometric mean titre; HPV: human papillomavirus; OR: odds ratio; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
1Downgraded two levels for serious imprecision: few events and a wide 95% confidence interval that incorporated a potential large beneficial effect and a potential large harmful
effect.
2Downgraded one level for indirectness: this outcome is a composite measure of events which may or may not be clinically relevant, may or may not be related to the vaccine
and may occur outside a biologically plausible time frame relative to vaccine exposure. This outcome is considered to provide indirect evidence about vaccine safety.
 
 
Summary of findings 2.   Two doses of HPV vaccine with longer interval compared with two doses of HPV vaccine with shorter interval in 9- to 14-year-
old females and males
Two doses of HPV vaccine with longer interval compared with two doses of HPV vaccine with shorter interval in 9- to 14-year-old females and males
Patient or population: 9- to 14-year-old females and males
Setting: community health centres in Africa, Asia Pacific, Europe, Latin America, North America
Intervention: two doses of bivalent or nonavalent HPV vaccine with longer interval (months 0 and 6 or 12)
Comparison: two doses of bivalent or nonavalent HPV vaccine with shorter interval (months 0 and 2 or 6)
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Anticipated absolute effects** (95% CI)Clinical and
harms out-
comes* Risk with two doses of HPV vac-
cine with shorter interval
Risk with two doses of
HPV vaccine with longer
interval
Relative effect
(95% CI)
№ of participants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Longer intervals between the first two doses of bivalent vaccine resulted in higher and non-inferior GMTs for HPV
16 (n = 971) and HPV 18 (n = 986) compared with shorter intervals in 9- to 14-year-old females at short-term fol-
low-up (2 studies; moderate- to high-certainty evidence, see Appendix 6).
MODERATE/
HIGH*
A longer interval between the first two doses of nonavalent vaccine resulted in higher and non-inferior GMTs than
a shorter interval for all HPV vaccine genotypes in girls and boys at short-term follow-up (1 study, number of par-
ticipants ranged from 778 to 815 depending on HPV type; high-certainty evidence, see Appendix 6).
HIGH*
Short-term re-
sults (follow-up
one month after
final dose)
Longer intervals between the first two doses of bivalent vaccine resulted in higher and non-inferior GMTs for HPV
16 (n=817) and HPV 18 (n=794) compared with shorter intervals in 9- to 14-year-old females at 36 months fol-
low-up (1 study; high-certainty evidence, see Appendix 6).
HIGH*
Antibody re-
sponse (geo-
metric mean
titre)
A longer interval between the first two doses of nonavalent vaccine resulted in higher and non-inferior GMTs than
a shorter interval for all HPV vaccine genotypes in girls and boys at seven and 36 months follow-up (1 study, num-
ber of participants ranged from 236 to 263 depending on HPV type; high-certainty evidence, see Appendix 6).
HIGH*
Long-term re-
sults (follow-up
36 months)
Invasive cervi-
cal, vaginal, vul-
val, anal, or pe-
nile cancer
No studies were identified that reported on this outcome.
High-grade cer-
vical, vulval,
vaginal, penile,
or anal intraep-
ithelial neopla-
sia
No studies were identified that reported on this outcome.
Overall local/in-
jection site ad-
verse events
No studies were identified that reported on this outcome. Data for specific local adverse events (pain/swelling/redness at injection site) are presented in
the analysis section.
Overall sys-
temic events
and general
symptoms
No studies were identified that reported on this outcome.
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Bivalent vaccine (0 and 2
months)
58 per 1000
Bivalent vaccine (0 and 6
months)
67 per 1000
(33 to 130)
OR 1.15
(0.55 to 2.41)
481
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1,2
Bivalent vaccine (0 and 6
months)
36 per 1000
Bivalent vaccine (0 and 12
months)
58 per 1000
(32 to 101)
OR 1.63 (0.89 to 2.99) 965
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1,2
Serious adverse
events
at up to 5-year
follow-up
Nonavalent vaccine (0 and 6
months)
25 per 1000
Nonavalent vaccine (0 and
12 months)
20 per 1000
(8 to 52)
OR 0.80
(0.31 to 2.07)
903
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1,2
Please see Table
2 for list of events
in each RCT.
Data for nonava-
lent vaccine in-
clude males and
females; fully dis-
aggregated da-
ta were not avail-
able.
Bivalent vaccine (0 and 2
months)
0 per 1000
Bivalent vaccine (0 and 6
months)
0 per 1000
(0 to 0)
Not estimable 481
(1 RCT)
⊕⊕⊝⊝
LOW 3
No deaths were
reported in the
trial.
Bivalent vaccine (0 and 6
months)
0 per 1000
Bivalent vaccine (0 and 12
months)
0 per 1000
(0 to 0)
Not estimable 965
(1 RCT)
⊕⊕⊝⊝
LOW 3
No deaths were
reported in the
trial.
Mortality
at up to 5-year
follow-up
Nonavalent vaccine (0 and 6
months)
0 per 1000
Nonavalent vaccine (0 and
12 months)
0 per 1000
(0 to 0)
Not estimable 452
(1 RCT)
⊕⊕⊝⊝
LOW 3
No deaths were
reported in the
trial.
*Certainty of the evidence (GRADE) for immunogenicity outcomes are presented in detail in Appendix 6.
**The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention
(and its 95% CI).
CI: confidence interval; GMT: geometric mean titre; HPV: human papillomavirus; OR: odds ratio; RCT: randomised controlled trial
GRADE Working Group grades of evidence
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High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
1Downgraded two levels for serious imprecision: few events and a wide 95% confidence interval that incorporates a potential large beneficial effect and a potential small harmful
effect.
2Downgraded one level for indirectness: this outcome is a composite measure of events which may or may not be clinically relevant, may or may not be related to the vaccine
and may occur outside a biologically plausible time frame relative to vaccine exposure. This outcome is considered to provide indirect evidence about vaccine safety.
3Downgraded two levels for serious imprecision: no events reported, the studies were not powered to detect a difference in mortality.
 
 
Summary of findings 3.   Three doses HPV vaccine compared with control in 10- to 26-year-old males
Three doses HPV vaccine compared with control in 10- to 26-year-old males
Patient or population: 10- to 26-year-old males
Setting: 18 countries in five regions (Africa, Asia-Pacific, Europe, Latin America, North America)
Intervention: quadrivalent HPV vaccine, 3 doses at months 0, 2, and 6; or bivalent HPV vaccine, 3 doses at months 0, 1, and 6
Comparison: control (vaccine adjuvant-containing placebo), 3 doses at months 0, 2, and 6 or hepatitis B vaccine, 3 doses at months 0, 1, and 6
Anticipated absolute effects* (95% CI)Outcomes
Risk/rate
with control
Risk/rate with HPV
vaccine
Relative effect
(95% CI)
№ of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Invasive anal or penile cancer No studies were identified that reported on this outcome
Penile or anal intraepithelial
neoplasia
at up to 3-year follow-up
3/2824 per-
son-years
0/2833 person-years Rate ratio 0.17
(0.01 to 3.27)
2805 partici-
pants (5657 per-
son-years)
(1 RCT)
⊕⊕⊝⊝
LOW 2
 
External genital lesions (any
genotype)
at up to 3-year follow-up
36/3081 per-
son-years
6/3173 person-years Rate ratio 0.16
(0.07 to 0.38)
2545 partici-
pants (6254 per-
son-years)
(1 RCT)
⊕⊕⊕⊝
MODERATE 1
 
Anogenital warts
at up to 3-year follow-up
28/2814 per-
son-years
3/2831 person-years Rate ratio 0.11
(0.03 to 0.38)
2805 partici-
pants (5645 per-
son-years)
⊕⊕⊕⊝
MODERATE 1
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(1 RCT)
Overall local/injection site ad-
verse events
at 15-day follow-up
537 per 1000 601 per 1000
(569 to 634)
RR 1.12
(1.06 to 1.18)
3895
(1 RCT)
⊕⊕⊕⊕
HIGH3
Data for specific local adverse
events (pain, swelling, redness
at injection site) are presented
in the analysis section.
Overall systemic events and
general symptoms
at 15-day follow-up
248 per 1000 245 per 1000
(223 to 268)
RR 0.99
(0.90 to 1.08)
5008
(2 RCTs)
⊕⊕⊕⊝
MODERATE4
 
Control:
11 per 1000
Bivalent vaccine: 17
per 1000 (2 to 141)
OR 1.48 (0.15 to
14.46)
270
(1 RCT)
⊕⊝⊝⊝
VERY LOW 2,4
In a subgroup from Lehtinen
2018, a cluster-RCT, 58/2436
HPV vaccine recipients (2.4%)
and 25/1267 control HBV vac-
cine recipients (2.0%) experi-
enced serious adverse events.
This was also considered very
low-certainty evidence2,4
Please see Table 2 for list of
events in each RCT.
Serious adverse events
at up to 3-year follow-up
Control:
4 per 1000
Quadrivalent vaccine:
3 per 1000
(1 to 7)
OR 0.69
(0.29 to 1.66)
5162
(2 RCTs)
⊕⊝⊝⊝
VERY LOW 2,4
Please see Table 2 for list of
events in each RCT.
Control:
see comment
Bivalent vaccine:
see comment
OR not estimable:
see comment
270
(1 RCT)
⊕⊕⊝⊝
LOW 5
No events were reportedMortality
at up to 3-year follow-up
Control:
4 per 1000
Quadrivalent vaccine:
1 per 1000
(0 to 4)
OR 0.30
(0.09 to 1.01)
5173
(2 RCTs)
⊕⊕⊝⊝
LOW 2
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; HPV: human papillomavirus; OR: odds ratio; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
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Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
1Downgraded one level for imprecision: few events.
2Downgraded two levels for serious imprecision: few events and a wide 95% confidence interval that incorporates a potential large beneficial effect as well as a potential large
harmful effect.
3Evidence for this outcome was not downgraded: the trial was a large multi-national trial with low risk of bias and precise estimates.
4Downgraded one level for indirectness: this outcome is a composite measure of events which may or may not be clinically relevant, may or may not be related to the vaccine
and may occur outside a biologically plausible time frame relative to vaccine exposure. This outcome is considered to provide indirect evidence about vaccine safety.
5Downgraded two levels for serious imprecision: no events reported.
 
 
Summary of findings 4.   Nonavalent HPV vaccine compared with quadrivalent HPV vaccine in 9- to 26-year-old females and males
Nonavalent HPV vaccine compared with quadrivalent HPV vaccine in 9- to 26-year-old females and males
Patient or population: 9- to 26-year-old females and males
Setting: community health centres in Asia-Pacific, Europe, Latin America, North America
Intervention: nonavalent HPV vaccine, 3 doses administered at months 0, 2, and 6
Comparison: quadrivalent HPV vaccine, 3 doses administered at months 0, 2, and 6
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
quadrivalent
HPV vaccine
Risk with
nonavalent
HPV vaccine
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Comments
High-grade cervical intraepithelial
neoplasia, adenocarcinoma in situ,
and cervical cancer
at up to 4.5-year follow-up
47 per 1000 47 per 1000
(41 to 55)
OR 1.00
(0.85 to 1.16)
13,753
(1 RCT)
⊕⊕⊕⊕
HIGH1
No studies were identified which reported on
invasive anal or penile cancer in males
High-grade cervical, vulval, and
vaginal disease
at up to 4.5-year follow-up
49 per 1000 48 per 1000
(42 to 56)
OR 0.99
(0.85 to 1.15)
14,054
(1 RCT)
⊕⊕⊕⊕
HIGH1
No studies were identified which reported
on penile or anal intraepithelial neoplasia in
males
Overall local/injection site adverse
events
at 15-day follow-up
846 per 1000 905 per 1000
(888 to 914)
RR 1.07
(1.05 to 1.08)
15,863
(3 RCTs)
⊕⊕⊕⊕
HIGH
Data for specific local adverse events (pain,
swelling, redness at injection site) are pre-
sented in the analysis section.
Overall systemic events and gener-
al symptoms
543 per 1000 548 per 1000
(532 to 565)
RR 1.01
(0.98 to 1.04)
15,863
(3 RCTs)
⊕⊕⊕⊝
MODERATE3
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at 15-day follow-up
Serious adverse events
at up to 4.5-year follow-up
25 per 1000 15 per 1000
(4 to 63)
OR 0.60
(0.14 to 2.61)
15,863
(3 RCTs)
⊕⊕⊝⊝
LOW 2,3
Please see Table 2 for list of events in each
RCT. Numbers of events/number of partic-
ipants (%) were: in 16- to 26-year-old fe-
males receiving nonavalent vaccine, 242/7686
(3.1%) vs quadrivalent vaccine, 184/7078
(2.6%) over a period of 4.5 years follow-up; in
16- to 26-year-old males receiving nonavalent
vaccine, 0/249 (0%) vs quadrivalent vaccine,
6/251 (2.4%) over 7 months follow-up; in 9-
to 15-year-old females receiving nonavalent
vaccine, 1/299 (0.3%) vs quadrivalent vaccine,
2/300 (0.7%) over 7 months follow-up.
Mortality
at up to 4.5-year follow-up
1 per 1000 1 per 1000
(0 to 3)
OR 1.20
(0.37 to 3.94)
15,248
(3 RCTs)
⊕⊕⊝⊝
LOW 4
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; HPV: human papillomavirus; OR: odds ratio; RCT: randomised controlled trial; RR: risk ratio; SAE: serious adverse event
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
1Evidence from this outcome was not downgraded: the included trial was a large multi-national trial with low risk of bias and precise estimates.
2Downgraded one level for imprecision: pooled estimate has a wide 95% confidence interval that incorporates a potential large beneficial effect and a potential large harmful
effect.
3Downgraded one level for indirectness: this outcome is a composite measure of events which may or may not be clinically relevant, may or may not be related to the vaccine
and may occur outside a biologically plausible time frame relative to vaccine exposure. This outcome is considered to provide indirect evidence about vaccine safety.
4Downgraded two levels for serious imprecision: few events and a wide 95% confidence interval that incorporates a potential large beneficial effect and a potential large harmful
effect.
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B A C K G R O U N D
Description of the condition
Human papillomavirus (HPV) is the most common viral infection of
the reproductive tract in women and men (WHO 2017). Although
most HPV infections resolve spontaneously, persistent infections
can lead to precancerous lesions and cancer of the cervix, vagi-
na, vulva, anus, penis, and head and neck. HPV-related cancers ac-
counted for an estimated 4.5% of all cancers worldwide in 2012 (de
Martel 2017). When stratified by sex, these represent 8.6% of can-
cers in women and 0.8% of cancers in men, and by development
status, 6.7% of all cancers in low- and middle-income countries and
2.8% in high-income countries (de Martel 2017). In 2012, of an esti-
mated 636,000 HPV-related cancers worldwide, 530,000 were cer-
vical cancer, 35,000 anal cancer, 8500 vulval cancer, 13,000 penile
cancer, and 37,000 head and neck cancers (de Martel 2017).
Amongst women with normal cytological findings, the worldwide
prevalence of infection with any HPV genotype has been estimated
in a meta-analysis to be 11.7%, with higher prevalence in sub-Saha-
ran Africa, Latin America, the Caribbean, south-east Asia and east-
ern Europe (Bruni 2010). Amongst heterosexual men assessed at
baseline in a multicentre trial in 18 countries in Africa, Asia-Pacific,
Europe, Latin America and North America, penile infection with any
HPV genotype was found in 18.7%, scrotal infection in 13.1%, peri-
anal infection in 7.9% and infection at any site in 21.0%. Prevalence
was highest in Africa and lowest in the Asia-Pacific region (Vardas
2011). Prevalence of HPV infections in general is higher in men with
HIV infection, men who have sex with men (MSM), and highest in
MSM with HIV infection (Schim van der Loeff 2014; Smith 2011).
The main types of lesions associated with anogenital HPV infec-
tion are anogenital warts (condylomata acuminata) and intraep-
ithelial neoplasia of the cervix (cervical intraepithelial neoplasia,
CIN), vulva, vagina, anal canal/perianal area, and penis. Intraep-
ithelial neoplasia is a precursor of some of these cancers, although
it can regress at earlier stages and does not progress to invasive
cancer in most affected people. A study that followed up women
with inadequately treated CIN3 found that 31.3% (95% CI 22.7 to
42.3) developed invasive cancer after 30 years (McCredie 2008). HPV
is also associated with squamous cell cancer of the head and neck
(HNSCC). Of all head and neck cancers globally in 2012 (534,000),
about 7% (37,000) were attributable to HPV, including 29,000 of
96,000 (31%) cases of oropharyngeal cancer (de Martel 2017). The
incidence of cancers of the oropharynx has increased over time,
more amongst men than women (Gillison 2015). It is likely that HPV
is a main contributor to the increase in men, whilst smoking domi-
nates the rise in women (Gillison 2015).
The International Agency for Research on Cancer classifies HPV
genotypes according to oncogenic potential, with HPV genotypes
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 considered as high-
risk genotypes (Bouvard 2009). HPV 16 and 18 are the most com-
mon genotypes in women worldwide and are associated with most
cases of invasive cervical cancer; combined, HPV 16, 18, 31, 33, 45,
52 and 58 cause approximately 90% of all HPV-positive squamous
cell carcinomas of the cervix (Alemany 2014; Bruni 2010; de San-
jose 2010). HPV 16 and 18 are also the cause of 90% of all anal can-
cers (Bosch 2002). HPV 16 is found in around 80% of HPV-related
anal squamous cell cancers, in 52% of invasive penile squamous
cell carcinoma, and in 90% of penile intraepithelial neoplasia (Krus-
trup 2009; Schim van der Loeff 2014). In a meta-analysis, HPV was
detected in 22% of HNSCC, with 86.7% of those being attributed
to HPV 16, although HPV 6 and 11 were also detected in a minori-
ty of cases (Syrjänen 2010). HPV 6 and 11 account for up to 90% of
anogenital warts (Greer 1995; Sturegard 2013).
Description of the intervention
Three prophylactic HPV vaccines, given by intramuscular injection,
are available. All three vaccines are made by genetic technologies
and are non-infectious because they do not contain viral DNA. They
are made from purified L1 capsid proteins, which form virus-like
particles that resemble the structure of specific genotypes of HPV.
Each vaccine is directed against two or more high-risk HPV geno-
types. All three vaccines contain L1 proteins of HPV genotypes 16
and 18 (WHO 2017), because these cause about 70% of cervical can-
cer globally. The vaccines are commonly known by the number of
different genotypes that they contain (i.e. the valency, Table 1). The
bivalent vaccine contains L1 proteins of two HPV genotypes; 16 and
18. The quadrivalent vaccine contains L1 proteins of four HPV geno-
types; 16 and 18, plus HPV 6 and 11, which cause genital warts. The
nonavalent vaccine is the most recent vaccine and contains L1 pro-
teins of nine HPV genotypes; 16, 18, 31, 33, 45, 52 and 58, plus HPV
6 and 11. All three vaccines contain adjuvants (Table 1). In addition
to the licensed vaccines, as of September 2018, there are three vac-
cines in stage 2 to 3 development, two bivalent vaccines manufac-
tured by Innovax and Walvax in China, and a quadrivalent vaccine
manufactured by the Serum Institute of India (LaMontagne 2017).
To prevent HPV infection, all HPV vaccines are intended to be ad-
ministered, where possible, before the first exposure to HPV, that
is, before onset of sexual activity. All national HPV vaccination pro-
grammes involve girls, and some countries have extended their
programme to boys. According to most modelling studies, HPV
vaccination programmes for preadolescent girls will be cost-ef-
fective for the prevention of cervical cancer, particularly in set-
tings in which infrastructure for cervical cancer screening is poor
(WHO 2017). HPV vaccination of females gives indirect protection
to males. These so-called herd effects mean that, at the population
level, female-only vaccination programmes have resulted in reduc-
tions in HPV infections in both men and women (Drolet 2019). How-
ever, herd effects from female-only vaccination do not affect MSM,
who experience a high burden of anal cancer and anogenital warts.
Modelling studies also indicate that female-only HPV vaccination,
even at high levels of coverage, will not prevent all HPV-related can-
cers in heterosexual men (Bogaards 2015). The cost-effectiveness
of vaccinating boys depends on vaccination coverage in girls, the
epidemiology of HPV-related disease, and the costs of the vaccine
and the programme (WHO 2017).
The uptake of HPV vaccination varies widely between countries
that have introduced it as part of their national immunisation pro-
grammes. In 2017, across 82 countries coverage rates ranged from
8% to 98% (Brotherton 2018). To date, few countries in Africa and
Asia have introduced HPV vaccine. Whilst there is evidence from
some low- and middle-income countries (LMICs) that HPV vaccine
can be effectively introduced, countries with challenges have also
been reported. For example, Uganda reported coverage of more
than 80% for the first dose of a two-dose vaccine schedule, but
this was not sustained for the second dose (Brotherton 2018). In
high-income countries, such as England, Scotland, and Australia,
school-based programmes have reached 70% to 80% of girls for all
doses. In other high-income countries, such as France, USA, Japan
and Denmark, coverage has either not reached, or has fallen below
Comparison of dierent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females
and males (Review)
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50%. The reasons for low coverage differ between countries, but in-
clude organisation of programme implementation, resistance from
healthcare providers, adverse media coverage, and concerns about
safety (Gallagher 2018).
How the intervention might work
HPV vaccines containing virus-like particles of the L1 protein are
prophylactic, meaning that they prevent infection and the devel-
opment of intraepithelial lesions caused by HPV genotypes that are
present in the vaccine (Stanley 2006). The virus-like particles in the
vaccines produce very high levels of antibodies in serum, but the
exact mechanisms by which the vaccines prevent HPV infection are
not completely understood. The levels of antibodies needed to pro-
vide protection against clinical disease caused by HPV (known as
the immunological correlate of protection) have not been estab-
lished because the number of breakthrough infections after vac-
cination has been too low. The International Agency for Research
on Cancer regards persistent HPV infection with HPV types 16 and
18, measured with standardised and validated tests, as an accu-
rate surrogate marker for the precancerous lesions of the cervix and
anus (IARC 2014). Post-licensure data from national immunisation
programmes show reductions in high-grade lesions of the cervix
and anus with three-dose regimens of the bivalent and quadriva-
lent vaccines (Markowitz 2018). Since precancer is on the causal
pathway to invasive cancer, it is assumed that prevention of pre-
cancerous lesions will also be shown to prevent cancer when suffi-
cient follow-up time has accrued in post-licensure studies. Less is
known about the prognostic value of persistent HPV infection in the
development of vaginal, vulval and oropharyngeal cancers (IARC
2014).
All of the randomised controlled trials (RCTs) that established the
efficacy of HPV vaccines in the prevention of high-grade precancer-
ous lesions of the cervix used a three-dose vaccination schedule
(Arbyn 2018). Because of low HPV exposure and ethical constraints
in conducting research that requires genital examination and spec-
imen collection in adolescent populations (under 15 years of age),
randomised efficacy trials of vaccines have typically been first con-
ducted in women aged 15 to 25 or 26 years (Arbyn 2018). Once im-
munogenicity and harms have been evaluated, non-inferiority of
immunological outcomes in 9- to 15-year-olds is assessed in non-
randomised bridging studies (e.g. Block 2006; Dobson 2013). The
International Agency for Research on Cancer regards bridging stud-
ies that demonstrate non-inferiority as a sufficient endpoint for in-
dividuals under 16 years of age (IARC 2014).
Vaccine schedules are designed to produce a strong and long-last-
ing antibody response so that, when challenged by exposure to
the real pathogen, the immune system prevents infection. A three-
dose vaccine schedule is typical for inactivated protein vaccines
for infants; the second dose is given one or two months after the
first dose and a third dose six months after the first dose. The first
two vaccine doses are called 'prime' doses that generate immune
memory via B-lymphocytes produced in the bone marrow (Stanley
2014). The second dose results in higher levels of antibodies than
the first and increases the binding affinity of the antibody to the
antigen, in a process that lasts several months. As a result of this
process (affinity maturation), B cells with very high levels of affinity,
differentiate in the bone marrow into memory B cells that respond
rapidly to produce antibodies on exposure to antigen and long-
lived plasma cells that continuously produce antibody at low lev-
els. A third vaccine dose given at least four months after the prime
doses 'boosts' these responses maximally to provide long-lasting
protection (Stanley 2014).
Simplified HPV vaccination schedules with fewer doses should al-
low more people to receive the vaccine. Preadolescents and ado-
lescents (age 9 to 15 years) produce stronger antibody responses to
virus-like protein HPV vaccines than older adolescents and adults
(Block 2006; Dobson 2013), even after a single dose (Sankara-
narayanan 2016). It appears that multiple repeated doses of these
vaccines are not required for affinity maturation and that long-lived
plasma cells are more important than memory B cells in the im-
mune response (Schiller 2018). It is thought that structural charac-
teristics of the virus-like particles allow efficient production of the
long-lived plasma cells, which continuously produce antigen-spe-
cific antibodies, resulting in strong long-lasting immune responses
with reduced dose schedules (Schiller 2018).
Evidence of the likely efficacy of a two-dose schedule of virus-like
particle HPV vaccines in preventing incident vaccine-type HPV in-
fection comes from studies in which data from RCTs were analysed
as cohort studies according to the number of doses of HPV vac-
cine received (Kreimer 2011; Sankaranarayanan 2016). Kreimer and
colleagues conducted a secondary analysis of data from an RCT
of the bivalent vaccine amongst 18- to 25-year-old women in Cos-
ta Rica (Kreimer 2011). In that trial, 20% of women did not receive
all three doses of the vaccine. Women were grouped according
to the number of HPV vaccine doses that they received. The pro-
portions of women with incident HPV 16/18 infection that persist-
ed for 12 months or more was similar amongst women who re-
ceived one, two and three doses (Kreimer 2011). An updated analy-
sis combined data from this Costa Rica vaccine trial and a pivotal
trial of the bivalent vaccine, Paavonen 2007, according to number
of doses received after four years of follow-up (Kreimer 2015). In
the modified total vaccinated cohort, vaccine efficacy against HPV
16/18 incident infection that persisted for 12 months or more was
83.7% (95% CI 35.7 to 97.5%) with two doses, and 92.6% (95% CI
89.2 to 95.1%) with three doses. Sankaranarayanan and colleagues
analysed an RCT of the quadrivalent vaccine in 10- to 18-year-olds
in India (which was stopped before enrolment was completed) ac-
cording to the number of HPV vaccine doses received (Sankara-
narayanan 2016). Incidence of HPV 16/18 was 0.8% (95% CI 0.2 to
1.9%, 4/526) amongst participants who received two doses, and
0.4% (95% CI 0.0 to 1.3%, 2/536) amongst those who received three
doses (Sankaranarayanan 2016). Additional data from a systemat-
ic review of post-licensure studies in national HPV vaccination pro-
grammes, show the receipt of two doses of HPV vaccine was asso-
ciated with a reduction in the incidence of vaccine-type HPV preva-
lence, anogenital warts and cervical abnormalities in some, but not
all, studies (Markowitz 2018).
Why it is important to do this review
In practice, HPV vaccination rates in many countries remain low.
Simpler HPV immunisation schedules have been identified as a po-
tential strategy to increase the coverage of vaccination (Walling
2016). The World Health Organization (WHO) recommended a two-
dose HPV vaccine schedule in 2014, based on a systematic review
of studies with immunogenicity as the end-point (D'Addario 2017;
WHO 2017). As of 30 December 2017, 80 countries had fully intro-
duced HPV vaccination and four countries had partially introduced
HPV vaccination into their national immunisation programmes,
with 65 countries having implemented a two-dose schedule in girls
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9 to 14 years old (www.who.int/immunization/monitoring_surveil-
lance/data/en).
In 2018, a Cochrane Review concluded that the licensed three-dose
schedules of the bivalent and quadrivalent HPV vaccines result in
limited adverse events and are effective against precancerous cer-
vical lesions in females (Arbyn 2018). Since the 2014 WHO recom-
mendation and original systematic review of two-dose HPV vacci-
nation schedules (D'Addario 2017; WHO 2017), the evidence base
from RCTs about alternative vaccination schedules has expanded
to include more data about the nonavalent HPV vaccine (Iversen
2016), about HPV vaccination in males, including MSM (Giuliano
2011), and amongst people living with HIV infection (ToM 2014). This
review was initially commissioned in 2016 by the WHO Initiative for
Vaccine Research to update the evidence for the two-dose recom-
mendation and is an update of D'Addario 2017. We produced a re-
vised protocol for this update (Bergman 2017).
Cochrane Reviews usually include only RCTs with major clinical dis-
ease endpoints because RCTs provide the highest level of certain-
ty about critical outcomes of interventions. However, precancer
and cancer do not develop until many years after the acquisition
of HPV infection, so it is difficult to determine the efficacy of vac-
cines against these outcomes. Persistent HPV infection is consid-
ered by the International Agency for Research on Cancer to be suf-
ficient as a surrogate marker for cervical and anal cancer and non-
inferiority of immunogenicity is sufficient to bridge results to un-
der-16-year-olds. It is therefore important to document all infection
and immunological outcomes measured in RCTs of HPV vaccines,
even if the intended use of the vaccine is to prevent cancer.
This review aims to extend the evidence base on the efficacy and
harms of HPV vaccines by including and evaluating RCTs of differ-
ent HPV vaccines and different dose schedules in adolescent and
adult females and males, as well as women and men living with HIV
infection.
While RCTs can identify adverse events that take place during the
study period, post-marketing surveillance is needed to continue
monitoring harms associated with HPV vaccines in the population,
and will be incorporated in future updates of this review.
O B J E C T I V E S
To evaluate the efficacy, immunogenicity, and harms of different
dose schedules and different types of HPV vaccines in females and
males.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs with no language restrictions. We included un-
published studies, studies in press, and abstracts without a full-text
publication, if they met the inclusion criteria.
Types of participants
Females or males aged 9 to 26 years, including MSM. For the com-
parisons among people living with HIV, we included all age groups.
Types of interventions
Prophylactic administration of licensed bivalent (Cervarix, Glax-
oSmithKline), quadrivalent (Gardasil, Merck), or nonavalent (Gar-
dasil 9, Merck) HPV vaccines. We excluded studies if they assessed
monovalent or plasmid vaccines, or assessed non-prophylactic us-
es of bivalent, quadrivalent or nonavalent vaccines. In addition,
we considered for inclusion any trials reporting on the efficacy, im-
munogenicity, or adverse events in vaccines currently in phase 2
or 3 development. Studies comparing bivalent versus quadrivalent
vaccines were excluded, as these will be included in an update of a
separate Cochrane Review (Arbyn 2018).
For males and people living with HIV, we included comparisons of
HPV vaccines to placebo containing no adjuvant or only the adju-
vant of the HPV vaccine, or another HPV vaccine.
In this review, we use the term 'control' to refer to comparator prod-
ucts that contain another vaccine or only vaccine adjuvants, re-
gardless of the terminology used in individual study reports. We use
the term 'placebo' only to refer to comparator products containing
no adjuvant or active vaccine. In Characteristics of included stud-
ies we have reported full details of the type of comparison group
compound.
The focus of the review was on different dose schedules and com-
parisons between different types of HPV vaccine. Where possible
we stratified data by participant characteristics of age, gender, and
HIV status. Specifically, we aimed to investigate the efficacy, im-
munogenicity, and harms of:
• fewer than three doses of HPV vaccine in females and males;• different intervals between doses in a two-dose schedule in fe-
males and males;• HPV vaccination compared to control for males (a Cochrane Re-
view for females has been published (Arbyn 2018));• nonavalent HPV vaccine compared to the other HPV vaccines in
females and males;• HPV vaccination in people living with HIV.
Types of outcome measures
Primary outcomes
Unless otherwise stated, primary outcomes were assessed at the
longest follow-up time reported by the included studies.
• Invasive cervical, vaginal, vulval, anal, or penile cancer• In females, histologically-confirmed high-grade cervical (CIN2,
CIN3, and adenocarcinoma in situ), vaginal, vulval, or anal in-
traepithelial neoplasia, irrespective of HPV genotype, or any le-
sions associated with the HPV genotypes included in the vaccine• In males, histologically-confirmed anal, or penile, perianal or
perineal intraepithelial neoplasia of any grade, irrespective of
HPV genotype, or any lesions associated with the HPV genotypes
included in the vaccine• Anogenital warts• Adverse events related to the vaccines: local adverse events
(overall local/injection site adverse events, redness, swelling,
pain at the injection site), assessed at the follow-up times re-
ported in the trials (usually up to seven days); overall systemic
events and general symptoms assessed at the follow-up times
reported in the trials (usually up to 15 days)
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• Serious adverse events and mortality: any events that are fa-
tal, life-threatening, or result in hospitalisation and mortality.
We collected information from each trial about whether these
events were considered to be vaccine-related and the meth-
ods of adverse events data monitoring and collection, including
mode of data collection, timing, attribution methods, intensity
of ascertainment, harms-related monitoring and stopping rules,
and reporting based on event frequency (i.e. frequency-based
filter), based on the CONSORT statement extension for reporting
harms (Ioannidis 2004; Lineberry 2016).
Secondary outcomes
Unless otherwise stated, secondary outcomes were assessed at the
longest follow-up time reported by the included studies.
• Incident infection with vaccine HPV genotypes (HPV 16 and HPV
18 jointly; HPV 6, HPV 11, HPV 16 and HPV 18 jointly; and HPV 31,
HPV 33, HPV 45, HPV 52, and HPV 58 jointly)• Persistent infection (persisting for at least six months or at least
12 months) with vaccine HPV genotypes• Immunological outcomes (geometric mean titre (GMT) and
seropositivity), assessed at one month following the last dose
and at the longest-term follow-up
For the comparisons of dose schedules (i.e. number of doses and
longer or shorter interval(s) between doses) we considered im-
munological outcomes as primary outcomes because these trials
were designed to show non-inferiority of immunogenicity. While
these trials were not designed to evaluate efficacy or safety of the
vaccines, we have included clinical outcomes when reported and
comparative estimates of harms associated with the different dose
schedules.
Search methods for identification of studies
We attempted to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press and
in progress).
Electronic searches
All searches were conducted on 27 September 2018. We searched
the following electronic databases:
• the Cochrane Central Register of Controlled Trials (CENTRAL, Is-
sue 9, 2018) (published in the Cochrane Library)• Ovid MEDLINE (1946 to September week 2 2018);• Ovid Embase (1980 to 2018 week 39).
The search terms used are detailed in Appendix 1, Appendix 2, and
Appendix 3. We also searched ClinicalTrials.gov and the WHO In-
ternational Clinical Trials Registry Platform (ICTRP) to identify on-
going trials using 'genital warts', 'condyloma', 'anogenital warts',
'venereal warts', 'human papilloma virus vaccine', and 'HPV vac-
cine' as search terms.
Searching other resources
We searched the reference lists of all included studies, as well as the
reference lists of any relevant systematic reviews published within
the search dates. We searched vaccine manufacturer web sites for
relevant clinical trial reports (GlaxoSmithKline; Merck). In addition,
we screened a list of HPV vaccine studies (Jørgensen 2018a), that
was constructed through enquiries to HPV vaccine manufacturers
and regulators, as well as searches of trial registers and journal
publication databases. For each included study, where available,
we identified and screened study governance documents (proto-
cols, trial registration listings and results, manufacturers' clinical
study reports) for relevant data and outcomes. We also contacted
the vaccine manufacturers through the WHO Initiative for Vaccine
Research for any additional, potentially relevant studies.
Data collection and analysis
Selection of studies
Two experienced systematic reviewers independently screened
citations and abstracts of studies identified from the electronic
searches for potential inclusion. A third reviewer resolved any dis-
agreements. We obtained full-text reports for all potentially eligi-
ble studies. Two independent reviewers determined the eligibility
of studies for inclusion in the review from the full reports according
to predefined criteria. A third reviewer resolved any disagreements.
Data extraction and management
For the purpose of the review, we named studies on the basis of
the first-named study author and year of publication. Many stud-
ies have more than one document associated with them: journal
publications (main study reports, reports of long-term follow-up,
secondary outcomes and post-hoc analyses), conference abstracts,
and study governance documents (protocols, trial registration list-
ings and results, manufacturers' clinical study reports). For each
study we grouped these documents together and designated one
report as the primary reference for the study; the study name is de-
rived from the name of the first author and year of publication of
this particular report.
In cases where study reports emanate from the same parent study,
but are planned or reported, or both, as distinct, discrete studies,
we have named and handled these separately.
Two reviewers carried out data extraction independently using
pretested data extraction forms. We resolved any differences by
discussion between the two reviewers and referral to the study re-
ports.
We cross-checked data for the efficacy outcomes and adverse
events between the primary trial publications, trial registries, and
clinical study reports. We used the data derived from these sources
with the longest follow-up time for the primary analysis.
Assessment of risk of bias in included studies
Two reviewers independently carried out 'Risk of bias' assessments
using the Cochrane 'Risk of bias' tool for all included studies (Hig-
gins 2011b). We judged the risk of bias for each domain as 'low risk',
'unclear risk' or 'high risk'. We resolved differences by discussion
between the two reviewers and if necessary we referred to a third
reviewer for arbitration.
Measures of treatment eect
We calculated risk ratios (RR) with 95% confidence intervals (CI)
for dichotomous outcomes. We calculated rate ratios with 95% CIs
for dichotomous clinical outcomes reported as incidence rates. For
outcomes with rare events (i.e. an event rate of < 10%), serious ad-
verse events, and deaths, we calculated Mantel-Haenszel odds ra-
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tios (OR) for dichotomous outcomes. We assessed the robustness
of the primary analysis for very rare events with alternative statis-
tical methods (see Sensitivity analysis).
For continuous geometric mean titre (GMT) data, we calculated in-
verse variance (IV) ratios of GMTs with 95% CIs. Initially, we trans-
formed the point estimates as well as the lower and upper bound
of the 95% CI of GMT for each group into the logarithmic scale in
order to obtain statistically correct standard deviations. Then we
calculated the mean difference of the compared group and back-
transformed the results (point estimate and 95% CIs) to the orig-
inal scale through exponentiation. Non-inferiority margins for im-
munological outcomes were derived from the individual trials (all
trials used 0.5 for the GMT ratio). For GMT ratios non-inferiority is
demonstrated if the lower 95% CI is greater than 0.5. If the lower
confidence interval was below the non-inferiority margin, but the
point estimate was within the margin, we considered the result to
be inconclusive (Piaggio 2012).
For adverse events and efficacy outcomes we carried out a com-
plete-case analysis (the number analysed) and an intention-to-
treat analysis when data were available. For immunogenicity out-
comes assessed in non-inferiority trials, we favoured data from per-
protocol analyses, in which all participants were HPV-seronegative
at baseline. We did not pool studies with participants who were
HPV-seropositive at baseline with studies with participants who
were HPV-seronegative at baseline.
Unit of analysis issues
If a single trial compared two or more vaccine arms (with or with-
out a control arm), we labelled the arms separately in analyses. We
grouped suitable multiple treatment arms (e.g. arms that evaluat-
ed different vaccine lots) and excluded irrelevant trial arms. We did
not pool data from cluster RCTs with those from individually ran-
domised studies.
Dealing with missing data
If data on specific outcomes or population groups were missing,
we attempted to contact study authors or data owners to request
this data. We did not impute missing outcome data. Where data
were missing or losses to follow-up were substantial, we downgrad-
ed the certainty of study evidence due to risk of bias according to
GRADE criteria (Guyatt 2011a).
Assessment of heterogeneity
We described potential sources of clinical heterogeneity, and
downgraded the certainty of the evidence according to GRADE cri-
teria due to inconsistency where appropriate (Guyatt 2011b). When
pooling of studies was feasible (i.e. at least two studies included),
we inspected forest plots visually for potential outlying studies and
variability in the estimated effects across studies. We assessed sta-
tistical heterogeneity using the I2 statistic. This statistic quanti-
fies the percentage of inconsistency in the treatment effects across
studies beyond simple chance. We regarded heterogeneity as po-
tentially unimportant if the I2 was 0% to 40%; that values of 30%
to 60% might represent moderate heterogeneity; values between
50% to 90% might represent substantial heterogeneity; and that
values between 75% to 100% would represent considerable hetero-
geneity (Higgins 2011a). Where considerable heterogeneity existed
(>75%), we did not pool study data.
Assessment of reporting biases
We had planned to use funnel plots to investigate the possible pres-
ence of small-study effects for each outcome. However, we did not
produce funnel plots, due to the limited number of studies per out-
come (i.e. fewer than 10) (Guyatt 2011c).
Data synthesis
When pooling was considered feasible, we employed a random-ef-
fects meta-analysis using the DerSimonian and Laird method
(DerSimonian 1986), as it was assumed that effect size might vary
across studies and settings. We used data from the last available
follow-up for clinical and adverse event outcomes, with the num-
ber of participants (rather than the number of events) used in the
analysis. For immunological outcomes, we extracted data from one
month after the last HPV dose and at the longest-term follow-up.
To assess the harms associated with the HPV vaccine comparisons
in this review, we recorded the methods used in each included
study to collect adverse event data, and extracted data on common
events that we determined a priori as: pain, swelling, redness at the
injection site and overall systemic adverse events. For all serious
adverse events reported in the included studies, we extracted the
number of participants, participants with events and a description
of the events. We also extracted information on whether the serious
adverse events were considered to be related to the vaccines. We
did not conduct statistical hypothesis testing because our protocol
did not prespecify hypotheses about differences in the occurrence
of any specific serious adverse event.
We prepared 'Summary of findings' tables for each comparison for
which data were available for the following outcomes that were as-
sessed as critical or important according to GRADE guidelines (Guy-
att 2011d):
• for females: high-grade cervical intraepithelial neoplasia, ade-
nocarcinoma in situ, or cervical cancer; high-grade vulval and
vaginal disease;• for males: invasive anal or penile cancer, external genital le-
sions;• for all populations: anogenital warts, overall local/injection site
adverse events, overall systemic events and general symptoms,
serious adverse events, deaths;• for comparisons of dose schedules (i.e. number of doses and
longer or shorter interval between doses): immunological out-
comes.
We assessed the certainty of evidence in the review through dis-
cussion between review authors using the GRADE approach using
GRADEpro online software (GRADEpro GDT). We assessed only the
primary outcomes reported in the 'Summary of findings' tables and
appendices using GRADE. We considered the following factors for
downgrading: limitations in the study design (risk of bias); inconsis-
tency of results (heterogeneity); indirectness of evidence (applica-
bility); imprecision (few events and wide confidence intervals); and
publication bias (Guyatt 2011a). When evidence was downgraded,
we detailed the reasons in footnotes of the 'Summary of findings'
tables and summarised these in the Quality of the evidence section.
Depending on whether evidence was downgraded or not, we rated
the certainty of the evidence for each outcome as follows:
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• high-certainty evidence indicates that we are very confident
that the true effect lies close to that of the estimate of the effect
(evidence was not downgraded);• moderate-certainty evidence indicates that we are moderately
confident in the effect estimate: the true effect is likely to be
close to the estimate of the effect, but there is a possibility that
it is substantially different (evidence was downgraded one step
for any of the factors described above);• low-certainty evidence indicates that our confidence in the ef-
fect estimate is limited: the true effect may be substantially dif-
ferent from the estimate of the effect (evidence was downgrad-
ed two steps for any of the factors described above);• very low-certainty evidence indicates that we have very little
confidence in the effect estimate: the true effect is likely to be
substantially different from the estimate of effect (evidence was
downgraded three steps for any of the factors described above).
We reported relative risks (ORs or RRs) in the Effects of interven-
tions section for all relevant outcomes, but where the evidence was
of very low-certainty we reported the number of events in each
group only.
Subgroup analysis and investigation of heterogeneity
We performed subgroup meta-analyses where possible, using vac-
cine type, gender, and age group (9 to 15 years; 16 to 26 years) as
stratifying variables.
Sensitivity analysis
We carried out one post-hoc sensitivity analysis for outcomes using
a Mantel-Haenszel odds ratio where events were very rare (i.e. an
event rate of < 1% across both trial arms). We compared the results
of the primary analysis calculated with Mantel-Haenzsel methods
against those with Peto methods (Bradburn 2007). We also planned
to conduct sensitivity analyses for the primary outcomes according
to allocation concealment (high risk of bias, low risk of bias, and un-
clear risk of bias) for outcomes for which data could not be pooled
because of considerable heterogeneity (I2 > 75%).
R E S U L T S
Description of studies
Overall, 20 RCTs were included for analysis in this review (Figure 1).
The characteristics of individual studies and assessment of risk of
bias are presented in the Characteristics of included studies section
and Figure 2.
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 2.   (Continued)
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Results of the search
The search identified a total of 3852 records; 3298 from electron-
ic databases and 554 from other sources (systematic reviews, vac-
cine manufacturers, online trial registrations, WHO IVR depart-
ment, HPV study index (Jørgensen 2018a)). After de-duplication,
3291 records remained. After excluding irrelevant abstracts, we as-
sessed 528 full texts. We excluded 438 full texts and included 20
RCTs (reported in 69 published and unpublished reports) in this re-
view for analysis (Denny 2013; Dobson 2013; Giuliano 2011; Hidal-
go-Tenorio 2017; Iversen 2016; Joura 2015; Lehtinen 2018; Leung
2015; Levin 2010; Lin 2014; NCT00941889 2016; NCT01031069 2017;
NCT01862874 2018; Petaja 2009; Puthanakit 2016; Romanowski
2011; ToM 2014; van Damme 2016; Vesikari 2015; Wilkin 2018). We
identified 15 ongoing studies (reported in 16 records) and two stud-
ies (reported in five references) are awaiting classification.
Included studies
We found 20 RCTs that contained data on vaccine efficacy or harms,
or both, and enrolled a total of 31,940 men, women, and children.
Ten studies were multi-national and were carried out in two to 18
countries in Africa, Asia, Asia-Pacific, Europe, Latin America, North
America, and South America. The other 10 studies were carried out
in one country only (USA, including Puerto Rico (3 studies), Finland
(2), Canada (1), Denmark (1), Japan (1), Spain (1), South Africa (1)).
Owing to differences in the protocols of the included trials, the max-
imum age for inclusion was either 25 or 26 years.
Description of studies
Four RCTs evaluated the effects of reduced dose schedules (Dobson
2013; Iversen 2016; Leung 2015; Romanowski 2011). All these trials
were designed as non-inferiority trials of antibody responses. They
reported on immunogenicity as the primary outcome and on ad-
verse events. None of these trials collected data on clinical events.
These four RCTs evaluated the effects of two doses of HPV vaccine
versus three doses of HPV vaccine in adolescent girls (9 to 15 years).
We did not identify any RCTs that evaluated the efficacy or harms
of one dose of HPV vaccine.
Four RCTs compared different intervals between doses. Two RCTs
compared a longer interval two-dose schedule with a shorter
schedule (0 and 6 months versus 0 and 2 months; or 0 and 12
months versus 0 and 6 months) of bivalent HPV vaccine in 9- to
14-year-old females (Puthanakit 2016; Romanowski 2011). One RCT
of nonavalent HPV vaccine compared a two-dose schedule with a
longer interval (0 and 12 months) and a shorter interval (0 and 6
months) in 9- to 14-year-old females and males (Iversen 2016). One
RCT compared a longer interval three-dose schedule (administered
at 0, 2 and 12 months) with a shorter schedule (administered at 0,
2 and 6 months) of quadrivalent HPV vaccine in 18- to 25-year-old
males (Lin 2014).
Two RCTs compared quadrivalent HPV vaccine versus control in
5189 males aged 16 to 26 years (Giuliano 2011; NCT01862874 2018).
A subgroup analysis of Giuliano 2011 also reported on the efficacy
and harms of the quadrivalent HPV vaccine compared with control
vaccine in MSM. Giuliano 2011 reported on clinical, adverse event,
and immunogenicity outcomes, and NCT01862874 2018 reported
on clinical outcomes and adverse events. One RCT compared biva-
lent HPV vaccine versus control hepatitis B virus (HBV) vaccine in
270 boys aged 10 to 18 years and reported on immunogenicity and
harms (Petaja 2009). In addition, a cluster-RCT investigating both
direct and indirect effects of HPV vaccination of girls and boys (gen-
der-neutral) and girls-only vaccination reported on adverse events
in a subgroup of 3703 12- to 15-year-old males vaccinated with the
bivalent vaccine or control HBV vaccine (Lehtinen 2018). We identi-
fied no studies investigating the clinical efficacy of the nonavalent
vaccine in males.
Three RCTs compared three doses of nonavalent vaccine with three
doses of quadrivalent vaccine: one in 9- to 15-year-old females
(Vesikari 2015), one in 16- to 26-year-old females (Joura 2015), and
one in males aged 16 to 26 years (van Damme 2016). Joura 2015 re-
ported clinical outcomes for the 16- to 26-year-old population. All
three studies reported on adverse event and immunogenicity out-
comes.
Studies including participants living with HIV
We identified seven RCTs that examined HPV vaccines in 1723 peo-
ple living with HIV (Denny 2013; Hidalgo-Tenorio 2017; Levin 2010;
NCT00941889 2016; NCT01031069 2017; ToM 2014; Wilkin 2018):
• ToM 2014 compared bivalent with quadrivalent vaccine in fe-
males and males ≥ 18-years old;• NCT01031069 2017 compared bivalent with quadrivalent vac-
cine in 15- to 25-year-old females;• Denny 2013 compared bivalent vaccine with control in women
aged 18 to 25 years;• Hidalgo-Tenorio 2017 compared quadrivalent vaccine with con-
trol in MSM ≥ 18-years old;• Wilkin 2018 compared quadrivalent vaccine with control in fe-
males and males ≥ 27-years old;• NCT00941889 2016 compared quadrivalent vaccine with control
in females and males ≥ 18-years old that had been treated for
anogenital warts;• Levin 2010 compared three doses of quadrivalent vaccine with
control in 126 children aged 7 to 12 years, and four versus three
doses of quadrivalent vaccine in the same participants.
The studies were carried out in Brazil, Denmark, Estonia, India,
South Africa, Spain, Thailand, and the USA, including Puerto Rico.
Of these, only two reported on clinical outcomes (NCT00941889
2016; Wilkin 2018), as most were designed as non-inferiority trials
of antibody responses.
Adverse events
Appendix 4 lists the methods used to collect adverse event data.
The mode of data collection was reported in 16 of the 20 stud-
ies and was passive in two studies (e.g. patients recording symp-
toms on diary cards); proactive in three (e.g. investigators observ-
ing participants after vaccine administration, or field workers visit-
ing or calling participants in their homes); both passive and proac-
tive in nine studies; and in two studies, the details were insufficient
for us to categorise as passive or proactive. Time frame (duration
of follow-up) was reported for all but three studies; for two stud-
ies it was unclear, and one study did not report on adverse events
(NCT00941889 2016). Methods to determine the relationship be-
tween vaccination and adverse events were reported by 10 studies:
attribution was done by study investigators in nine studies and by
a study co-ordinator in one study. Where the attribution method
was not reported, we assumed this role was performed by study
investigators. Fourteen studies (74%) provided definitions for the
adverse events outcomes. Withdrawals due to adverse events were
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reported in 14 (70%) studies, but most studies (95%) did not re-
port on how withdrawals would be handled in the analysis. Only
one study reported harms-related monitoring and stopping rules
(Hidalgo-Tenorio 2017). Seventeen studies reported on all adverse
events regardless of frequency (i.e. they did not use a frequen-
cy-based filter); NCT01862874 2018 used a 5% threshold for oth-
er adverse events; it was unclear whether Dobson 2013 used a fil-
ter, and one study did not report on adverse events (NCT00941889
2016).
The length of follow-up for serious adverse events in the included
studies ranged from seven months to five years. Table 2 lists the se-
rious adverse events reported in each study. In all studies, the indi-
vidual serious events were listed for each study arm. In five of the 20
RCTs, 50 or more serious adverse events were reported (Joura 2015,
Lehtinen 2018; Puthanakit 2016; Romanowski 2011; Wilkin 2018).
Information on whether serious adverse events were considered to
be related to the vaccine is reported in the section Effects of inter-
ventions.
Studies awaiting classification
We identified two studies that included both males and females
randomised to HPV vaccine and control (Li 2012; Reisinger 2007).
The male population in these studies would qualify for inclusion in
our review, but at the time of preparing this review we were not able
to access data for males only. We have requested this information
from the study investigators and, should these data become avail-
able, they will be included in a future update of this review.
Li 2012 and Reisinger 2007 both compared quadrivalent HPV vac-
cine to vaccine adjuvant-containing control in 9- to 15-year-old
males. The studies reported on the comparison of males with fe-
males for immunogenicity outcomes and adverse events for males
and females as one group. Li 2012 was carried out in China, and
Reisinger 2007 was carried out in 10 countries in North Ameri-
ca, Latin America, Europe and Asia. See Characteristics of studies
awaiting classification for further details.
Ongoing studies
We identified 15 potentially relevant ongoing studies that have not
been completed, but might be relevant for inclusion in future up-
dates of this review. All studies are RCTs and studies may appear in
more than one category of the list below:
• eight include healthy females (NCT01735006; NCT02009800;
NCT02405520; NCT02562508; NCT02733068; NCT02740777;
NCT02834637; NCT03180034);• four include healthy males and females (NCT01824537;
NCT02567955; NCT02710851; NCT02888418);• one includes HIV-positive MSM (NCT02087384);• one includes males and females cured of genital warts
(NCT03296397);• one includes females with genital warts (NCT02750202);• seven are evaluating new vaccines in development in Chi-
na (NCT01735006; NCT02405520; NCT02562508; NCT02710851;
NCT02733068; NCT02740777; NCT02888418);• four are evaluating the quadrivalent vaccine (NCT02009800;
NCT02087384; NCT02750202; NCT03296397);• one is evaluating the nonavalent vaccine (NCT01824537); and
• three are comparing the bivalent to the nonavalent vaccine
(NCT02567955; NCT02834637; NCT03180034).
In addition to the seven studies ongoing in China, three of these
studies are ongoing in Canada, and one study each in Costa Rica,
France, the Netherlands, South Africa, and Tanzania. See Charac-
teristics of ongoing studies for further details.
Excluded studies
We excluded 438 full texts. Twenty-two of these were potentially
relevant studies, and the reasons for their exclusion are included in
the Characteristics of excluded studies table. We excluded six stud-
ies because they were not RCTs, and two studies because they in-
cluded females over 26 years of age. Most of the excluded studies
contained no comparison of relevance to the review: seven studies
compared HPV-vaccinated to HPV-unvaccinated females, five com-
pared different intervals in three-dose schedules in females, one
compared three-dose schedules of the bivalent and quadrivalent
vaccine in young females, and one evaluated the effect of a booster
dose of HPV vaccine.
Risk of bias in included studies
The risk of bias for each included study is detailed in Characteristics
of included studies and an overview is presented in Figure 2. Overall
risk of bias for each comparison is discussed in each results section
below.
Allocation
We assessed most studies as being at low risk of selection bias,
as they reported adequate randomisation sequence generation
(15/20 = 75%) and allocation concealment procedures (15/20 =
75%). Five studies did not report their methods to conceal al-
location adequately (Levin 2010; Lin 2014; NCT01031069 2017;
NCT00941889 2016; NCT01862874 2018), and five did not re-
port the method of sequence generation adequately (Levin 2010;
NCT01031069 2017; NCT00941889 2016; NCT01862874 2018; Wilkin
2018); we assessed them as being at unclear risk of bias.
Blinding
Blinding of participants and providers was explicitly reported by
less than half of the included studies (7/20 = 35%), we assessed
those studies that did as being at low risk of performance bias.
We assessed eight studies as being at unclear risk of performance
bias as they did not report blinding status of participants and
personnel clearly (Denny 2013; Hidalgo-Tenorio 2017; Levin 2010;
NCT00941889 2016; NCT01031069 2017; NCT01862874 2018; Ro-
manowski 2011; Wilkin 2018), and five studies as being at high risk
of performance bias due to no, or partial blinding, of participants,
personnel, or both (Dobson 2013; Lehtinen 2018; Puthanakit 2016;
Iversen 2016; Lin 2014).
Less than half of the studies reported adequate blinding of out-
come assessors (9/20 = 45%); we considered those that did to
be at low risk of detection bias. Eight studies did not report de-
tails regarding blinding of outcome assessment and we assessed
them as being at unclear risk of bias (Denny 2013; Hidalgo-Tenorio
2017; Levin 2010; Lin 2014; NCT01031069 2017; NCT00941889 2016;
NCT01862874 2018; Wilkin 2018), and three studies did not blind
outcome assessment and were assessed as being at high risk of de-
tection bias (Iversen 2016; Lehtinen 2018; Puthanakit 2016).
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Incomplete outcome data
We assessed most included studies (18/20 = 90%) as having a low
risk of attrition bias, as they reported withdrawals and provided
adequate reasons for dropouts. We assessed one study as having
a high risk of attrition bias because only a subgroup of included
participants were analysed (Lehtinen 2018). We assessed another
study as having a high risk of attrition bias because data for 62.5%
(20/32) of the participants enrolled were missing due to early with-
drawals from the study (NCT00941889 2016).
Selective reporting
For the majority of studies (16/20 = 80%) either a study protocol
or clinical trial registry entry was available to determine that selec-
tive reporting was unlikely; we assessed these studies as having a
low risk of reporting bias. We assessed four studies as having a high
risk of selective reporting bias; Lehtinen 2018 because most out-
comes were not reported separately for boys and girls, indeed, on-
ly adverse events were reported separately in boys, but in a select-
ed subset; NCT00941889 2016 because predetermined outcomes,
including serious adverse events, were not reported; NCT01031069
2017 because not all outcomes listed in the online trial record were
reported in the trial result summary report; and NCT01862874 2018
because HPV disease was not reported as a separate outcome, but
were reported as an outcome combined with persistent HPV infec-
tion.
Other potential sources of bias
All included studies provided a statement of the funding source for
the trial. Thirteen studies were funded by the vaccine manufactur-
ers (GSK, Merck or Sanofi Pasteur) and we rated them as having an
unclear risk of other bias. Industry sponsored studies are associat-
ed with favourable efficacy results and conclusions (Lundh 2017)
which may be mediated by factors other than those assessed by the
Cochrane 'Risk of bias' tool. We also rated a further two studies as
having an unclear risk of other bias because no published report
was identified for either (NCT00941889 2016; NCT01031069 2017),
and we extracted data from the clinical trials records, which provid-
ed insufficient information to establish whether there was a risk of
other bias. We assessed the remaining five studies as being at low
risk of other bias (Dobson 2013; ToM 2014; Hidalgo-Tenorio 2017;
Levin 2010; Wilkin 2018).
Eects of interventions
See: Summary of findings for the main comparison Two doses of
HPV vaccine compared with three doses of HPV vaccine in 9- to 15-
year-old females; Summary of findings 2 Two doses of HPV vaccine
with longer interval compared with two doses of HPV vaccine with
shorter interval in 9- to 14-year-old females and males; Summary
of findings 3 Three doses HPV vaccine compared with control in
10- to 26-year-old males; Summary of findings 4 Nonavalent HPV
vaccine compared with quadrivalent HPV vaccine in 9- to 26-year-
old females and males
1. Two doses of HPV vaccine versus three doses of HPV vaccine
in 9- to 15-year-old females or males
The results for this comparison are presented in Summary of find-
ings for the main comparison and Appendix 5. We analysed four
studies in females that compared two doses (months 0 and 2, or
0 and 6, or 0 and 12) versus three doses (months 0, 1, and 6; or 0,
2, and 6) of HPV vaccine (Dobson 2013; Iversen 2016; Leung 2015;
Romanowski 2011), and reported immunogenicity outcomes (sev-
en months to five years) for all vaccine types and adverse event
outcomes throughout the study period (one to five years). No stud-
ies included for this comparison collected data about clinical out-
comes. No evidence was found from RCTs making this comparison
in males.
Immunogenicity results comparing two doses with three doses of
HPV vaccine are reported in Appendix 5. Briefly, two doses were
non-inferior to or had higher GMTs than three doses for all nine HPV
genotypes measured except HPV 45 (where non-inferiority was in-
conclusive) one month after the last dose (moderate- to high-cer-
tainty evidence). For seroconversion one month after the last dose,
there was evidence of little to no difference between groups for
all nine HPV genotypes measured (high-certainty evidence). At 60-
month follow-up after the first dose, non-inferiority of two doses of
bivalent vaccine was inconclusive for GMTs of HPV 16 and HPV 18
(low-certainty evidence). Two doses of quadrivalent vaccine result-
ed in non-inferior GMTs for HPV 6, HPV 11 and HPV 16, while results
were inconclusive for HPV 18 (low-certainty evidence). At 36-month
follow-up after the first dose, two doses of nonavalent vaccine re-
sulted in non-inferior GMTs for all HPV genotypes measured except
HPV 45 and HPV 52 where non-inferiority was inconclusive (high-
certainty evidence).
Two studies found that two doses of HPV vaccine resulted in little
to no difference in pain at the injection site compared with three
doses of HPV vaccine (RR 0.96, 95% CI 0.91 to 1.03; 2 studies; 1189
participants; Analysis 1.1), but reduced swelling (RR 0.76, 95% CI
0.65 to 0.89; 2 studies; 1189 participants; Analysis 1.2) and redness
(RR 0.85, 95% CI 0.75 to 0.96; 2 studies; 1189 participants; Analysis
1.3) at the injection site at up to seven days follow-up. The compar-
ative evidence about serious adverse events was considered to be
of very low-certainty (risk with two doses 36/1158, risk with three
doses 35/1159; 4 studies; 2317 participants; Analysis 1.4). We down-
graded certainty for imprecision and indirectness of the compos-
ite measure of all serious adverse events, which may or may not
be clinically relevant, may or may not be related to the vaccine,
and may occur outside a biologically plausible time frame relative
to vaccine exposure. Two of the studies reported on withdrawals
from the study and reported that no participants had withdrawn
because of adverse events. One death was reported in the three-
dose group (1/898) and no deaths (0/899) in the two-dose group (OR
0.33, 95% CI 0.01 to 8.19; 3 studies; 1797 participants; low-certainty
evidence; Analysis 1.5).
2. Two doses of HPV vaccine with longer interval compared
with two doses of HPV vaccine with shorter interval in 9- to 14-
year-old females or males
The results for this comparison are presented in Summary of find-
ings 2 and Appendix 6. We included three studies in females that
compared two doses with a longer interval between the first and
second doses (months 0 and 6 or 12) with a shorter interval be-
tween the first and second doses (months 0 and 2 or 6) for im-
munogenicity outcomes at seven months for all vaccine types and
adverse event outcomes throughout the study period (one to five
years) (Iversen 2016; Puthanakit 2016; Romanowski 2011). One of
these studies compared a longer interval (months 0 and 12) with a
shorter interval (months 0 and 6) in males (Iversen 2016). No stud-
ies included for this comparison collected data about clinical out-
comes. As each study compared different intervals, we did not pool
the results in the meta-analysis.
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Immunogenicity results are reported in Appendix 6. At one month
after the final dose, there was evidence of higher (and non-inferi-
or) GMTs for HPV 16 and HPV 18 with the longer interval schedules
compared with the shorter intervals in 9- to 14-year-old females
who received bivalent HPV vaccine (moderate- to high-certainty ev-
idence). There was also evidence of higher GMTs for HPV 16 and HPV
18 at 36 months with the longer interval schedules compared with
the shorter intervals in 9- to 14-year-old females who received biva-
lent HPV vaccine (high-certainty evidence). For seroconversion to
HPV 16 and HPV 18, there was evidence of no difference between
groups one month after the final dose (high-certainty evidence).
For the nonavalent vaccine in girls and boys, there was evidence
that a longer interval produced higher and non-inferior GMTs than
a shorter interval for all HPV genotypes (high-certainty evidence).
In Romanowski 2011 there was little to no difference in pain (RR
1.01, 95% CI 0.96 to 1.06; 1 study; 477 participants; Analysis 2.1),
swelling (RR 0.95, 95% CI 0.76 to 1.20; 1 study; 477 participants;
Analysis 2.2), or redness at the injection site (RR 1.02, 95% CI 0.84
to 1.24; 1 study; 477 participants; Analysis 2.3) when comparing
a two-month interval between doses to a six-month interval. In
Puthanakit 2016 there was also little to no difference in pain (RR
1.02, 95% CI 0.98 to 1.06; 1 study; 963 participants; Analysis 2.1),
swelling (RR 1.01, 95% CI 0.87 to 1.18; 1 study; 963 participants;
Analysis 2.2), or redness at the injection site (RR 1.06, 95% CI 0.93 to
1.22; 1 study; 963 participants; Analysis 2.3) when comparing a six-
month interval between doses to a 12-month interval.
The evidence about serious adverse events was considered to be
of very low-certainty, due to imprecision and indirectness, for com-
parisons of a two-month (14/240) versus a six-month (16/241) in-
terval (1 study; 481 participants; Analysis 2.4) (Romanowski 2011),
and of a six-month (20/550) versus a 12-month (24/415) interval
(1 study; 965 participants; Analysis 2.4) (Puthanakit 2016). The ev-
idence about serious adverse events was also considered to be of
very low-certainty for the comparison of an interval of six months
(15/602) versus 12 months (6/301) between doses of the nonavalent
vaccine (1 study; 903 participants; Analysis 2.4) (Iversen 2016). The
Iversen 2016 study reported on serious adverse events in males and
females, but disaggregated data were not available by sex (Table
2). One of the reported serious adverse events (one case of systemic
lupus erythematosus) in the 12-month interval group (Puthanakit
2016), was considered by the study investigators to be related to
the vaccine and was the only withdrawal from the studies because
of adverse events. No deaths were reported in any of the included
trials (Analysis 2.5).
3. Longer interval versus shorter interval between second and
third doses of quadrivalent HPV vaccine in 18- to 25-year-old
males
The results for this comparison are presented in Appendix 7. We in-
cluded one study that compared three doses of quadrivalent HPV
vaccine with a longer interval between the second and third dos-
es (doses administered at months 0, 2, and 12) against a shorter in-
terval between the second and third doses (doses administered at
months 0, 2, and 6) (Lin 2014). For the immunogenicity outcomes
(Appendix 8), there was evidence of higher GMTs for HPV 11 with
the longer interval schedule compared with the shorter schedule at
one month (2 to 6 weeks test window allowed) after the last dose.
For GMTs for HPV 6, 16, and 18, there was evidence of little to no dif-
ference between groups. The study did not collect data about clin-
ical outcomes.
This study reported local, general, and serious adverse events. No
usable data were available for analysis of local and general adverse
events so we summarised the results in Analysis 3.1. Briefly, among
all study participants 172 local and general reactions were report-
ed. The authors reported no significant difference between groups
(P = 0.26). No serious adverse events were reported (120 partici-
pants; Analysis 3.2).
4. HPV vaccines versus control in 10- to 26-year-old males
The results for this comparison are presented in Summary of find-
ings 3. Two studies compared quadrivalent HPV vaccine with con-
trol (vaccine adjuvant only) (three doses administered at months
0, 2, and 6) in males (Giuliano 2011, NCT01862874 2018), and two
studies compared bivalent vaccine with HBV vaccine (Lehtinen
2018; Petaja 2009). Lehtinen 2018, a cluster-randomised trial, was
designed to investigate direct and indirect effects of vaccinating
boys and girls (gender-neutral) compared with girls-only HPV vac-
cination. They reported that gender-neutral vaccination was asso-
ciated with herd effects and cross-protection against a number of
non-vaccine HPV types. Clinical outcomes in girls are presented in
another Cochrane Review (Arbyn 2018), which covers comparison
of bivalent and quadrivalent HPV vaccine with a control HBV vac-
cine in females; no clinical outcomes in boys were reported.
One study reported clinical outcomes at a median of 2.9 years
(Giuliano 2011). There were fewer outcomes of external genital
lesions (any genotype) (rate ratio 0.16, 95% CI 0.07 to 0.38; 1
study; 2545 participants; 6254 person-years; moderate-certainty
evidence; Analysis 4.1), external genital lesions (HPV 6, 11, 16, 18)
(rate ratio 0.10, 95% CI 0.03 to 0.31; 1 study; 2805 participants; 5643
person-years; Analysis 4.2), and anogenital warts (rate ratio 0.11,
95% CI 0.03 to 0.38; 1 study; 2805 participants; 5645 person-years;
moderate-certainty evidence; Analysis 4.3) with the quadrivalent
HPV vaccine than the control, in both intention-to-treat and per-
protocol analyses (per-protocol analyses not shown). There was ev-
idence in favour of quadrivalent HPV vaccine for the outcomes of all
penile, perianal, or perineal intraepithelial neoplasia (PIN) lesions
(rate ratio 0.17, 95% CI 0.01 to 3.27; 1 study; 2805 participants; 5657
person-years; Analysis 4.4), PIN grade 1 (rate ratio 0.25, 95% CI 0.01
to 6.22; 1 study; 2805 participants; 5659 person-years; Analysis 4.5),
or PIN grade 2 or 3 (rate ratio 0.50, 95% CI 0.02 to 14.80; 1 study; 2805
participants; 5658 person-years; Analysis 4.6), with confidence in-
tervals that included the possibility of both fewer and more events
with the quadrivalent vaccine (low-certainty evidence for all out-
comes).
In the quadrivalent vaccine group, there were more overall local/in-
jection site adverse events than with the control (RR 1.12, 95% CI
1.06 to 1.18; 1 study; 3895 participants; high-certainty evidence;
Analysis 4.7); the events included pain at injection site (RR 1.13, 95%
CI 1.07 to 1.19; 2 studies; 5162 participants; Analysis 4.8), swelling
at injection site (RR 1.29, 95% CI 1.04 to 1.60; 2 studies; 5162 par-
ticipants; Analysis 4.9), and redness at injection site (RR 1.12, 95%
CI 0.99 to 1.27; 2 studies; 5162 participants; Analysis 4.10). There
was little to no difference in overall systemic events and gener-
al symptoms (RR 0.99, 95% CI 0.90 to 1.08; 2 studies; 5008 partic-
ipants; moderate-certainty evidence; Analysis 4.11) at 15-day fol-
low-up. The bivalent HPV vaccine resulted in more pain (RR 1.99,
95% CI 1.57 to 2.53; 1 study; 268 participants; Analysis 4.8), swelling
(RR 2.51, 95% CI 1.17 to 5.42; 1 study; 268 participants; Analysis
4.9), and redness (RR 1.66, 95% CI 0.99 to 2.79; 1 study; 268 par-
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ticipants; Analysis 4.10) at the injection site than the HBV vaccine
(Petaja 2009).
Evidence about serious adverse events in the Giuliano 2011 study
was of very low-certainty due to imprecision and indirectness
(8/2574 participants (0.3%) in the quadrivalent vaccine group and
12/2588 participants (0.5%) in the control group; 2 studies; Analysis
4.12). None of the reported serious adverse events was considered
by the study investigators to be vaccine-related. Two participants
from the quadrivalent group and seven participants from the con-
trol group discontinued participation in the studies because of ad-
verse events. There were fewer deaths in the group that received
quadrivalent vaccine (3 deaths in quadrivalent group; 11 deaths
in control group), but confidence intervals for the difference were
compatible with no effect (OR 0.30, 95% CI 0.09 to 1.01; 2 stud-
ies; 5173 participants; low-certainty evidence; Analysis 4.13) at up
to three years of follow-up (Giuliano 2011). Lehtinen 2018 report-
ed on serious adverse events for a selected subset of males (da-
ta not shown). FiMy-eight of the 2436 subset participants (2.4%)
who received the HPV vaccine and 25/1267 subset participants
(2.0%) who received the control HBV vaccine experienced serious
adverse events (very low-certainty evidence). The investigators re-
ported that four serious adverse events among the males who re-
ceived the HPV vaccine (abdominal pain, ulcerative colitis, type 1
diabetes mellitus, juvenile idiopathic arthritis) could possibly be
vaccine-related and one event among the males who received the
control (type 1 diabetes mellitus) could possibly be vaccine-relat-
ed. In the study on bivalent vaccine (Petaja 2009), three serious ad-
verse events were reported in the bivalent vaccine group (3/181)
and one in the control group (1/89) (Analysis 4.12; very low-certain-
ty evidence). The study investigators did not consider these to be
related to the vaccine, and no deaths were reported in either group.
For the secondary outcome of persistent HPV infection, there was
evidence that quadrivalent HPV vaccine reduced persistent infec-
tion caused by HPV 6, 11, 16 or 18 combined, or by each HPV geno-
type individually, in 16- to 26-year-old males compared with con-
trol (Appendix 9).
The Giuliano 2011 study also reported immunogenicity outcomes
(data not shown). Briefly, there was evidence that quadrivalent vac-
cine increased GMTs for HPV 6, 11, 16 and 18 when compared with
control at 7, 24 and 36 months. There was a trend towards GMTs
levelling o+ after reaching a peak at month seven. Comparative da-
ta between quadrivalent vaccine and control were not available for
the seropositivity outcomes (control group data not reported), but
seropositivity for HPV 6, 11, 16 and 18 at seven months was above
97%. Petaja 2009 also reported immunogenicity outcomes seven
months after the first dose of bivalent vaccine were higher than the
HBV vaccine (Appendix 10).
5. Nonavalent HPV vaccine versus quadrivalent HPV vaccine in
9- to 26-year-old females and males
The results of this comparison are presented in Summary of find-
ings 4. We included three RCTs that compared nonavalent with
quadrivalent HPV vaccine (three doses administered at months 0, 2,
and 6): two in females (Joura 2015; Vesikari 2015), and one in males
(van Damme 2016). The Joura 2015 study collected data on clinical
outcomes in females at up to 4.5 years follow-up. All three trials re-
ported adverse event outcomes throughout the study period and
immunogenicity outcomes at seven months for all vaccine types.
We did not identify any studies that collected data about clinical
outcomes in males.
In females there was little to no difference between nonavalent and
quadrivalent HPV vaccines in the incidence of the combined out-
come of high-grade cervical epithelial neoplasia, adenocarcinoma
in situ, or cervical cancer (OR 1.00, 95% CI 0.85 to 1.16; 1 study;
13,753 participants; high-certainty evidence; Analysis 5.1), or high-
grade cervical, vulval, or vaginal disease (OR 0.99, 95% CI 0.85 to
1.15; 1 study; 14,054 participants; high-certainty evidence; Analysis
5.2) at up to 4.5 years follow-up. For high grade cervical disease re-
lated to HPV 31, 33, 45, 52, or 58 (i.e. genotypes covered by the non-
avalent vaccine but not the quadrivalent vaccine), the effect was
in favour of the nonavalent vaccine (OR 0.03, 95% CI 0.00 to 0.21; 1
study; 11,892 participants; Analysis 5.5), but few cases were report-
ed (1/5949 women in the nonavalent vaccine group and 35/5943
women in the quadrivalent vaccine group).
Nonavalent HPV vaccine resulted in slightly more local/injection
site adverse events than the quadrivalent vaccine (RR 1.07, 95%
CI 1.05 to 1.08; 3 studies; 15,863 participants; high-certainty ev-
idence; Analysis 5.11). There was little to no difference between
the vaccines for overall systemic events and general symptoms at
15-day follow-up (RR 1.01, 95% CI 0.98 to 1.04; 3 studies; 15,863
participants; moderate-certainty evidence, Analysis 5.15). For seri-
ous adverse events overall, the evidence was considered to be of
low-certainty due to imprecision and indirectness (OR 0.60, 95% CI
0.14 to 2.61; 3 studies; 15,863 participants; I2 = 51%; Analysis 5.16).
One study reported similar numbers of events (1/299 with the non-
avalent vaccine, 2/300 with the quadrivalent vaccine) in females
aged 9 to 15 years over a period of 7 months follow-up (Vesikari
2015). In males, there were no events in 249 participants receiv-
ing the nonavalent vaccine and 6/251 with the quadrivalent vac-
cine over a period of 7 months follow-up (van Damme 2016). In
the largest study, in 16- to 26-year-old females, 3.1% (242/7686) of
those who received the nonavalent vaccine and 2.6% (184/7078) of
those who received the quadrivalent vaccine experienced any seri-
ous adverse event after up to 4.5 years of follow-up (Joura 2015).
No serious adverse events, when analysed by system organ class,
were more common with the nonavalent than with the quadriva-
lent vaccine. The study authors examined 2269 pregnancy-relat-
ed events in 2321 women and found no differences between the
nonavalent and quadrivalent vaccine arms. The study investigators
considered seven serious adverse events to be related to the vac-
cines, four in the nonavalent group (allergic reaction; fever, body
pain, and headache; hypersomnia; postural orthostatic tachycar-
dia syndrome) and three in the quadrivalent group (headache;
paraesthesia and burning sensation; orthostatic intolerance). Thir-
teen participants who received nonavalent vaccine and six who
received quadrivalent vaccine discontinued participation because
of adverse events. There was little to no difference in the number
of deaths between nonavalent (6/7370) and quadrivalent (5/7378)
HPV vaccine groups (OR 1.20, 95% CI 0.37 to 3.94; 2 studies; 15,248
participants; low-certainty evidence; Analysis 5.17) at up to 4.5
years follow-up. The study investigators considered none of the
deaths reported to be related to the vaccine.
Secondary outcomes (persistent infection and immunogenicity)
are presented in Appendix 11 and Appendix 12. Briefly, there was
evidence of decreased rates of persistent infection with HPV 31, 33,
45, 52, and 58 at six and 12 months with nonavalent vaccine com-
pared with quadrivalent vaccine (Joura 2015). There was little to no
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difference in immunogenicity between the nonavalent and quadri-
valent HPV vaccines and GMTs were non-inferior for HPV 6, 11, 16,
and 18 at up to 42 months. The nonavalent HPV vaccine resulted
in substantially higher GMTs for HPV 31, 33, 45, 52, and 58 than the
quadrivalent HPV vaccine. For seroconversion to HPV 6, 11, 16, and
18 up to 24 months follow-up, 100% of participants seroconverted
in both the nonavalent and quadrivalent HPV vaccine groups. The
data for GMTs and seroconversion to HPV 31, 33, 45, 52, and 58 were
not reported in full (Joura 2015; Vesikari 2015).
6. HPV vaccination in HIV-positive females, males and MSM
Seven RCTs reported on the effects of bivalent and quadrivalent
HPV vaccines in females, males, or children living with HIV (Den-
ny 2013; Hidalgo-Tenorio 2017; Levin 2010; NCT00941889 2016;
NCT01031069 2017; ToM 2014; Wilkin 2018). Two of the studies col-
lected data about clinical outcomes such as anal intraepithelial
neoplasia, anogenital warts or persistent infection (NCT00941889
2016; Wilkin 2018). These results are summarised in Table 3; Table
4; and Table 5.
6.1 Quadrivalent HPV vaccine compared with control
6.1.1 Quadrivalent HPV vaccine compared with control in children
living with HIV
Levin 2010 included 7- to 12-year-old girls and boys with HIV. The
study reported immunogenicity outcomes at seven months (Ap-
pendix 13). GMTs for HPV 6, 11, 16 and 18 were 123.8 to 935.8-
fold higher at seven months, and 29.6 to 189.4-fold higher at 24
months, than in the control group (described as 'identical place-
bo', the study did not specify the contents of the placebo) (low-
certainty evidence). Seroconversion for the four HPV genotypes
was over 97% at seven months (low-certainty evidence). Injection
site adverse events were more common with quadrivalent vaccine
(21/96) than control (3/30) (1 study; 126 participants; very low-cer-
tainty evidence; Analysis 6.4). Three systemic adverse events were
reported, two in the quadrivalent group (2/96) and one in the con-
trol group (1/30) (1 study; 126 participants; very low-certainty evi-
dence; Analysis 6.5) at 14-day follow-up (three doses administered
at months 0, 2, and 6). The study did not report on serious adverse
events, but reported that 5/96 (5.2%) children in the quadrivalent
vaccine group and 2/30 (6.7%) children in the control group experi-
enced adverse events of grade 3 or 4 severity (OR 0.77, 95% CI 0.14
to 4.18, analysis not shown).
6.1.2 Quadrivalent HPV vaccine compared with control in MSM living
with HIV
Hidalgo-Tenorio 2017 included HIV-positive MSM of 18 years of age
and above, and compared quadrivalent HPV vaccine with control
(saline placebo) (three doses administered at months 0, 2, and 6).
This trial reported that 76% of the HPV vaccinated participants
were seropositive for at least one of HPV 6, 11, 16, or 18 genotype at
seven months compared with 30.2% in the control group (moder-
ate-certainty evidence; Appendix 13). No serious adverse events (1
study; 129 participants; Analysis 6.6) or deaths (1 study; 129 partic-
ipants; Analysis 6.7) were reported in either group at seven-month
follow-up (Table 3).
6.1.3 Quadrivalent HPV vaccine compared with control in adults living
with HIV
Two studies included HIV-positive males and females of 18 years of
age and above and compared quadrivalent HPV vaccine with con-
trol (saline placebo in NCT00941889 2016 and 'placebo vaccine' in
Wilkin 2018 - the contents of the placebo were not specified). There
was only very low-certainty evidence on high-grade anal intraep-
ithelial neoplasia (46/288 in the quadrivalent group, 45/286 in the
control group; 1 study; Analysis 6.1), recurrence of anogenital warts
in participants treated for anogenital warts (1/7 in the quadrivalent
group, 1/5 in the control group; 1 study; Analysis 6.2), or abnormal
anal cytology (58/130 in the quadrivalent group, 72/132 in the con-
trol group; 1 study; Analysis 6.3). There was limited evidence for se-
rious adverse events (quadrivalent 33/288 events; control 46/287
events; Analysis 6.6) or deaths (quadrivalent 3/288 deaths; control
6/287 deaths; Analysis 6.7) between the groups. The study investi-
gators considered no serious adverse events to be related to vacci-
nation, and no withdrawals from the studies due to adverse events
were reported (Table 3).
6.2 Bivalent HPV vaccine compared with control in females
living with HIV
Denny 2013 included HIV-positive 18- to 25-year-old females and re-
ported that, irrespective of baseline HPV serostatus, all participants
who received the bivalent HPV vaccine were seropositive for both
HPV 16 and HPV 18 after the second vaccine dose (month two), and
remained seropositive at month 12 (moderate-certainty evidence).
Pain at injection site (RR 1.86, 95% CI 1.38 to 2.51; 1 study; 120 par-
ticipants; Analysis 7.1) and swelling at injection site (RR 9.19, 95%
CI 2.24 to 37.73; 1 study; 120 participants; Analysis 7.2) were more
common in the bivalent group than in the control group (vaccine
adjuvant only) at seven-day follow-up. The study reported 3/61 se-
rious adverse events in the bivalent vaccine group and 2/59 events
in the control group (OR 1.47, 95% CI 0.24 to 9.15; 1 study; 120 par-
ticipants; low-certainty evidence; Analysis 7.3). No deaths were re-
ported (Analysis 7.4). The study investigators considered no serious
adverse events to be related to vaccination, and no withdrawals
from the study due to adverse events were reported (Table 4).
6.3 Bivalent HPV vaccine compared with quadrivalent HPV
vaccine
6.3.1 Bivalent HPV vaccine compared with quadrivalent HPV vaccine in
adults living with HIV
ToM 2014 included 92 HIV-positive females and males of 18 years of
age and above, and compared bivalent with quadrivalent HPV vac-
cine (3 doses administered at months 0, 1.5, and 6). There was ev-
idence of no difference, and inconclusive non-inferiority, in GMTs
for HPV 16 between the bivalent and quadrivalent HPV vaccines
at seven- and 12-month follow-up (moderate- to low-certainty evi-
dence; Appendix 13). There was evidence that the quadrivalent vac-
cine was inferior to bivalent vaccine for GMTs for HPV 18 at seven
months (ratio of GMTs 0.13, 95% CI 0.04 to 0.41; moderate-certainty
evidence). Injection site reactions were more common in the biva-
lent group than in the quadrivalent group (RR 1.31, 95% CI 1.06 to
1.62; 1 study; 92 participants; low-certainty evidence; Analysis 8.1)
at four-day follow-up. No serious adverse events at six-month fol-
low-up were reported (Analysis 8.2; Table 5).
6.3.2 Bivalent HPV vaccine compared with quadrivalent HPV vaccine in
15- to 25-year-old females living with HIV
One study reported on serious adverse events in 15- to 25-year-
old females with HIV who were randomised to receive bivalent or
quadrivalent HPV vaccine (NCT01031069 2017). Data for this study
were only available through the clinical trials registry, so full de-
tails on the methods and other outcome measures were not avail-
able. There were nine serious adverse events in 167 female partic-
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ipants with HIV in the bivalent vaccine group and nine in 165 par-
ticipants in the quadrivalent group (1 study; 332 participants; very
low-certainty evidence; Analysis 8.2; Table 5). One participant in
the quadrivalent group withdrew due to an adverse event. One se-
rious adverse event (immune thrombocytopenic purpura) was con-
sidered by study investigators to be related to the bivalent HPV vac-
cine.
Sensitivity analysis
We compared the results from the primary analysis with a sensitiv-
ity analysis using Peto odds ratios for outcomes with very low event
rates (< 1%; Bradburn 2007). This did not change the size of effect
for most of the analyses, with the exception of some clinical out-
comes in the comparison of nonavalent HPV vaccine versus quadri-
valent HPV vaccine in 9- to 26-year-old females (Appendix 14).
Changes were seen in the effect sizes and 95% CIs for the following
outcomes:
• high-grade cervical disease related to HPV 31, 33, 45, 52, or 58
(Analysis 5.5) changed from OR 0.03 (0.00 to 0.21) to Peto OR 0.15
(0.08 to 0.29) (Appendix 14);• cervical intraepithelial neoplasia 2 (CIN2) related to HPV 6, 11,
16, or 18 (Analysis 5.7) changed from OR 3.00 (0.12 to 73.77) to
Peto OR 7.40 (0.15 to 373.90) (Appendix 14);• CIN2 related to HPV 31, 33, 45, 52, or 58 (Analysis 5.8) changed
from OR 0.03 (0.00 to 0.23) to Peto OR 0.15 (0.08 to 0.30) (Appen-
dix 14);• CIN3, adenocarcinoma in situ, and cervical cancer related to
HPV 6, 11, 16, or 18 (Analysis 5.9) changed from OR 0.33 (0.01 to
8.19) to Peto OR 0.14 (0.00 to 6.83) (Appendix 14);• CIN3, adenocarcinoma in situ, and cervical cancer related to
HPV 31, 33, 45, 52, or 58 (Analysis 5.10) changed from OR 0.07
(0.00 to 1.16) to Peto OR 0.14 (0.03 to 0.59) (Appendix 14).
D I S C U S S I O N
This review reports on evidence about the efficacy, immunogenic-
ity, and adverse events following reduced dose or alternative vac-
cine schedules in females and males, HPV vaccination compared to
control for males, and effects of HPV vaccines in people with HIV
infection.
Summary of main results
Immunogenicity, eicacy and adverse events with fewer than
three doses of HPV vaccine in females
In adolescent girls (9 to 15 years) a two-dose schedule was non-in-
ferior to a three-dose schedule of any HPV vaccine. There was some
evidence that GMTs decrease over time following both two-dose
and three-dose schedules, and that a two-dose schedule is non-in-
ferior to a three-dose schedule after five years. There was no differ-
ence in seroconversion between two-dose and three-dose sched-
ules at all time points reported; almost all participants serocon-
verted in both intervention groups. We identified no studies that
collected data about efficacy against clinical outcomes. There was
very low-certainty evidence of little to no difference in serious ad-
verse events or deaths between dose schedules. No RCTs that eval-
uated the efficacy or harms of one dose of HPV vaccine were iden-
tified.
Immunogenicity, eicacy and adverse events with dierent
intervals between doses of HPV vaccine in females and males
In both females and males, for all HPV vaccines evaluated, a sched-
ule with a longer interval between doses resulted in higher GMTs
than a shorter interval. There was very low certainty evidence on
the comparative risk of serious adverse events with different inter-
vals between two-doses of HPV vaccine, owing to the very low num-
ber of events and indirectness. Results from single studies were
consistent with lower or higher rates of serious adverse events with
the different intervals tested in the studies.
Eicacy, immunogenicity and adverse events with HPV
vaccines in males
Three doses of quadrivalent HPV vaccine reduced the incidence of
external genital lesions, anogenital warts, and persistent infection
by HPV 6, 11, 16 or 18 compared with control among 16- to 26-year-
old males over a median follow-up of 2.9 years (moderate-certainty
evidence). The quadrivalent vaccine resulted in more injection-site
adverse events, such as pain or redness, than control (high-certain-
ty evidence). There was very low certainty evidence on the compar-
ative risk of serious adverse events and low certainty evidence on
the comparative risk of deaths between quadrivalent vaccine and
control among 10- to 26-year old males. Limited data were avail-
able regarding the efficacy and adverse events with bivalent HPV
vaccine in males. We identified no RCTs that evaluated the efficacy
of nonavalent vaccine compared with control in males.
Eicacy, immunogenicity and adverse events with the
nonavalent HPV vaccine compared with other HPV vaccines in
females and males
Among 16- to 26-year-old women, three doses of nonavalent vac-
cine or of quadrivalent vaccine resulted in a similar incidence of
clinical outcomes regardless of HPV genotype at up to 4.5-year fol-
low-up (one RCT, high certainty evidence). The nonavalent vaccine
resulted in reduced incidence of persistent HPV infections, CIN1,
CIN 2/3, vulval or vaginal intraepithelial neoplasia (grade 1) relat-
ed to the HPV genotypes unique to the nonavalent vaccine (HPV
31, 33, 45, 52, and 58) compared with the quadrivalent vaccine. Im-
munogenicity outcomes for nonavalent and quadrivalent HPV vac-
cines were similar for males and females. There was high-certainty
evidence that the nonavalent vaccine resulted in slightly more lo-
cal or injection site events but little to no difference in overall sys-
temic events. The evidence comparing serious adverse events was
of low-certainty. There was low-certainty evidence of no difference
in mortality between these vaccines. There were few vaccine-relat-
ed serious adverse events reported (seven participants in total) in
the included studies.
Eicacy, immunogenicity and adverse events with HPV
vaccines in people living with HIV
In children living with HIV, the quadrivalent HPV vaccine results in
higher GMTs than control at seven months, but there was only very
low-certainty evidence about local or systemic adverse events. In
adults living with HIV, the evidence about clinical outcomes and
harms of quadrivalent HPV vaccine compared with control or oth-
er HPV vaccines, was of very low-certainty. One RCT in adults living
with HIV reported that the bivalent vaccine had similar immuno-
genicity outcomes for HPV 16 to the quadrivalent vaccine, but re-
sulted in higher GMTs and greater rate of seroconversion to HPV 18.
Comparison of dierent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females
and males (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
29
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Overall completeness and applicability of evidence
This review collated evidence about the efficacy - in terms of clini-
cal and immunological endpoints - and harms of different HPV vac-
cines and different dose schedules in females and males. The infor-
mation sources searched include electronic databases, websites of
the vaccine manufacturers, and a published index of HPV studies
(Jørgensen 2018a), so the level of completeness is high. The applic-
ability of the evidence to determine clinical efficacy and harms is,
however, limited by the nature of HPV-related disease, as well as
the design and outcomes of the studies. The evidence from RCTs
about efficacy against severe HPV-related disease, including can-
cer, is limited for three main reasons. First, it is unethical to collect
specimens from the cervix of girls who have not had sexual inter-
course. Second, few severe clinical outcome events related to HPV
infection occur during the study follow-up periods because they
take a number of years to develop following HPV infection. Third,
trial participants are offered treatment when HPV-related precan-
cer is found, so progression to cervical cancer would be expected
to be very low, even without vaccination.
The focus of this review was on clinical outcomes and harms. Im-
munogenicity is the primary outcome for many trials of alterna-
tive HPV vaccine schedules, however, as noted in the Background,
randomised efficacy trials of HPV vaccines were first conducted in
women aged 15 to 25 or 26 years (Arbyn 2018). Once efficacy, im-
munogenicity and safety were established in this age group, non-
randomised bridging studies assessed non-inferiority of immuno-
genicity outcomes in 9- to 15-year-old girls (e.g. Block 2006, Dob-
son 2013). The International Agency for Research on Cancer regards
bridging studies that demonstrate non-inferiority as a sufficient
endpoint for individuals under 16 years of age (IARC 2014). Bridging
studies have also demonstrated non-inferiority of immunogenicity
outcomes of a two-dose schedule in boys aged 9- to 14-years com-
pared to three doses in young women aged 15 to 26 years (Iversen
2016). Use of immunogenicity outcomes has limitations because
the immunological correlate of protection and the duration of pro-
tection remain unknown (Donken 2015). These studies provide low-
er certainty of evidence, because estimates of clinical outcomes are
imprecise and indirect.
The nonavalent HPV vaccine was introduced more recently than
the bivalent and quadrivalent HPV vaccines. This review included
all studies that compared the nonavalent HPV vaccine with oth-
er HPV vaccines; two RCTs were identified in females (Joura 2015;
Vesikari 2015), and one in males (van Damme 2016). A separate
Cochrane Review of completed RCTs of three-dose schedules with
bivalent and quadrivalent HPV vaccines in women aged 16 to 26
years shows protection against lesions of grade CIN3, but not in-
vasive cervical cancer (Arbyn 2018). Further comparisons between
the different HPV vaccines in women will be included in an update
of the Arbyn 2018 review. Observational studies in countries that
have licensed more than one HPV vaccine will also provide impor-
tant information on the comparative efficacy and harms of the dif-
ferent HPV vaccines.
With regard to serious adverse events, there is a large degree of
uncertainty in the evidence comparing different HPV vaccines and
different dose schedules. The 'Summary of findings' tables show
low numbers of serious adverse events and deaths in most includ-
ed studies. Even when the total number of events is high (e.g. Joura
2015), specific events of clinical relevance are still too rare for mean-
ingful comparative analyses. In this review, we used a composite
outcome, that is, the overall frequency of serious adverse events,
for each comparison, however, analyses based on a composite out-
come can produce results that are difficult to interpret for sever-
al reasons. This outcome can include events that are not clinical-
ly relevant or are not biologically related to the vaccine (Lineber-
ry 2016), occur outside a plausible time frame relative to vaccine
exposure (Huang 2011), or are not based on standardised defini-
tions (Bonhoeffer 2002). In addition, trials measure serious adverse
events at different time points and there is a large variation in du-
ration of follow-up, which could produce misleading summary es-
timates (Huang 2011). Finally, there is heterogeneity among trials
with regard to the age and gender of participants and clinical mea-
surements of serious adverse events (Appendix 4). Meta-analyses
of serious adverse events, such as those presented in this review,
should be considered exploratory rather than confirmatory as the
analyses are not planned in advance (i.e. when the included stud-
ies were designed) (Huang 2011). Despite the uncertainty in the ev-
idence about harms when comparing different HPV vaccines and
dose schedules, a previous systematic review reported similar rates
of serious adverse events when HPV vaccines were compared to
control (Arbyn 2018).
Quality of the evidence
The risk of bias of the included studies in this review is generally
low. We rated studies that received funding from the vaccine man-
ufacturer as 'unclear' for the 'other risk of bias' domain. This judge-
ment was based on the results of a systematic review which showed
more favourable efficacy results and conclusions in studies spon-
sored by manufacturing companies (Lundh 2017). It has been sug-
gested that industry sponsorship of studies results in overly posi-
tive results through a variety of choices in the design and conduct
of the trials that leads to bias. Based on the low risk of bias in other
methodological domains and adequate reporting in the trials, we
did not downgrade the certainty of the evidence using GRADE for
this factor. In accordance with Higgins 2017, information on indus-
try sponsorship and other funding sources is captured in the Char-
acteristics of included studies tables.
In studies where participants received a control injection - specifi-
cally for the comparisons of HPV vaccines with control in males and
people living with HIV, and different interval schedules - many of
the included studies used an adjuvant (either aluminium hydrox-
ide or another aluminium compound) as the control rather than
a 'true' placebo (NCT00941889 2016 used a saline placebo; Levin
2010 and Wilkin 2018 did not specify the type of placebo). Alumini-
um adjuvants have been used in vaccines for many years as they
are thought to enhance the immune response (HogenEsch 2018),
but their suitability as control vaccines in RCTs has been ques-
tioned (Jørgensen 2018b). A previous systematic review found no
evidence that aluminium adjuvants in diptheria, tetanus, and per-
tussis vaccines cause any serious or long-lasting adverse events
(Jefferson 2004). The rate of serious adverse events was low for
both vaccine and control groups in the studies included in the cur-
rent review. However, the benefits and harms of aluminium-con-
taining adjuvants are being further assessed in a Cochrane Review
(Djurisic 2017), and research is underway to determine how suit-
able they are as control vaccines for RCTs.
For a number of outcomes presented in the 'Summary of findings'
tables, especially serious adverse events and deaths, we down-
graded the certainty of the evidence for imprecision. In most cas-
es the sample size of the included RCTs was too small to be able
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to detect an effect between groups for these outcomes - especially
for rare outcomes such as death. This is another limitation of RCTs
in determining the harms associated with HPV vaccines, and lends
further weight to the future use of large observational studies. We
also downgraded the evidence on serious adverse events for indi-
rectness because of the limitations to the use of a composite out-
come measure of events, as described in the section on applicabil-
ity.
Potential biases in the review process
We made great efforts to identify relevant published and unpub-
lished data, through a sensitive electronic database search and
screening of vaccine manufacturer websites. By linking clinical
trial registry entries with published database searches, and by
cross-checking the studies included and excluded from our review
against a published index of HPV studies (Jørgensen 2018a), we at-
tempted to minimise the risk of missed studies, though relevant da-
ta may remain unregistered or unpublished (Jørgensen 2018a).
We used a priori categories of common adverse events - such as
pain or swelling at the injection site - or important outcomes such
as serious adverse events and deaths when extracting data from
included studies. This method of data extraction could have been
limited by the reporting in the included studies, as composite out-
comes, such as 'overall injection site/local adverse events', could
not be calculated by reports of all events within the study popula-
tions. The range of different adverse events reported in the includ-
ed studies, as well as the range of methods used to assess these in
the studies, makes it unfeasible to extract all adverse events for the
purpose of meta-analysis.
We analysed and reported on all serious adverse events in the in-
cluded studies. Serious adverse events are any events that result in
hospitalisation and life-threatening illness. This means that any se-
rious injury or illness is included, even if it is unlikely to be related to
the vaccine. We also reported on results and attribution methods
used to determine whether serious adverse events were related to
the vaccine. We did not analyse these results or report them in the
‘Summary of findings’ tables because attribution methods were ei-
ther not transparent, or not independent of the study investigators
(Appendix 4). These results are reported narratively in the Effects of
interventions section.
We restricted the sensitivity analysis of very rare events to alter-
native statistical methods available in Review Manager 5 software.
We applied a sensitivity analysis to a number of outcomes where
there were studies with zero events in both arms, but they did not
contribute information when either method was used. It is possible
that other methods could yield different results where there are ze-
ro events in both trial arms (Sharma 2017).
Agreements and disagreements with other studies or
reviews
The results of this systematic review are in agreement with oth-
er published reviews on the efficacy of fewer than three doses of
HPV vaccine (D'Addario 2017; Markowitz 2018). The current review
aimed to provide further information on clinical outcomes and ad-
verse events. This review provides evidence about other compar-
isons, such as vaccination of boys and comparisons across types of
HPV vaccine, which have not previously been assessed.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
In general, the bivalent, quadrivalent and nonavalent human pa-
pillomavirus (HPV) vaccines appear to be efficacious in eliciting im-
munogenic responses in both males and females for the targeted
HPV genotypes and, typically, conversion to seropositivity is almost
100% amongst recipients. A two-dose HPV vaccination schedule is
simpler to administer than a three-dose schedule. Immunogenic-
ity data show non-inferior results for a two-dose when compared
with a three-dose schedule of bivalent, quadrivalent and nonava-
lent HPV vaccine. The World Health Organization (WHO) strategic
advisory group of experts on vaccination recommends a two-dose
schedule with at least six months between the first and second
dose, irrespective of sex, if the first dose is given before 15 years of
age (WHO 2017). In practice, 65 countries worldwide have adopted
two-dose HPV vaccination schedules for girls, as of 31 December
2017. Amongst high-income countries that recommend HPV vacci-
nation for boys, Australia, Switzerland and the USA recommend a
two-dose schedule. Given the decision of the International Agency
for Research on Cancer that immunogenicity is a surrogate end-
point for individuals under 16 years of age, randomised controlled
trials (RCTs) with clinical endpoints in this age group are unlikely.
For males, including men who have sex with men (MSM), the quadri-
valent HPV vaccine probably reduces the incidence of external gen-
ital lesions and anogenital warts (condylomata acuminata) com-
pared with control. There were slightly more injection-site adverse
events with the quadrivalent vaccine compared to control, but in-
sufficient evidence to determine the effects of HPV vaccine on seri-
ous adverse events or deaths when compared with control.
The nonavalent vaccine and quadrivalent vaccines offer similar
protection levels against cervical, vaginal, and vulval precancer le-
sions and cancer in young women and similar levels of immuno-
genicity for the four HPV genotypes included in both vaccines in
females and males. For high-grade disease related to HPV 31, 33,
45, 52, or 58 (i.e. those genotypes covered by the nonavalent vac-
cine and not the quadrivalent vaccine) in women, the effect favours
the nonavalent vaccine. No studies that compared nonavalent and
quadrivalent HPV vaccines reported on clinical outcomes in males.
The nonavalent vaccine was associated with an increase in local ad-
verse events compared to the quadrivalent vaccine. Comparative
evidence about serious adverse events was limited by imprecision
and indirectness. Most of the evidence for this comparison comes
from the 16 to 26 year-old age group in females, and there are far
fewer data for younger females and males.
Evidence about the efficacy and harms of HPV vaccines in people
living with HIV is limited because very few trials measured clini-
cal outcomes. In children living with HIV, quadrivalent HPV vaccine
probably results in higher GMTs than control at seven months. In
adults living with HIV the evidence about clinical outcomes and
harms of quadrivalent HPV vaccine, compared with control or oth-
er HPV vaccines, was of very low-certainty. The duration of protec-
tion of HPV vaccines in people with HIV infection and the effect of
declining immunity on protection are unknown.
We identified no studies for any new HPV vaccines in phase 2 or 3
development that plan to report on the comparisons of interest in
this review.
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Implications for research
Further long-term post-licensure studies are needed to determine
the duration of protection of one-dose and two-dose schedules,
as well as the efficacy against HPV-related cancer endpoints in
women, men, MSM, and people with HIV infection. RCTs of the ef-
fects of virus-like particle HPV vaccines on cervical and anal can-
cer are likely to study surrogate endpoints such as immunogenicity
and persistent HPV infection. For vulval and vaginal cancer, clinical
disease is still recommended as an endpoint because of insufficient
knowledge about persistent infection (IARC 2014). The natural his-
tory of HPV-associated oropharyngeal cancer is even less well un-
derstood. RCTs of the effects of HPV vaccines will be needed, but
might rely on persistent HPV infection as an outcome. The elucida-
tion of the immune correlate of protection for HPV vaccines would
be extremely valuable.
Further RCTs to compare different vaccine schedules are needed to
determine the most cost-effective strategy to reduce the incidence
of persistent HPV infection and related cancers. Evidence about the
effectiveness of a two-dose HPV vaccine schedule on clinical HPV-
related disease still relies on non-randomised comparisons of RCTs
(Kreimer 2015; Sankaranarayanan 2016), and on data from nation-
al immunisation programmes (Markowitz 2018). These studies pro-
vide essential ongoing data, but cannot fully overcome confound-
ing effects of differences between groups that receive a certain
number of doses. In immunisation programme data in particular,
those receiving two doses as part of a three-dose schedule might
only have received the first two doses with a one or two month gap
and might be beyond the recommended age for vaccination. In this
situation, these studies might actually underestimate the effective-
ness of a recommended two-dose schedule with at least six months
between doses (Markowitz 2018).
An RCT that commenced in August 2018 will provide informa-
tion about the non-inferiority of one and two doses of biva-
lent and nonavalent HPV vaccines against incident HPV genotype
16/18 infections that persist for six months or more in young
women (NCT03180034). In addition, long-term surveillance and
registry-based studies, such as linking vaccination databases with
disease- and population-based registries, are needed to establish
vaccine effectiveness and harms over time.
This review included a wide range of comparisons of alternative
HPV vaccine schedules. In future, studies of the efficacy of differ-
ent types of HPV vaccine, studies of alternative dose schedules, and
studies of the effectiveness of HPV vaccines in people living with
HIV infection could be examined in separate systematic reviews.
This review has highlighted the limitations of data about harms col-
lected in RCTs, especially imprecision, owing to the low frequen-
cy of serious adverse events. Longer-term follow-up is needed to
investigate links with specific adverse events, such as new chron-
ic diseases or adverse pregnancy outcomes. Post-marketing sur-
veillance allows continued monitoring and reports events follow-
ing HPV vaccination in the population beyond the duration of fol-
low-up in RCTs. Surveillance studies of large registry-based data
from real-world vaccination programmes can also provide more
precise estimates of the incidence of specific adverse events and
investigate prespecified hypotheses. In these studies, attribution of
whether serious adverse events and deaths are related to the vac-
cine can be performed independently of study investigators and
potential conflicts of interest. Future updates of this review will in-
clude observational long-term post-licensure studies to allow more
detailed investigation of specific harms associated with HPV vac-
cines, long-term data on the effectiveness of HPV vaccines, and the
value of different dose schedules in increasing vaccine coverage.
Future reviews should also consider the synthesis of evidence from
vaccination programmes in the context of gender-neutral HPV vac-
cination, where consideration of indirect effects of HPV vaccination
is needed to provide more relevant estimates of vaccine effective-
ness for public health stakeholders.
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Methods Phase I/II, partially-blind, partially-randomised, placebo-controlled trial
Participants Participants: 120 HIV-positive women (61 in bivalent vaccine group and 59 in control group) in South
Africa
Age range: 18–25 years
Inclusion criteria: women with an intact cervix who reported no more than 6 lifetime sexual partners
and whom the investigator believed would comply with the protocol requirements. Sexually active
Denny 2013 
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women had to have a normal colposcopy and normal cervical cytology or no worse than atypical squa-
mous cells of undetermined significance at the screening visit. All women had to be willing to undergo
HIV counselling and testing and to be informed of their HIV status.
Interventions Vaccine: bivalent HPV vaccine; 3 doses: day 0, month 1, month 6
Control: aluminium adjuvant placebo (aluminium hydroxide (Al(OH)3)); 3 doses: day 0, month 1, month
6
Outcomes Harms: adverse events
Immunogenicity: GMT, seroconversion
Notes Other groups: 30 HIV-negative women were enrolled as a control group and received bivalent HPV vac-
cine
Last report average follow-up time: 12 months
Funding: GlaxoSmithKline Biologicals SA. The study sponsor designed the study in collaboration with
the investigators, and co-ordinated collection, analysis, and interpretation of data.
Trial ID: NCT00586339.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Centralised, Internet-based randomisation system
Allocation concealment
(selection bias)
Low risk Centralised, Internet-based randomisation system
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Participants were blinded to allocation. No clear statement presented regard-
ing blinding of personnel or outcome assessors.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Participants were blinded to allocation. No clear statement presented regard-
ing blinding of personnel or outcome assessors.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Most analysis per protocol, but baseline data on full cohort provided, data on
withdrawals and reasons for withdrawing also provided.
Selective reporting (re-
porting bias)
Low risk No reasons to suspect that reporting was selective. Clinical trial record
checked.
Other bias Unclear risk Trial funded by vaccine manufacturer.
Denny 2013  (Continued)
 
 
Methods Phase III, open-label, non-inferiority, controlled, randomised, multi-centre trial
Participants Participants: 520 women and young girls (259 to 2-dose quadrivalent HPV vaccine and 261 to 3-dose
quadrivalent HPV vaccine) recruited from 3 Canadian provincial centres
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Age range: girls aged 9-13 years, young women aged 16-26 years
Inclusion criteria: healthy participants 9-13 years of age (girls) or 16-26 years of age (young women),
with 4 or fewer lifetime sexual partners
Interventions Vaccine 1: quadrivalent HPV vaccine; 2 doses: day 1, month 6
Vaccine 2: quadrivalent HPV vaccine; 3 doses: day 1, month 2, month 6
Outcomes Harms: adverse events
Immunogenicity: GMT, seroconversion
Notes Other groups: in our analyses we did not include the cohort of 16-26-year-old women that were not ran-
domised within the trial
Last report average follow-up time: 36 months
Funding: Ministries of Health in the provinces of British Columbia, Nova Scotia, and Quebec. Merck Lab-
oratories Inc conducted the antibody assays at no cost to the study.
Merck had no role in the design or conduct of the study; collection, management, analysis, or interpre-
tation of the data; or preparation, review, or approval of the manuscript.
Trial ID: NCT00501137
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Girls were randomised (1:1) in balanced, stratified blocks of 6 to receive either
2 doses (at 0 and 6 months) or 3 doses (at 0, 2, and 6 months). The co-ordinat-
ing centre used SAS, version 9.2 (SAS Institute Inc) to generate randomisation
lists for each site.
Allocation concealment
(selection bias)
Low risk Co-ordinating centre generated randomisation sequence and allocated girls.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Impossible to blind girls as to whether they were randomised to 2 or 3 doses;
the young women were not randomised, all receiving 3 doses.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory sta+, blinded to group assignment, conducted the HPV antibody
assays.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data were reported for both ITT and per protocol populations, with full infor-
mation on exclusions and withdrawals.
Selective reporting (re-
porting bias)
Low risk The primary interest was in the per-protocol population; however, the results
presented were the ITT population because these results could be generalised
more readily.
Other bias Low risk No other bias apparent
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Methods Phase III, double-blind, parallel, placebo-controlled, randomised and multi-site trial
Participants Participants: 4065 boys and men (2032 to the vaccine group and 2033 to the control group) recruited
from 18 countries in five regions (Africa, Asia-Pacific, Europe, Latin America, North America)
Age range: 16-26 years
Inclusion criteria: heterosexual males 16-23 years old with between 1-5 lifetime female sexual partners,
plus males who have sex with male partners 16-26 years old with 1-5 lifetime male or female partners
Interventions Vaccine: quadrivalent HPV vaccine; 3 doses: day 1, month 2, month 6
Control: aluminium adjuvant placebo (amorphous aluminium hydroxy-phosphate sulphate (AAHS)); 3
doses: day 1, month 2, month 6
Outcomes Clinical: external genital lesions; penile, perianal, or perineal intraepithelial neoplasia; or penile, peri-
anal, or perineal cancer
Harms: adverse events, deaths
Immunogenicity: GMT, seroconversion
Notes Other groups: N/A
Last report average follow-up time: 36 months
Funding: Merck, in collaboration with external investigators and an external data and safety monitor-
ing board. The sponsor co-designed the trial, collated the data, monitored the conduct of the trial, per-
formed statistical analyses, and co-ordinated the writing of the manuscript with all the authors.
Trial ID: NCT00090285
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A computer-generated allocation schedule was produced by the sponsor. Fol-
lowing informed consent and determination that all entry criteria were met,
eligible subjects were randomised to a vaccination group. (Hillman 2012, com-
panion paper)
Allocation concealment
(selection bias)
Low risk Following informed consent and determination that all entry criteria were
met, eligible subjects were randomised to a vaccination group. All investi-
gators and site personnel, subjects, monitors, and laboratory personnel re-
mained blinded to treatment allocation throughout the study. Sta+ of the
sponsor were blinded from the study onset through the database lock for this
analysis. (Hillman 2012, companion paper)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "visually indistinguishable AAHS-containing placebo"; All investigators
and site personnel, subjects, monitors, and laboratory personnel remained
blinded to treatment allocation throughout the study. Sta+ of the sponsor
were blinded from the study onset through the database lock for this analysis.
(Hillman 2012)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All biopsy specimens were processed independently to prevent contamina-
tion of HPV DNA and were assessed in a blinded fashion, first for the purpose of
clinical management by pathologists at the central laboratory (Diagnostic Cy-
tology Laboratories) and then for end-point adjudication by a 4-member panel
of pathologists.
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data reported adequately.
Selective reporting (re-
porting bias)
Low risk No reason to suspect that reporting was selective - clinical trial registry
checked.
Other bias Unclear risk Trial funded by vaccine manufacturer.
Giuliano 2011  (Continued)
 
 
Methods Randomised, double blind, placebo-controlled trial
Participants Participants: 129 HIV-positive men who have sex with men (66 received quadrivalent HPV vaccine and
63 received control) recruited from the Infectious Diseases Service in Spain
Age range: ≥18 years of age
Inclusion criteria: participants not infected simultaneously by the 4 genotypes of HPV that the quadri-
valent vaccine addresses; with a normal high-resolution anoscopy at screening for inclusion, or with
only condylomas or low squamous intraepithelial lesion, or both, in anal biopsy.
Interventions Vaccine: quadrivalent HPV vaccine; 3 doses: day 1, month 2, month 6
Control: saline placebo ("water used in the preparation of injectable with <1 mmol of Na"); 3 doses: day
1, month 2, month 6
Outcomes Harms: adverse events, deaths
Notes Other groups: N/A
Last report average follow-up time: 7 months
Funding: Public Health and Social Progress Foundation of the Government of Andalucia [La Fundación
Pública Andaluza Progreso y Salud de la Consejería de Igualdad Salud y Política Social]
Trial ID: ISRCTN14732216
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated list of random numbers
Allocation concealment
(selection bias)
Low risk Quote: "The person in charge of generating and keeping the list was not part
of the research team and did not participate in evaluation or enrolment of pa-
tients, therefore guaranteeing patient blinding."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Participants were blinded to allocation. No clear statement provided regard-
ing blinding of personnel or outcome assessors.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Participants were blinded to allocation. No clear statement provided regard-
ing blinding of personnel or outcome assessors.
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 129 of 162 screened subjects were included. Reasons for ineligibility, with-
drawal, and protocol violation fully reported.
Selective reporting (re-
porting bias)
Low risk No reason to suspect that reporting was selective. Trial registered retrospec-
tively.
Other bias Low risk No other bias apparent.
Hidalgo-Tenorio 2017  (Continued)
 
 
Methods Phasae III, open-label, controlled, randomised and multi-centre trial
Participants Participants: 1518 girls, boys, and young women (301 girls aged 9–14 years and 301 boys aged 9-14
years received 2 doses 6 months apart; 301 girls and boys aged 9–14 years received 2 doses 12 months
apart; 301 girls aged 9-14 years and 314 young women aged 16-26 years received 3 doses at 0, 2, 6
months) recruited from 15 countries (Canada, Chile, Colombia, Czech Republic, Denmark, Israel,
Malaysia, Norway, South Korea, South Africa, Spain, Taiwan, Thailand, Turkey, and the USA)
Age range: girls and boys aged 9-14 years and girls and young women aged 16-26 years
Inclusion criteria: girls and boys 9-14 years had to be generally healthy and not sexually active prior to
enrolment. Girls and young women 16-26 years had to be generally healthy with 4 or fewer lifetime sex-
ual partners, without a history of abnormal Papanicolaou test results or other cervical abnormalities,
and to agree to use effective contraception through to study month 7.
Interventions Vaccine 1: nonavalent HPV vaccine; 2 doses: day 1, month 6
Vaccine 2: nonavalent HPV vaccine; 2 doses: day 1, month 12
Vaccine 3: nonavalent HPV vaccine; 3 doses: day 1, month 2, month 6
Outcomes Harms: adverse events, deaths
Immunogenicity: GMT, seroconversion
Notes Other groups:
• boys aged 9-14 years receiving 2 doses nonavalent HPV vaccine;• adolescent girls and young women 16-26 years receiving 3 doses of nonavalent HPV vaccine
Last report average follow-up time: 13 months (1 month after the last dose)
Funding: Merck & Co, manufacturer of the quadrivalent and nonavalent HPV vaccines. Merck, as the
study sponsor, was directly involved in the design and conduct of the study in conjunction with exter-
nal investigators; collection, management, analysis, and interpretation of the data; and preparation
and review of the manuscript. The presentation also underwent formal review by Merck. However, Mer-
ck could not prevent submission of the manuscript.
Trial ID: NCT01984697
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation occurred centrally using interactive voice response system/in-
tegrated web response system (IVRS/IWRS). Subjects were assigned randomly
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to 1 of the 3 vaccination arms based on their age stratum according to a com-
puter-generated allocation schedule.
Allocation concealment
(selection bias)
Low risk Randomisation occurred centrally using interactive voice response system/in-
tegrated web response system (IVRS/IWRS). Subjects were assigned randomly
to 1 of the 3 vaccination arms based on their age stratum according to a com-
puter-generated allocation schedule.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk This was an open-label trial; therefore, the sponsor, investigator and subject
knew the treatment administered.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk This was an open-label trial; therefore, the sponsor, investigator and subject
knew the treatment administered.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Acceptable dropout rate and reasons for withdrawal provided.
Selective reporting (re-
porting bias)
Low risk No reason to suspect that reporting was selective. Trial protocol and clinical
trial registry checked.
Other bias Unclear risk Trial funded by vaccine manufacturer.
Iversen 2016  (Continued)
 
 
Methods Phase II/III, double-blind, randomised, multi-centre trial
Participants Participants: 14215 women (6792 in the nonavalent HPV vaccine group and 6795 in the quadrivalent
HPV vaccine group) recruited from 18 countries (Austria, Brazil, Canada, Chile, Colombia, Denmark,
Germany, Hong Kong, Japan, Korea, Mexico, New Zealand, Norway, Peru, Sweden, Taiwan, Thailand,
and the USA (including Puerto Rico))
Age range: 16-26 years
Inclusion criteria: no history of an abnormal result on a Papanicolaou (Pap) test, no more than 4 life-
time sexual partners, and no previous abnormal finding on cervical biopsy
Interventions Vaccine 1: nonavalent HPV vaccine; 3 doses: day 1, month 2, month 6
Vaccine 2: quadrivalent HPV vaccine; 3 doses: day 1, month 2, month 6
Outcomes Clinical: high grade cervical, vulval, and vaginal disease; cervical cancer; persistent HPV infection
Harms: adverse events, deaths
Immunogenicity: GMT, seroconversion
Notes Other groups: N/A
Last report average follow-up time: 54 months
Funding: Merck
Trial ID: NCT00543543
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "An Interactive Voice Response System (IVRS) was used to allocate
study subjects and balance randomisation between sites. Subjects were as-
signed an allocation number from an allocation schedule via the IVRS. Study
personnel utilized IVRS at each vaccination visit for assignment of the clini-
cal material from the appropriate vaccination group to be administered to the
subject." (From protocol, supplementary material online)
Allocation concealment
(selection bias)
Low risk Quote: "An Interactive Voice Response System (IVRS) was used to allocate
study subjects and balance randomisation between sites. Subjects were as-
signed an allocation number from an allocation schedule via the IVRS. Study
personnel utilized IVRS at each vaccination visit for assignment of the clini-
cal material from the appropriate vaccination group to be administered to the
subject." (From protocol, supplementary material online)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "The subjects, investigators (and his/her sta+), laboratory sta+, mem-
bers of the Scientific Advisory Committee, and HPV Vaccine Program Pathol-
ogy Panel will remain blinded to subject vaccination group allocations for the
duration of the study." (From protocol, supplementary material online)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "The subjects, investigators (and his/her sta+), laboratory sta+, mem-
bers of the Scientific Advisory Committee, and HPV Vaccine Program Patholo-
gy Panel will remain blinded to subject vaccination group allocations for the
duration of the study. The SPONSOR will remain blinded to subject vaccina-
tion allocations until the required number of cases of the primary efficacy end-
point have been observed and the database is unblinded for the primary effi-
cacy analysis, with the exception of unblinded personnel who will provide da-
ta summaries for dose selection and DSMB meetings, and those who will de-
termine when the required number of cases of the primary efficacy endpoint
have been observed. These unblinded personnel will not be associated with
the conduct of the study or the design of any of the statistical analyses for the
study (other than those requested by the DSMB)." (From protocol, supplemen-
tary material online)
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data reported adequately in published report, with extra data published in
Supplementary materials online.
Selective reporting (re-
porting bias)
Low risk Full protocol published as supplementary material alongside published paper,
including analysis plan.
Other bias Unclear risk Trial funded by vaccine manufacturer.
Joura 2015  (Continued)
 
 
Methods Partially blind cluster-randomised trial
Participants Participants: 32,175 early adolescents (20,514 girls and 11,661 boys) living in 33 community clusters in
Finland; 3703 male participants were included in narrative results
Age range: 12-15 years
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Inclusion criteria: born 1992–1995; parental consent; healthy, as established by medical history. If fe-
male, not pregnant and not of child-bearing potential or using adequate contraception for 30 days pri-
or to vaccination and to continue for 2 months after completion of the vaccination series
Interventions Vaccine 1: 90% of the girls and boys assigned to receive bivalent HPV vaccine (Cervarix) and 10% as-
signed to receive hepatitis B vaccine (HBV; Engerix) at 0,1 and 6 months (11 clusters)
Vaccine 2: 90% of the girls assigned to receive bivalent HPV vaccine, 10% of girls assigned to receive
HBV vaccine and all boys received HBV-vaccine (11 clusters)
Control: all participants assigned to receive active control HBV vaccine (11 clusters)
Outcomes Harms: adverse events (active surveillance subgroup 12-month follow-up)
Notes Other groups: the data provided on harms in the male participants was based on the 2436 in group 1
who received bivalent vaccine and a sub-set of 1267 of those who received HBV vaccine in group 2.
Last report average follow-up time: 4 years
Funding: GlaxoSmithKline
Trial ID: NCT00534638
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Cluster-randomised: "communities were randomly assigned in equal numbers
(1:1:1) to the three intervention arms using a random number generator"
Allocation concealment
(selection bias)
Low risk Although the trial used central randomisation: "study participants were to be
administered the vaccine dose according to a central randomisation system
on Internet"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Although the study was blinded for participants in the first arm (HPV or HBV
vaccine), the participants in the third arm were aware of their allocation (all re-
ceived HBV vaccine).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "For investigators, the study was open"
Incomplete outcome data
(attrition bias) 
All outcomes
High risk For active adverse event surveillance, data were collected only for a subset of
male participants and it was unclear how these participants were selected.
Passive adverse event surveillance was conducted for all participants, but not
reported for males separately.
Selective reporting (re-
porting bias)
High risk No outcomes were reported completely separately for boys and girls. Adverse
events were reported in boys separately, but in a selected subset.
Other bias Unclear risk Trial funded by vaccine manufacturer.
Lehtinen 2018  (Continued)
 
 
Methods Phase III, observer-blind, parallel, randomised trial
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Participants Participants:1075 girls (359 to 2 doses of bivalent HPV; 358 to 2 doses of quadrivalent HPV; 358 to 3 dos-
es of quadrivalent HPV; recruited at 21 sites in France, Hong Kong, Singapore and Sweden
Age range: 9-14 years
Inclusion criteria: healthy girls aged 9–14 years; girls of childbearing potential could be enrolled if
they were abstinent or practised adequate contraception for 30 days prior to vaccination, had a neg-
ative pregnancy test on the day of each vaccination, and agreed to continue contraception for up to 2
months after completion of the vaccination series.
Interventions Vaccine 1: quadrivalent HPV vaccine; 2 doses: day 1, month 6
Vaccine 2: quadrivalent HPV vaccine; 3 doses: day 1, month 2, month 6
Girls in the 2-dose group received aluminium adjuvant placebo (Al(OH)3) at month 2 to maintain the
observer blinding.
Outcomes Harms: adverse events, deaths
Immunogenicity: GMT, seroconversion
Notes Other groups: 358 girls aged 9-14 years who received 2 doses of bivalent HPV vaccine.
Last report average follow-up time: 36 months
Funding: GlaxoSmithKline Biologicals SA funded this study and was involved in all stages of study con-
duct, including analysis of the data and the development and publication of the manuscript.
Trial ID: NCT01462357
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The randomisation code was generated using MATEX, a program developed
for use in SAS (Cary, NC, USA), by GSK Vaccines, Belgium.
Allocation concealment
(selection bias)
Low risk Quote: "Treatment allocation at the investigator site was performed using a
centralized internet-based randomisation system"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk The study was conducted in an observer-blind manner (i.e. vaccines were
prepared and administered by qualified medical personnel not otherwise in-
volved in the conduct of this study). Personnel involved in subject evaluation
and subjects themselves were blinded to group assignments. Girls in the 2-
dose groups received control Al(OH)3 at month 2 to maintain observer blind-
ing.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Personnel involved in subject evaluation, and subjects themselves, were blind-
ed to group assignments.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data appeared to be reported adequately, including reasons for withdrawals.
Selective reporting (re-
porting bias)
Low risk No reason to suspect that reporting was selective. Clinical trial registry
checked.
Other bias Unclear risk Trial funded by vaccine manufacturer.
Leung 2015  (Continued)
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Methods Randomised, double-blind, placebo-controlled trial
Participants Participants: 126 children with HIV infection (96 received quadrivalent HPV vaccine and 30 received
control) from the USA and Puerto Rico
Age range: children 7-12 years old
Inclusion criteria: CD4% ≥15; at least 3 months of HAART was required for subjects with a CD4% < 25.
Interventions Vaccine: quadrivalent HPV vaccine; 3 doses: day 1, month 2, month 6
Control: 'identical placebo' (contents of placebo were not specified (e.g. whether it was aluminium ad-
juvant or saline)); 3 doses: day 1, month 2, month 6
Outcomes Harms: adverse events
Immunological: GMT, seroconversion
Notes Other groups: N/A
Last report average follow-up time: 4-5 years
Funding: overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group
(IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID), the Eunice
Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National
Institute of Mental Health (NIMH)
Trial ID: NCT01206556
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly assigned"
Allocation concealment
(selection bias)
Unclear risk No statement provided about allocation concealment.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No detailed statement provided about how blinding was maintained or who
was blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No detailed statement provided about how blinding was maintained or who
was blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data were provided for the total vaccinated cohort (100% of enrolled partici-
pants), together with full information about reasons for exclusions and with-
drawals from follow-up.
Selective reporting (re-
porting bias)
Low risk No reason to suspect that reporting was selective. Clinical trial record checked.
Other bias Low risk No other bias apparent.
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Methods Open-label, parallel, randomised trial
Participants Participants: 220 males (111 to the alternate schedule and 109 to the standard schedule) recruited from
the USA
Age range: 18-25 years old
Inclusion criteria: males 18-25 years with 4 or fewer lifetime sexual partners
Interventions Vaccine 1: standard schedule quadrivalent HPV vaccine; 3 doses at 0, 2, and 6 months
Vaccine 2: alternate schedule quadrivalent HPV vaccine; 3 doses at 0, 2 and 12 months
Outcomes Harms: compliance with third dose, adverse events
Immunogenicity: GMT
Notes Other groups: N/A
Last report average follow-up time: month 7 or 13 (depending on group)
Funding: the authors and this work were supported in part by a research grant from the Investiga-
tor-Initiated Studies Program of Merck & Co, Inc, manufacturer of Gardasil® quadrivalent human papil-
lomavirus vaccine.
Trial ID: NCT01184079
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Participants were randomised as they were scheduled for the initial
visit using a simple random number sequence to determine the order of as-
signment into the Standard schedule or the Alternate schedule"
Allocation concealment
(selection bias)
Unclear risk Not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label; "Participants were aware of their group assignment"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not described
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "Out of 220 participants enrolled, 204 completed the study"
Reasons for withdrawal and protocol violation fully reported. Results for both
ITT and per protocol populations reported.
Selective reporting (re-
porting bias)
Low risk No reason to suspect that reporting was selective - clinical trial registry
checked
Other bias Unclear risk Trial funded by vaccine manufacturer.
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Methods Double blind, controlled, randomised, single-centre trial
Participants Participants: 32 HIV-positive males and females with anal warts (15 to the vaccine group and 17 to the
control group) recruited from the USA
Age range: 18 to 65 years old
Inclusion criteria: HIV positive, ≥ 18 years of age, CD4 > 200 and viral RNA < 400 on HAART or CD4 > 350 if
not on HARRT, presence of anal warts that required surgical excision or ablation
Interventions Vaccine: quadrivalent HPV vaccine; 3 doses at 0, 2, and 6 months
Control: saline placebo; 3 doses at 0, 2 and 6 months
Outcomes Clinical: persistence and recurrence of anal warts
Notes Other groups: N/A
Last report average follow-up time: month 18
Funding: Washington University School of Medicine
Trial ID: NCT00941889
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The online clinical trials record states "Randomized", but details about how
randomisation was achieved were not reported.
Allocation concealment
(selection bias)
Unclear risk Details of allocation concealment were not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk The online clinical trials record states "Masking: Double (Participant, Investiga-
tor)", but details about how blinding was achieved were not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk The online clinical trials record states "Masking: Double (Participant, Investiga-
tor)", but details about how blinding was achieved were not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Data for 62.5% (20/32) of the participants enrolled were missing due to with-
drawal from the study, the online trial record states "No outcomes data were
collected or analysed due to lack of participant follow-up"
Selective reporting (re-
porting bias)
High risk The study did not report on adverse events and the online trial record states
"No outcomes data were collected or analysed due to lack of participant fol-
low-up"
Other bias Unclear risk No published report was identified for this study, data were extracted from the
clinical trials record which had insufficient information to establish whether
there was a risk of other bias.
NCT00941889 2016 
 
 
Comparison of dierent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females
and males (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
53
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Methods Phase IV, observer-blind, randomised, controlled, multi-centric study
Participants Participants: 649 HIV seropositive and seronegative females aged 15-25 years (331 to the bivalent vac-
cine group and 330 to the quadrivalent vaccine group) recruited from Brazil, Estonia, India, and Thai-
land
Age range: 15-25 years
Inclusion criteria: female 15-25 years old, HIV voluntary counselling and testing
Interventions Vaccine 1: bivalent HPV vaccine; 3 doses at day 0, week 6, and month 6
Vaccine 2: quadrivalent HPV vaccine; 3 doses at day 0, week 6, and month 6
Outcomes Harms: adverse events
Immunogenicity
Notes Other groups: N/A
Last report average follow-up time: month 7
Funding: GlaxoSmithKline
Trial ID: NCT01031069
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The online clinical trials record and clinical trial result summary state "Ran-
domized", but details about how randomisation was achieved were not re-
ported.
Allocation concealment
(selection bias)
Unclear risk Details of allocation concealment were not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk The online clinical trials record states "Triple (Participant, Investigator, Out-
comes Assessor)", but details about how blinding was achieved were not re-
ported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk The online clinical trials record states "Triple (Participant, Investigator, Out-
comes Assessor)", but details about how blinding was achieved were not re-
ported.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data were provided for the total vaccinated cohort (100% of enrolled partici-
pants), together with full information about reasons for exclusions and with-
drawals from follow-up.
Selective reporting (re-
porting bias)
High risk Not all outcomes listed in the online trial registration were reported in the trial
result summary report.
Other bias Unclear risk No published report was identified for this study; data were extracted from
the clinical trials results summary on the manufacturer's web site (https://
www.gsk-clinicalstudyregister.com/) which had insufficient information to es-
tablish whether there was a risk of other bias.
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Methods Phase 3, parallel, randomised, controlled trial
Participants Participants: 1124 boys and men (562 received vaccine, 562 received placebo) recruited from Japan
Age range:16-26 years
Inclusion criteria: Japanese males with no clinical evidence of sexually transmitted disease and no clin-
ically present external genital warts
Interventions Vaccine: quadrivalent HPV vaccine; 3 doses at day 1, month 2, month 6
Control: aluminium adjuvant placebo (placebo formulated with aluminium hydroxyphosphate sulfate
adjuvant); 3 doses at day 1, month 2, month 6
Outcomes Incidence of persistent HPV-6/11/16/18 infection or disease
Adverse events
Notes Other groups: N/A
Last report average follow-up time: month 36
Funding: Merck Sharp & Dohme Corp
Trial ID: NCT01862874
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The online clinical trials record and clinical trial result summary state "Ran-
domized", details about how randomisation was achieved were not reported.
Allocation concealment
(selection bias)
Unclear risk Details of allocation concealment were not reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk The clinical trial record states "masking: triple (participant, investigator, out-
comes assessor" but no other details were provided.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk The clinical trial record states "masking: triple (participant, investigator, out-
comes assessor" but no other details were provided.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reasons for withdrawals were reported and balanced between groups.
Selective reporting (re-
porting bias)
High risk HPV disease (HPV Type 6, 11, 16, or 18-related condyloma acuminate, penile,
perianal, or perineal intraepithelial neoplasia or cancer) was not reported sep-
arately; persistent HPV infection and HPV disease were reported as a com-
bined outcome.
Other bias Unclear risk No published report was identified for this trial. Trial funded by vaccine manu-
facturer.
NCT01862874 2018 
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Methods Phase I/II, observer-blind, parallel-group, randomised study
Participants Participants: 270 boys (181 received bivalent HPV vaccine and 89 received hepatitis B vaccine) recruit-
ed from 7 study sites in Finland
Age range: 10-18 years old
Inclusion criteria: boys free of obvious health problems as established by medical history and clinical
examination before entering into the study
Interventions Vaccine: bivalent HPV vaccine; 3 doses: day 1, month 1, month 6
Control: hepatitis B active control vaccine; 3 doses: day 1, month 1, month 6
Outcomes Harms: adverse events, deaths
Immunogenicity: GMT, seroconversion
Notes Other groups: N/A
Last report average follow-up time: 12 months
Funding: GlaxoSmithKline
Trial ID: NCT00309166
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation list generated at GlaxoSmithKline Biologicals (Rixensart, Bel-
gium) using a standard SAS program (SAS Institute, Cary, NC).
Allocation concealment
(selection bias)
Low risk Participants were assigned a vaccine treatment number; blinding was main-
tained to the individual treatment allocated.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Participants were assigned a vaccine treatment number; blinding was main-
tained to the individual treatment allocated. All study personnel were blinded
to the vaccines used, except the study nurse administrating the vaccines.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Participants were assigned a vaccine treatment number; blinding was main-
tained to the individual treatment allocated. All study personnel were blinded
to the vaccines used, except the study nurse administrating the vaccines.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data for all participants enrolled were reported for adverse events. Reasons for
exclusion from immunogenicity analysis was provided.
Selective reporting (re-
porting bias)
Low risk All relevant outcomes were reported in clinical trials record and clinical study
report.
Other bias Unclear risk No report of industry funding in publication, though the study report is avail-
able on GSK web site.
Petaja 2009 
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Methods Phase III, open-label, controlled, randomised, multi-centre trial
Participants Participants: 1447 participants (482 women to the 3-dose schedule (months 0, 1, 6); 550 girls to the 2-
dose schedule (months 0 and 6); 415 girls to the 2-dose schedule (0 and 12 months)) recruited from
Canada, Germany, Italy, Taiwan, and Thailand
Age range: girls 9-14 years old and women 15-25 years old
Inclusion criteria: women of childbearing age required to be abstinent or use adequate contraceptive
precautions for 30 days before first vaccination and agree to continue such precautions for 2 months
after the last vaccine dose
Interventions Vaccine 1: bivalent HPV vaccine; 2 doses: month 0 and month 6
Vaccine 2: bivalent HPV vaccine; 2 doses: month 0 and month 12
Outcomes Harms: adverse events, deaths
Immunogenicity: GMT, seroconversion
Notes Other groups: 482 women aged 15-25 years received 3 doses bivalent HPV vaccine, data not extracted
Last report average follow-up time: 13 months, study ongoing
Funding: GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals designed the study in collabora-
tion with investigators and co-ordinated gathering, analysis, and interpretation of data and writing of
the report.
Trial ID: NCT01381575
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The randomisation list was generated by GSK Vaccines using a standard SAS
program. A randomisation blocking scheme (1:1 ratio) ensured that balance
between the two 2-dose schedules was maintained. Treatment allocation at
each site used a central randomisation system on the Internet.
Allocation concealment
(selection bias)
Low risk Treatment allocation at each site used a central randomisation system on the
Internet.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Investigators and participants were not blinded to group assignment. Girls
aged 9–14 years were randomised (1:1) to receive 2-dose schedule (months 0,
and 6 or months 0, and 12) and women aged 15–25 years were allocated to re-
ceive 3-dose schedule (months 0, 1, and 6).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Investigators and participants were not blinded to group assignment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data reported adequately in published report, with extra data published in
Supplementary materials online.
Selective reporting (re-
porting bias)
Low risk No reason to suspect that reporting was selective. Clinical trial registry
checked.
Other bias Unclear risk Trial funded by vaccine manufacturer.
Puthanakit 2016 
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Methods Phase I/II, partially blind, controlled, age-stratified, randomised and multi-centre trial
Participants Participants: 960 girls and women (240 in 2-dose schedule 20 μg dose (months 0 and 6); 241 in 2-dose
schedule 40 μg dose (months 0 and 6); 240 in 2-dose schedule 40 μg dose (months 0 and 2); 239 in 3-
dose schedule 20 μg dose (months 0, 1, and 6)) recruited from Canada and Germany
Age range: girls and young women aged 9-25 years at the time of first vaccination
Inclusion criteria: participants with childbearing potential had to use adequate contraception for 30
days prior to vaccination, have a negative pregnancy test, and continue contraceptive precautions for 2
months after completion of the vaccination series
Interventions Vaccine 1: bivalent HPV vaccine; 20 μg dose; 3 doses: day 1, month 1, month 6
Vaccine 2: bivalent HPV vaccine; 20 μg dose; 2 doses: day 1, month 6
Vaccine 3: bivalent HPV vaccine; 40 μg dose; 2 doses: day 1, month 6
Vaccine 4: bivalent HPV vaccine; 40 μg dose; 2 doses: day 1, month 2
In the 2-dose schedule groups, an aluminium adjuvant placebo was administered at month 2 (Groups
20 μg dose (months 0 and 6) and 40 μg dose (months 0 and 6)) or at month 6 (Group 40 μg dose months
0 and 2) to maintain blinding.
Outcomes Harms: adverse events, deaths
Immunogenicity: GMT, seroconversion
Notes Other groups: N/A
Last report average follow-up time: up to month 60
Funding: GlaxoSmithKline Biologicals
Trial ID: NCT00541970
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The randomisation list was computer-generated at GlaxoSmithKline Biologi-
cals.
Allocation concealment
(selection bias)
Low risk Treatment allocation at the investigator site was performed using a central
randomisation call-in system on the Internet; the randomisation algorithm
used a minimisation procedure accounting for centre and age (9–14, 15–19
and 20–25 years).
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk The trial was partially blinded within the 2-dose schedule groups (observers
were blinded to group assignment) and open in the 3-dose schedule group. In
the 2-dose schedule groups, a placebo was administered at month 2 (Groups
20 μg dose (months 0 and 6) and 40 μg dose (months 0 and 6)) or at month 6
(Group 40 μg dose (months 0 and 2) to maintain blinding.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The trial was partially blinded within the 2-dose schedule groups (observers
were blinded to group assignment).
Romanowski 2011 
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data appeared to be reported adequately, and included reasons for with-
drawals.
Selective reporting (re-
porting bias)
Low risk No reason to suspect that reporting was selective. Clinical trial registry
checked.
Other bias Unclear risk Trial funded by vaccine manufacturer.
Romanowski 2011  (Continued)
 
 
Methods Randomised, double-blind, head-to-head trial
Participants Participants: 92 male and female HIV-positive participants (46 to 3-dose bivalent vaccine and 46 to 3-
dose quadrivalent vaccine) recruited from outpatient clinic in Denmark.
Age range: at least 18 years old
Inclusion criteria: consenting HIV-seropositive volunteers at least 18 years old
Interventions Vaccine 1: bivalent HPV vaccine; 3 doses: day 1, month 1.5, month 6
Vaccine 2: quadrivalent HPV vaccine; 3 doses: day 1, month 1.5, month 6
Outcomes Harms: adverse events
Immunogenicity: GMT, seroconversion
Notes Other groups: N/A
Last report average follow-up time: 6 months
Funding: Aarhus University, Henrik Henriksen’s Foundation, The Hede Nielsen Family Foundation, Aase
and Ejnar Danielsen’s Foundation, Jørgen Holm and Wife’s Foundation, Lykfeldt andWife’s Foundation,
and the Danish Medical Association
Trial ID: NCT01386164
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random allocation sequences were computer generated by the hospital phar-
macy. Participants were assigned their study identification number according
to the chronological order in which they were enrolled. Participants and inves-
tigators were masked to the assigned vaccine throughout the study.
Allocation concealment
(selection bias)
Low risk Random allocation sequences were computer generated by the hospital phar-
macy. Participants were assigned their study identification number according
to the chronological order in which they were enrolled. Participants and inves-
tigators were masked to the assigned vaccine throughout the study.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Participants and investigators were masked to the assigned vaccine through-
out the study.
ToN 2014 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Blinded analysis at the joint Chemical Biology Core Facility of the German Can-
cer Research Center and the European Molecular Biology Laboratory, Heidel-
berg, Germany
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data appeared to be reported adequately, and included reasons for with-
drawals.
Selective reporting (re-
porting bias)
Low risk No reason to suspect that reporting was selective. Clinical trials registry
checked.
Other bias Low risk No other bias apparent.
ToN 2014  (Continued)
 
 
Methods Phase III, double-blind, controlled, randomised and multicenter trial
Participants Participants: 500 males (249 to the nonavalent HPV vaccine arm, 251 to the quadrivalent HPV vaccine
arm) recruited from Belgium, Germany, and the Netherlands
Age range: 16-26 years
Inclusion criteria: good physical health, no more than 5 lifetime female and no male sexual partners
Interventions Vaccine 1: nonavalent HPV vaccine; 3 doses: day 1, month 2, and month 6
Vaccine 2: quadrivalent HPV vaccine; 3 doses: day 1, month 2, and month 6
Outcomes Harms: adverse events, deaths
Immunogenicity: GMT, seroconversion
Notes Other groups: N/A
Last report average follow-up time: 7 months
Funding: Sanofi Pasteur MSD provided financial support for the conduct of the research and prepara-
tion of the article and were involved in the study design, in the collection, analysis and interpretation of
data and in the writing of the trial report.
Trial ID: NCT02114385
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "An interactive Web Response System (IWRS) was used to allocate par-
ticipants to 9vHPV or qHPV vaccine in a blinded manner. The system assigned
an allocation number from a randomised, age-stratified (16-17 years and 18-26
years) allocation schedule."
Allocation concealment
(selection bias)
Low risk Quote: "An interactive Web Response System (IWRS) was used to allocate par-
ticipants to 9vHPV or qHPV vaccine in a blinded manner. The system assigned
an allocation number from a randomised, age-stratified (16-17 years and 18-26
years) allocation schedule."
van Damme 2016 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Participants and personnel were blinded: "Masking: Quadruple (Participant,
Care Provider, Investigator, Outcomes Assessor)"
"We conducted a double-blind, randomised controlled with qHPV vaccine, im-
munogenicity and safety of the 9vHPV vaccine in young men aged 16-26 years
of age."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome assessors were blinded: "Masking: Quadruple (Participant, Care
Provider, Investigator, Outcomes Assessor)"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Fig 1 shows 97.8% completed.
Selective reporting (re-
porting bias)
Low risk No reason to suspect that reporting was selective - clinical trial record checked
and all immunogenicity outcomes reported.
Other bias Unclear risk Trial funded by vaccine manufacturer.
van Damme 2016  (Continued)
 
 
Methods Phase III, double-blind, controlled, randomised and multi-centre trial
Participants Participants: 600 girls (300 in the nonavalent HPV vaccine arm, 300 in the quadrivalent HPV vaccine
arm), recruited from Belgium, Denmark, Finland, Italy, Spain, and Sweden)
Age range: 9-15 years old
Inclusion criteria: girls aged ≥ 9 to < 16 years at enrolment, in good physical health, who were virgins
and who were not planning to become sexually active before month 7 of the study.
Interventions Vaccine 1: nonavalent HPV vaccine; 3 doses: day 1, month 2, month 6
Vaccine 2: quadrivalent HPV vaccine; 3 doses: day 1, month 2, month 6
Outcomes Harms: adverse events, deaths
Immunogenicity: GMT, seroconversion
Notes Other groups: N/A
Last report average follow-up time: 7 months
Funding: Sanofi Pasteur MSD
Trial ID: NCT01304498
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A central randomisation system, which used an interactive web response sys-
tem, assigned participants to a vaccine group (blinded) and an allocation
number according to the randomised allocation schedules.
Vesikari 2015 
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Allocation concealment
(selection bias)
Low risk A central randomisation system, which used an interactive web response sys-
tem, assigned participants to a vaccine group (blinded) and an allocation
number according to the randomised allocation schedules.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Study reported to be double-blind. Not explicitly stated, however both groups
received vaccines at the same time points.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Described as double blind; however, not explicit that outcome assessment was
blinded. Given that the outcomes were objective (serology), assessed as low
risk of bias.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 98.2% completed study (Figure 1), with full information on exclusions and
withdrawals.
Selective reporting (re-
porting bias)
Low risk No reason to suspect that reporting was selective, clinical trial registry
checked
Other bias Unclear risk Trial funded by vaccine manufacturer.
Vesikari 2015  (Continued)
 
 
Methods Phase III, double blind, placebo-controlled, randomised, multi-centre trial
Participants Participants: 575 HIV-positive males and females (288 to the vaccine group and 287 to the control
group) recruited from the USA, Brazil, and Puerto Rico
Age range: at least 27 years old
Inclusion criteria: HIV-1 infection, laboratory values and anal cytology result obtained within 45 days
prior to entry
Interventions Vaccine: quadrivalent HPV vaccine; 3 doses at 0, 8, and 24 weeks
Control: 'placebo vaccine' (contents of placebo vaccine were not specified (e.g. whether it was alumini-
um adjuvant-containing or saline)); 3 doses at 0, 8, and 24 weeks
Outcomes Clinical: anal intraepithelial neoplasia, persistent infection
Harms: adverse events
Notes Other groups: N/A
Last report average follow-up time: 4 years
Funding: National Institute of Allergy and Infectious Diseases
Trial ID: NCT01461096
Risk of bias
Bias Authors' judgement Support for judgement
Wilkin 2018 
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Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Permuted-block randomisation was balanced by site and stratified by
sex and presence of bHSIL at study screening.", details on how randomisation
sequence was generated was not fully reported
Allocation concealment
(selection bias)
Low risk Central allocation: "The treatment assignment was provided electronically to
local study pharmacists who prepared identical prefilled vaccine syringes.”
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: ""Investigators, participants, and study sta+ were masked to treatment
allocation.", details about how blinding was achieved were not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: ""Investigators, participants, and study sta+ were masked to treatment
allocation.", details about how blinding was achieved were not reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data were provided for 99% (569/575) participants; full information about rea-
sons for exclusions and withdrawals were provided.
Selective reporting (re-
porting bias)
Low risk All outcomes listed in online trial registration were reported.
Other bias Low risk No other bias apparent.
Wilkin 2018  (Continued)
Abbreviations
AAHS: amorphous aluminium hydroxy-phosphate sulphate
CD4%: percentage of white blood cells that are CD4 cells
GMT: geometric mean titre
HAART: highly active antiretroviral therapy
HPV: human papillomavirus
ITT: intention-to-treat
qHPV: quadrivalent human papillomavirus vaccine
9vHPV: nonavalent human papillomavirus vaccine
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Beachler 2016 No relevant comparison, does not meet protocol: bivalent HPV vs hepatitis A vaccine (control) in
women (NCT00128661)
Bhatia 2016 No relevant comparison, does not meet protocol: observational study of vaccinated vs unvaccinat-
ed females
Bianchi 2016 No relevant comparison, does not meet protocol: observational study of vaccinated vs unvaccinat-
ed females
Brown 2012 No relevant comparison, does not meet protocol: 3 doses vs 3 doses comparing intervals in females
(NCT00925288)
Canfell 2017 Not a relevant population: women 25-64 years (ACTRN12613001207707)
Carozzi 2016 No relevant comparison, does not meet protocol: vaccinated vs unvaccinated females
(NCT02296255)
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Study Reason for exclusion
Choudhury 2016 No relevant comparison, does not meet protocol: observational study of vaccinated vs unvaccinat-
ed in HIV+ females, none of the HIV+ population was vaccinated
Esposito 2011 No relevant comparison, does not meet protocol: 3 doses vs 3 doses comparing intervals in females
(NCT00552279)
Flagg 2018 No relevant comparison, does not meet protocol: observational study of anogenital warts preva-
lence before and after national HPV vaccination introduction for females, males were not vaccinat-
ed
Garland 2016 No relevant comparison, does not meet protocol: vaccinated versus unvaccinated females
(NCT00122681 PATRICIA)
Gilca 2015 No relevant comparison, does not meet protocol: booster dose given to girls who had already re-
ceived 2 doses of vaccine (NCT01456715)
Hamsikova 2017 No relevant comparison, does not meet protocol: observational study of bivalent versus quadriva-
lent HPV vaccines
Harari 2016 No relevant comparison, does not meet protocol: HPV vaccine vs hepatitis A vaccine (control) in fe-
males (NCT00128661)
Haskins-Coulter 2017 No relevant comparison, does not meet protocol: 3-dose bivalent vaccine vs 3-dose quadrivalent
vaccine in young females (NCT00956553)
Lamontagne 2013 No relevant comparison, does not meet protocol: 3 doses vs 3 doses comparing intervals in females
(NCT00524745)
Lehtinen 2017 No relevant comparison, does not meet protocol: long-term follow-up of vaccinated versus unvac-
cinated females combining arms from 3 RCTs (NCT01393470 (unvaccinated arm); NCT00122681
(PATRICIA vaccinated arm); NCT00169494 (HPV-012 vaccinated arm))
Luxembourg 2017 No relevant comparison, does not meet protocol: vaccinated versus unvaccinated females (proto-
col) (V503-021, NCT02653118)
Money 2016 No relevant comparison, does not meet protocol: single arm HIV+ cohort (ISRCTN33674451)
Neuzil 2011 No relevant comparison, does not meet protocol: 3 doses vs 3 doses comparing intervals in adoles-
cent girls (NCT00524745)
Wheeler 2016 Not a relevant population: women 26 years and older, 7-year follow-up of VIVIANE study
(NCT00294047)
Zhu 2017 No relevant comparison, does not meet protocol: HPV vaccine versus aluminium hydroxide control
in females (NCT00779766)
Zimmerman 2010 No relevant comparison, does not meet protocol: 3 doses vs 3 doses comparing intervals in females
(NCT00572832)
Abbreviations
HIV+: HIV positive
HPV: human papillomavirus
RCT: randomised controlled trial
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Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Randomised, double-blind, placebo-controlled trial
Participants Participants: 100 healthy Chinese males and 500 healthy Chinese females (302 received the quadri-
valent vaccine and 298 received the control vaccine) from Wuzhou, Guangxi, China
Age range: males aged 9–15 years and females aged 9–45 years
Inclusion criteria: no history of severe allergic reaction or allergic reaction to any vaccine compo-
nent and a lifetime number of no more than 4 sex partners.
Exclusion criteria: pregnant post-pubertal females; history of an abnormal Papanicolaou test or
biopsy showing cervical intraepithelial neoplasia (CIN) or worse
Interventions Vaccine: quadrivalent HPV vaccine (Gardasil/Silgard, Merck, Whitehouse Station, NJ) (3 doses: day
1, month 2, month 6)
Control: adjuvant-containing placebo (3 doses: day 1, month 2, month 6)
Outcomes Immunogenicity: GMTs, seroconversion
Safety: adverse events, serious adverse events, death
Notes Other groups: N/A
Last report average follow-up time: 7 months
Funding: Merck Sharp & Dohme Corp
Trial ID: NCT01427777
Li 2012 
 
 
Methods Randomised, double-blind, placebo-controlled, multicenter study
Participants Participants: 1781 boys and girls (1181 received the quadrivalent vaccine and 597 received the non-
aluminium placebo) from 47 study sites located in 10 countries in North America, Latin America,
Europe and Asia
Age: 9-15 years old
Inclusion criteria: healthy, sexually naive boys and girls
Interventions Vaccine: quadrivalent HPV-6/11/16/18 L1 VLP vaccine (GARDASIL/SILGARD, Merck and Co, Inc,
Whitehouse Station, NJ)
Control: placebo vaccine (identical components to those in the vaccine, with the exception of HPV
L1 VLPs and aluminium adjuvant)
Outcomes Immunogenicity: GMT, seroconversion
Safety: adverse events, serious adverse events, death
Notes Other groups: N/A
Last report average follow-up time: 18 months
Funding: Merck and Co, Inc
Reisinger 2007 
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Trial ID: NCT00092547
Reisinger 2007  (Continued)
Abbreviations
GMT: geometric mean titre
HPV: human papillomavirus
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Efficacy and immunogenicity study of recombinant human papillomavirus bivalent (genotype
16/18) vaccine
Methods RCT
Participants Females 18-45 years
Country: China
Interventions • HPV vaccine containing 40 μg HPV 16 virus-like particle antigen and 20 μg HPV 18 virus-like particle
antigen adsorbed in alum-adjuvant• Hepatitis E virus (HEV) vaccine contains 30 μg HEV antigen adsorbed in alum-adjuvant
Outcomes Clinical outcomes, adverse events, immunogenicity
Starting date November 2012
Contact information Jun Zhang, Xiamen University; Youlin Qiao, Cancer Institute and Hospital, Chinese Academy of
Medical Sciences; Ting Wu, Xiamen University
Notes Sponsors: Xiamen University; Xiamen Innovax Biotech Co, Ltd; Beijing Wantai Biological Pharmacy
Enterprise Co, Ltd; Ministry of Science and Technology of the People's Republic of China
Trial status in August 2018: active, not recruiting
NCT01735006 
 
 
Trial name or title Transmission reduction and prevention with HPV vaccination (TRAP-HPV) study (TRAP-HPV)
Methods RCT
Participants 18-45 year-old couples, males and females
Country: Canada
Interventions • Nonavalent HPV vaccine (Gardasil 9, Merck)• Hepatitis A virus vaccine (Havrix, Merck)
Outcomes HPV DNA positivity
Starting date September 2013
Contact information Allita Rodrigues (allita.rodrigues@mcgill.ca); Anna Tzagourni (canepiadm.med@mcgill.ca)
Notes Sponsors: McGill University
NCT01824537 
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Trial status in August 2018: recruiting
NCT01824537  (Continued)
 
 
Trial name or title ICI-VPH: Impact of HPV immunisation schedules against HPV (ICI-VPH)
Methods RCT
Participants Females 14-16 years old
Country: Canada
Interventions • 2 doses quadrivalent HPV vaccine (Gardasil, Merck)• 3 doses quadrivalent HPV vaccine (Gardasil, Merck)
Outcomes Incidence of persistent HPV-16/18 infections; GMT of antibodies and seropositivity for HPV geno-
types 6, 11, 16 and 18
Starting date November 2013
Contact information Chantal Sauvageau, CHU de Quebec-Universite Laval
Notes Sponsors: CHU de Quebec-Universite Laval; Centre hospitalier de l'Université de Montréal; Quebec
Public Health National Institute; Quebec Ministry of Health and Social Services
Trial status in August 2018: active, not recruiting
NCT02009800 
 
 
Trial name or title HPV (human papilloma virus) vaccination after treatment of anal intraepithelial neoplasia (AIN)
(VACCAIN-P)
Methods RCT
Participants HIV positive MSM ≥ 18 years old
Country: the Netherlands
Interventions • Quadrivalent HPV vaccine: intramuscular Gardasil vaccination at 0, 2 and 6 months• Control: intramuscular saline 0.9% vaccination at 0, 2 and 6 months
Outcomes Recurrence of intra-anal or peri-anal high-grade AIN; toxicity/safety; Intra-anal or peri-anal low-
grade AIN; anogenital warts; causative HPV genotype in recurrent AIN lesions; HPV genotype-spe-
cific antibody response
Starting date March 2014
Contact information Jan M Prins, Academisch Medisch Centrum, Universiteit van Amsterdam; Henry JC de Vries, Acad-
emisch Medisch Centrum, Universiteit van Amsterdam
Notes Sponsors: Prof Jan Prins
Trial status in August 2018: active, not recruiting
NCT02087384 
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Trial name or title Safety and immunogenicity study of the recombinant human papillomavirus virus type 6/11 biva-
lent vaccine
Methods RCT
Participants Males and females 18-55 years
Country: China
Interventions • Low dosage HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses• Medium dosage HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses• High dosage HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses• Aluminium adjuvant at 0, 1, 6 month for 3 doses
Outcomes Adverse events; anti-HPV 6/11 antibody
Starting date March 2015
Contact information Jun Zhang, Xiamen University; Zhao-Jun Mo, Guangxi Center for Disease Prevention and Control;
Ting Wu, Xiamen University
Notes Sponsors: Jun Zhang; Xiamen Innovax Biotech Co, Ltd; Beijing Wantai Biological Pharmacy Enter-
prise Co, Ltd
Trial status in August 2018: active, not recruiting
NCT02405520 
 
 
Trial name or title Immunogenicity and safety study of a bivalent human papillomavirus (type 16, 18) recombinant
vaccine (E.coli) in healthy female subjects aged 9-17 years
Methods RCT
Participants Females 9-26 years
Country: China
Interventions • 3 doses of HPV 16/18 bivalent vaccine• 2 doses of HPV 16/18 bivalent vaccine
Outcomes Adverse events and immunogenicity
Starting date 5 December 2015
Contact information Ting Wu, Xiamen University; Yuemei Hu, Jiangsu Provincial Centre for Disease Control and Preven-
tion
Notes Sponsors: Jun Zhang; Xiamen Innovax Biotech Co, Ltd; Beijing Wantai Biological Pharmacy Enter-
prise Co, Ltd
Trial status in August 2018: completed in August 2016, we contacted study investigators but they
had provided no data at the time of submitting this review for publication
NCT02562508 
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Trial name or title Immunogenicity and safety of Gardasil-9 and Cervarix
Methods RCT
Participants Boys and girls 9-10 years old
Country: Canada
Interventions • Nonavalent HPV vaccine (Gardasil-9) (0.5 mL), 2 doses according to 0-6 month schedule• 1 dose bivalent HPV vaccine (Cervarix) (0.5 mlL) and 1 dose nonavalent HPV vaccine (Gardasil-9)
(0.5 mL) according to 0-6 month schedule
Outcomes Antibodies to 9 HPV genotypes included in the Gardasil-9 vaccine; tolerability profile
Starting date September 2015
Contact information Vladimir Gilca (vladimir.gilca@inspq.qc.ca); Chantal Sauvageau (chantal.sauvageau@inspq.qc.ca)
Notes Sponsors: Laval University
Trial status in August 2018: recruiting
NCT02567955 
 
 
Trial name or title Immunogenicity study of the recombinant human papillomavirus virus type 6/11 bivalent vaccine
Methods RCT
Participants Males and females 18-55 years old
Country: China
Interventions • Low dosage (1:1) bivalent HPV vaccine: virus-like particles genotype 6 and 11 at 1:1 ratio• Low dosage (1:2) bivalent HPV vaccine: virus-like particles genotype 6 and 11 at 1:2 ratio• High dosage (1:1) bivalent HPV vaccine: virus-like particles genotype 6 and 11 at 1:1 ratio• Control: hepatitis E vaccine (Hecolin)
Outcomes Anti-HPV 6 and anti-HPV 11 seroconversion rates; serious adverse events
Starting date March 2016
Contact information Jun Zhang, Xiamen University; Yuemei Hu, Jiangsu Center for Disease Prevention and Control
Notes Sponsors: Jun Zhang; Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enter-
prise Co, Ltd
Trial status in August 2018: active, not recruiting
NCT02710851 
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Trial name or title A phase III double blinded, randomized controlled study to evaluate efficacy of protection against
HPV-16 and 18 related diseases, immunogenicity and safety of HPV-16/18 vaccine in healthy fe-
males aged 18-30 years
Methods RCT
Participants Females aged 18-30 years
Country: China
Interventions • HPV-16/18 vaccine• placebo
Outcomes Clinical outcomes, adverse events, immunogenicity
Starting date November 2014
Contact information Zhaojun Mo, Guangxi Center for Disease Prevention and Control
Notes Sponsors: Shanghai Zerun Biotechnology Co, Ltd; Guangxi Center for Disease Control and Preven-
tion
Trial status in August 2018: active, not recruiting
NCT02733068 
 
 
Trial name or title Immunogenicity study of a 2-dose immunization schedule of recombinant human papillomavirus
virus-like particle vaccine (type 16 and 18 l1 proteins, yeast) in adolescent females aged 9 to 14
years
Methods RCT
Participants Females aged 9-14 years
Country: China
Interventions HPV-16/18 vaccine (2 doses)
HPV-16/18 vaccine (3 doses)
Outcomes Adverse events and immunogenicity
Starting date February 2016
Contact information Zhaojun Mo, Guangxi Center for Disease Prevention and Control
Notes Sponsors: Shanghai Zerun Biotechnology Co, Ltd; Guangxi Center for Disease Control and Preven-
tion
Trial status in August 2018: recruiting
NCT02740777 
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Trial name or title Effectiveness study of human papilloma virus (HPV) vaccines to prevent recurrence of genital warts
(TheraVACCS)
Methods RCT
Participants Females ≦ 16 years with vulval vaginal genital warts
Country: South Africa
Interventions • Quadrivalent HPV vaccine (Gardasil) doses administered intramuscular as 3 separate 0.5 mL doses
at month 0, month 2 and month 6• Control: hepatitis B vaccine doses administered intramuscular as 3 separate 0.5 mL doses at
month 0, month 2 and month 6
Outcomes Change in size of genital wart lesion; surgical treatment of warts; surgical treatment of cervical dis-
ease; immunogenicity; HIV status
Starting date July 2016
Contact information Greta G Dreyer (Greta.Dreyer@up.ac.za); Cathy Visser (visser.cathy@gmail.com)
Notes Sponsors: University of Pretoria; University of Stellenbosch
Trial status in August 2018: not yet recruiting
NCT02750202 
 
 
Trial name or title A dose reduction immunobridging and safety study of two HPV vaccines in Tanzanian girls
Methods RCT
Participants Females 9 -14 years
Country: Tanzania
Interventions • Bivalent HPV vaccine• Nonavalent HPV vaccine
Outcomes Adverse events and immunogenicity
Starting date 23 February 2017
Contact information Deborah Watson-Jones, London School of Hygiene and Tropical Medicine
Notes Sponsors: London School of Hygiene and Tropical Medicine; University of York; Catalan Institute of
Oncology; National Cancer Institute (NCI); Karolinska Institutet; Technische Universität Berlin; Tan-
zanian National Institute for Medical Research; University of Glasgow
Trial status in August 2018: active, not recruiting
NCT02834637 
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Trial name or title Random, double blind, placebo controlled phase I clinical trials to estimate the safety and prelimi-
nary immunogenicity of tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type)
(Hansenula polymorpha) in women of 9-30 years old and men of 9-17 years old
Methods RCT
Participants Males 9-17 years old, females 9-30 years old
Country China
Interventions • Tetravalent recombinant human papillomavirus vaccine (6,11,16,18 type) (Hansenula polymor-
pha)• Control vaccine
Outcomes Adverse events and immunogenicity
Starting date October 2016
Contact information Beijing Chaoyang District Centre for Disease Control and Prevention
Notes Sponsors: Beijing Chaoyang District Centre for Disease Control and Prevention
Trial status in August 2018: unknown, in August 2016 it was 'Not yet recruiting'
NCT02888418 
 
 
Trial name or title A scientific evaluation of one or two doses of vaccine against human papillomavirus: the ESCUDDO
study
Methods RCT
Participants Females 12-16 years old
Country: Costa Rica
Interventions • Cervarix, 1 dose• Gardasil 9, 1 dose• Cervarix, 2 doses• Gardasil 9, 2 doses
Outcomes Clinical outcomes, adverse events, immunogenicity
Starting date 26 June 2018
Contact information Aimee R Kreimer (kreimera@mail.nih.gov), National Cancer Institute
Notes Sponsors: National Cancer Institute; Bill and Melinda Gates Foundation
Trial status in August 2018: recruiting
NCT03180034 
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Trial name or title Efficacy of quadrivalent HPV vaccine to prevent relapses of genital warts after initial therapeutic re-
sponse (CONDYVAC)
Methods RCT
Participants Males and females ≥ 18 years old, cured of genital warts
Country: France
Interventions • Quadrivalent HPV vaccine (Gardasil)• Saline placebo
Outcomes Relapse free survival; Improvement of quality of life; adverse events
Starting date November 2017
Contact information Sebastien Fouere (sebastien.fouere@aphp.fr); Olivier Chosidow (olivier.chosidow@aphp.fr)
Notes Sponsors: Assistance Publique - Hôpitaux de Paris
Trial status in August 2018: recruiting
NCT03296397 
Abbreviations
AIN: anal intraepithelial neoplasia
HPV: human papillomavirus
MSM: men who have sex with men
RCT: randomised controlled trial
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Two versus three doses of HPV vaccines in 9- to 15-year-old females
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain at injection site 2 1189 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.91, 1.03]
1.1 Bivalent vaccine 1 476 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.03]
1.2 Quadrivalent vaccine 1 713 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.87, 1.00]
2 Swelling at injection site 2 1189 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.65, 0.89]
2.1 Bivalent vaccine 1 476 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.57, 0.87]
2.2 Quadrivalent vaccine 1 713 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.66, 1.04]
3 Redness at injection site 2 1189 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.75, 0.96]
3.1 Bivalent vaccine 1 476 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.72, 0.99]
3.2 Quadrivalent vaccine 1 713 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.71, 1.02]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4 Serious adverse events (overall) 4 2317 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.64, 1.66]
4.1 Bivalent vaccine 1 479 Odds Ratio (M-H, Random, 95% CI) 1.28 [0.64, 2.59]
4.2 Quadrivalent vaccine 2 1236 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.35, 1.74]
4.3 Nonavalent vaccine 1 602 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.32, 3.14]
5 Deaths 3 1797 Odds Ratio (M-H, Random, 95% CI) 0.33 [0.01, 8.19]
5.1 Bivalent vaccine 1 479 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Quadrivalent vaccine 1 716 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.3 Nonavalent vaccine 1 602 Odds Ratio (M-H, Random, 95% CI) 0.33 [0.01, 8.19]
 
 
Analysis 1.1.   Comparison 1 Two versus three doses of HPV vaccines
in 9- to 15-year-old females, Outcome 1 Pain at injection site.
Study or subgroup 2 doses 3 doses Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Bivalent vaccine  
Romanowski 2011 222/238 225/238 59.84% 0.99[0.94,1.03]
Subtotal (95% CI) 238 238 59.84% 0.99[0.94,1.03]
Total events: 222 (2 doses), 225 (3 doses)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
   
1.1.2 Quadrivalent vaccine  
Leung 2015 276/357 295/356 40.16% 0.93[0.87,1]
Subtotal (95% CI) 357 356 40.16% 0.93[0.87,1]
Total events: 276 (2 doses), 295 (3 doses)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.85(P=0.06)  
   
Total (95% CI) 595 594 100% 0.96[0.91,1.03]
Total events: 498 (2 doses), 520 (3 doses)  
Heterogeneity: Tau2=0; Chi2=2.24, df=1(P=0.13); I2=55.26%  
Test for overall effect: Z=1.11(P=0.27)  
Test for subgroup differences: Chi2=1.61, df=1 (P=0.2), I2=37.77%  
Favours 2 doses 1 Favours 3 doses
 
 
Comparison of dierent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females
and males (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
74
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Analysis 1.2.   Comparison 1 Two versus three doses of HPV vaccines
in 9- to 15-year-old females, Outcome 2 Swelling at injection site.
Study or subgroup 2 doses 3 doses Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 Bivalent vaccine  
Romanowski 2011 83/238 118/238 51.77% 0.7[0.57,0.87]
Subtotal (95% CI) 238 238 51.77% 0.7[0.57,0.87]
Total events: 83 (2 doses), 118 (3 doses)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.2(P=0)  
   
1.2.2 Quadrivalent vaccine  
Leung 2015 98/357 118/356 48.23% 0.83[0.66,1.04]
Subtotal (95% CI) 357 356 48.23% 0.83[0.66,1.04]
Total events: 98 (2 doses), 118 (3 doses)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.65(P=0.1)  
   
Total (95% CI) 595 594 100% 0.76[0.65,0.89]
Total events: 181 (2 doses), 236 (3 doses)  
Heterogeneity: Tau2=0; Chi2=1.07, df=1(P=0.3); I2=6.16%  
Test for overall effect: Z=3.34(P=0)  
Test for subgroup differences: Chi2=1.06, df=1 (P=0.3), I2=5.57%  
Favours 2 doses 20.5 1.50.7 1 Favours 3 doses
 
 
Analysis 1.3.   Comparison 1 Two versus three doses of HPV vaccines
in 9- to 15-year-old females, Outcome 3 Redness at injection site.
Study or subgroup 2 doses 3 doses Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 Bivalent vaccine  
Romanowski 2011 123/238 145/238 55.38% 0.85[0.72,0.99]
Subtotal (95% CI) 238 238 55.38% 0.85[0.72,0.99]
Total events: 123 (2 doses), 145 (3 doses)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.02(P=0.04)  
   
1.3.2 Quadrivalent vaccine  
Leung 2015 134/357 157/356 44.62% 0.85[0.71,1.02]
Subtotal (95% CI) 357 356 44.62% 0.85[0.71,1.02]
Total events: 134 (2 doses), 157 (3 doses)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.78(P=0.08)  
   
Total (95% CI) 595 594 100% 0.85[0.75,0.96]
Total events: 257 (2 doses), 302 (3 doses)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%  
Test for overall effect: Z=2.69(P=0.01)  
Test for subgroup differences: Chi2=0, df=1 (P=0.98), I2=0%  
Favours 2 doses 20.5 1.50.7 1 Favours 3 doses
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Analysis 1.4.   Comparison 1 Two versus three doses of HPV vaccines in
9- to 15-year-old females, Outcome 4 Serious adverse events (overall).
Study or subgroup 2 doses 3 doses Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.4.1 Bivalent vaccine  
Romanowski 2011 19/240 15/239 46.72% 1.28[0.64,2.59]
Subtotal (95% CI) 240 239 46.72% 1.28[0.64,2.59]
Total events: 19 (2 doses), 15 (3 doses)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.7(P=0.49)  
   
1.4.2 Quadrivalent vaccine  
Dobson 2013 0/259 0/261   Not estimable
Leung 2015 11/358 14/358 35.65% 0.78[0.35,1.74]
Subtotal (95% CI) 617 619 35.65% 0.78[0.35,1.74]
Total events: 11 (2 doses), 14 (3 doses)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.61(P=0.54)  
   
1.4.3 Nonavalent vaccine  
Iversen 2016 6/301 6/301 17.62% 1[0.32,3.14]
Subtotal (95% CI) 301 301 17.62% 1[0.32,3.14]
Total events: 6 (2 doses), 6 (3 doses)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 1158 1159 100% 1.03[0.64,1.66]
Total events: 36 (2 doses), 35 (3 doses)  
Heterogeneity: Tau2=0; Chi2=0.85, df=2(P=0.66); I2=0%  
Test for overall effect: Z=0.11(P=0.91)  
Test for subgroup differences: Chi2=0.85, df=1 (P=0.66), I2=0%  
Favours 2 doses 1000.01 100.1 1 Favours 3 doses
 
 
Analysis 1.5.   Comparison 1 Two versus three doses of HPV vaccines in 9- to 15-year-old females, Outcome 5 Deaths.
Study or subgroup 2 doses 3 doses Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.5.1 Bivalent vaccine  
Romanowski 2011 0/240 0/239   Not estimable
Subtotal (95% CI) 240 239 Not estimable
Total events: 0 (2 doses), 0 (3 doses)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.5.2 Quadrivalent vaccine  
Leung 2015 0/358 0/358   Not estimable
Subtotal (95% CI) 358 358 Not estimable
Total events: 0 (2 doses), 0 (3 doses)  
Heterogeneity: Not applicable  
Favours 2 doses 1000.01 100.1 1 Favours 3 doses
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Study or subgroup 2 doses 3 doses Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Not applicable  
   
1.5.3 Nonavalent vaccine  
Iversen 2016 0/301 1/301 100% 0.33[0.01,8.19]
Subtotal (95% CI) 301 301 100% 0.33[0.01,8.19]
Total events: 0 (2 doses), 1 (3 doses)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.67(P=0.5)  
   
Total (95% CI) 899 898 100% 0.33[0.01,8.19]
Total events: 0 (2 doses), 1 (3 doses)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.67(P=0.5)  
Test for subgroup differences: Not applicable  
Favours 2 doses 1000.01 100.1 1 Favours 3 doses
 
 
Comparison 2.   Two doses of HPV vaccine with longer interval versus two doses of HPV vaccine with shorter interval
in 9- to 14-year-olds
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain at injection site 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Bivalent vaccine (0 and 2 months vs
0 and 6 months)
1 477 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.96, 1.06]
1.2 Bivalent vaccine (0 and 6 months vs
0 and 12 months)
1 963 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.98, 1.06]
2 Swelling at injection site 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Bivalent vaccine (0 and 2 months vs
0 and 6 months)
1 477 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.76, 1.20]
2.2 Bivalent vaccine (0 and 6 months vs
0 and 12 months)
1 963 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.87, 1.18]
3 Redness at injection site 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Bivalent vaccine (0 and 2 months vs
0 and 6 months)
1 477 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.84, 1.24]
3.2 Bivalent vaccine (0 and 6 months vs
0 and 12 months)
1 963 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.93, 1.22]
4 Serious adverse events (overall) 3   Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Bivalent vaccine (0, 2 months vs 0, 6
months)
1 481 Odds Ratio (M-H, Random, 95% CI) 1.15 [0.55, 2.41]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4.2 Bivalent vaccine (0 and 6 months vs
0 and 12 months)
1 965 Odds Ratio (M-H, Random, 95% CI) 1.63 [0.89, 2.99]
4.3 Nonavalent vaccine (0 and 6 months
vs 0 and 12 months) - females and males
1 903 Odds Ratio (M-H, Random, 95% CI) 0.80 [0.31, 2.07]
5 Deaths 3   Odds Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Bivalent vaccine (0 and 2 months vs
0 and 6 months)
1 481 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Bivalent vaccine (0 and 6 months vs
0 and 12 months)
1 965 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.3 Nonavalent vaccine (0 and 6 months
vs 0 and 12 months)
1 452 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 2.1.   Comparison 2 Two doses of HPV vaccine with longer interval versus two doses
of HPV vaccine with shorter interval in 9- to 14-year-olds, Outcome 1 Pain at injection site.
Study or subgroup Longer interval Shorter
interval
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.1.1 Bivalent vaccine (0 and 2 months vs 0 and 6 months)  
Romanowski 2011 225/239 222/238 100% 1.01[0.96,1.06]
Subtotal (95% CI) 239 238 100% 1.01[0.96,1.06]
Total events: 225 (Longer interval), 222 (Shorter interval)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.39(P=0.7)  
   
2.1.2 Bivalent vaccine (0 and 6 months vs 0 and 12 months)  
Puthanakit 2016 381/413 499/550 100% 1.02[0.98,1.06]
Subtotal (95% CI) 413 550 100% 1.02[0.98,1.06]
Total events: 381 (Longer interval), 499 (Shorter interval)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.84(P=0.4)  
Favours longer interval 1 Favours shorter interval
 
 
Analysis 2.2.   Comparison 2 Two doses of HPV vaccine with longer interval versus two doses
of HPV vaccine with shorter interval in 9- to 14-year-olds, Outcome 2 Swelling at injection site.
Study or subgroup Longer interval Shorter
interval
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.2.1 Bivalent vaccine (0 and 2 months vs 0 and 6 months)  
Romanowski 2011 88/239 92/238 100% 0.95[0.76,1.2]
Favours longer interval 1 Favours shorter interval
Comparison of dierent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females
and males (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
78
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Longer interval Shorter
interval
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 239 238 100% 0.95[0.76,1.2]
Total events: 88 (Longer interval), 92 (Shorter interval)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
   
2.2.2 Bivalent vaccine (0 and 6 months vs 0 and 12 months)  
Puthanakit 2016 171/413 225/550 100% 1.01[0.87,1.18]
Subtotal (95% CI) 413 550 100% 1.01[0.87,1.18]
Total events: 171 (Longer interval), 225 (Shorter interval)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.15(P=0.88)  
Test for subgroup differences: Chi2=0.19, df=1 (P=0.67), I2=0%  
Favours longer interval 1 Favours shorter interval
 
 
Analysis 2.3.   Comparison 2 Two doses of HPV vaccine with longer interval versus two doses
of HPV vaccine with shorter interval in 9- to 14-year-olds, Outcome 3 Redness at injection site.
Study or subgroup Longer interval Shorter
interval
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.3.1 Bivalent vaccine (0 and 2 months vs 0 and 6 months)  
Romanowski 2011 112/239 109/238 100% 1.02[0.84,1.24]
Subtotal (95% CI) 239 238 100% 1.02[0.84,1.24]
Total events: 112 (Longer interval), 109 (Shorter interval)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.23(P=0.82)  
   
2.3.2 Bivalent vaccine (0 and 6 months vs 0 and 12 months)  
Puthanakit 2016 197/413 247/550 100% 1.06[0.93,1.22]
Subtotal (95% CI) 413 550 100% 1.06[0.93,1.22]
Total events: 197 (Longer interval), 247 (Shorter interval)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.86(P=0.39)  
Test for subgroup differences: Chi2=0.1, df=1 (P=0.76), I2=0%  
Favours longer interval 20.5 1.50.7 1 Favours shorter interval
 
 
Analysis 2.4.   Comparison 2 Two doses of HPV vaccine with longer interval versus two doses of HPV
vaccine with shorter interval in 9- to 14-year-olds, Outcome 4 Serious adverse events (overall).
Study or subgroup Longer interval Shorter
interval
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.4.1 Bivalent vaccine (0, 2 months vs 0, 6 months)  
Romanowski 2011 16/241 14/240 100% 1.15[0.55,2.41]
Subtotal (95% CI) 241 240 100% 1.15[0.55,2.41]
Total events: 16 (Longer interval), 14 (Shorter interval)  
Favours longer interval 1000.01 100.1 1 Favours shorter interval
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Study or subgroup Longer interval Shorter
interval
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.37(P=0.72)  
   
2.4.2 Bivalent vaccine (0 and 6 months vs 0 and 12 months)  
Puthanakit 2016 24/415 20/550 100% 1.63[0.89,2.99]
Subtotal (95% CI) 415 550 100% 1.63[0.89,2.99]
Total events: 24 (Longer interval), 20 (Shorter interval)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.57(P=0.12)  
   
2.4.3 Nonavalent vaccine (0 and 6 months vs 0 and 12 months) - fe-
males and males
 
Iversen 2016 6/301 15/602 100% 0.8[0.31,2.07]
Subtotal (95% CI) 301 602 100% 0.8[0.31,2.07]
Total events: 6 (Longer interval), 15 (Shorter interval)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.47(P=0.64)  
Test for subgroup differences: Chi2=1.62, df=1 (P=0.44), I2=0%  
Favours longer interval 1000.01 100.1 1 Favours shorter interval
 
 
Analysis 2.5.   Comparison 2 Two doses of HPV vaccine with longer interval versus two
doses of HPV vaccine with shorter interval in 9- to 14-year-olds, Outcome 5 Deaths.
Study or subgroup Longer interval Shorter
interval
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.5.1 Bivalent vaccine (0 and 2 months vs 0 and 6 months)  
Romanowski 2011 0/241 0/240   Not estimable
Subtotal (95% CI) 241 240 Not estimable
Total events: 0 (Longer interval), 0 (Shorter interval)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.5.2 Bivalent vaccine (0 and 6 months vs 0 and 12 months)  
Puthanakit 2016 0/415 0/550   Not estimable
Subtotal (95% CI) 415 550 Not estimable
Total events: 0 (Longer interval), 0 (Shorter interval)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.5.3 Nonavalent vaccine (0 and 6 months vs 0 and 12 months)  
Iversen 2016 0/151 0/301   Not estimable
Subtotal (95% CI) 151 301 Not estimable
Total events: 0 (Longer interval), 0 (Shorter interval)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours longer interval 1000.01 100.1 1 Favours shorter interval
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Comparison 3.   Three doses of HPV vaccine with longer interval versus three doses of HPV vaccine with shorter
interval in 18- to 25-year-old males
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Adverse events     Other data No numeric data
2 Serious adverse events (overall) 1 220 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 3.1.   Comparison 3 Three doses of HPV vaccine with longer interval versus three doses
of HPV vaccine with shorter interval in 18- to 25-year-old males, Outcome 1 Adverse events.
Adverse events
Study  
Lin 2014 Adverse events data not reported separately for each arm.
"Participants reported side effects following 646 separate vaccinations; 172 local
and general reactions were reported, with no difference in proportion of side ef-
fects reported between Standard (24.4%) and Alternate (28.9%) schedule groups (P
= 0.26). The majority of side effects were pain and redness at the injection site (86%;
n = 148), with the remainder composed of fever (3.5%; n = 6), and miscellaneous
symptoms (10.5%; n = 18). There were no reports of any serious side effects."
 
 
Analysis 3.2.   Comparison 3 Three doses of HPV vaccine with longer interval versus three doses of HPV
vaccine with shorter interval in 18- to 25-year-old males, Outcome 2 Serious adverse events (overall).
Study or subgroup Longer interval Shorter
interval
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Lin 2014 0/111 0/109   Not estimable
   
Total (95% CI) 111 109 Not estimable
Total events: 0 (Longer interval), 0 (Shorter interval)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours longer interval 1000.01 100.1 1 Favours shorter interval
 
 
Comparison 4.   HPV vaccine versus control in males
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 External genital lesions (any type) 1   Rate Ratio (Random, 95% CI) Subtotals only
1.1 Quadrivalent vaccine (16- to 26-
year olds)
1   Rate Ratio (Random, 95% CI) 0.16 [0.07, 0.38]
2 External genital lesions (HPV 6, 11,
16, or 18)
1   Rate Ratio (Random, 95% CI) Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2.1 Quadrivalent vaccine (16- to 26-
year olds)
1   Rate Ratio (Random, 95% CI) 0.10 [0.03, 0.31]
3 Anogenital warts 1   Rate Ratio (Random, 95% CI) Subtotals only
3.1 Quadrivalent vaccine (16- to 26-
year olds)
1   Rate Ratio (Random, 95% CI) 0.11 [0.03, 0.38]
4 All penile, perianal, or perineal in-
traepithelial neoplasia lesions
1   Rate Ratio (Random, 95% CI) Subtotals only
4.1 Quadrivalent vaccine (16- to 26-
year olds)
1   Rate Ratio (Random, 95% CI) 0.17 [0.01, 3.27]
5 Penile, perianal, or perineal intraep-
ithelial neoplasia grade 1
1   Rate Ratio (Random, 95% CI) Subtotals only
5.1 Quadrivalent vaccine (16- to 26-
year olds)
1   Rate Ratio (Random, 95% CI) 0.25 [0.01, 6.22]
6 Penile, perianal, or perineal intraep-
ithelial neoplasia grade 2 or 3
1   Rate Ratio (Random, 95% CI) Subtotals only
6.1 Quadrivalent vaccine (16- to 26-
year olds)
1   Rate Ratio (Random, 95% CI) 0.50 [0.02, 14.80]
7 Overall local/injection site adverse
events
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Quadrivalent vaccine (16- to 26-
year olds)
1 3895 Risk Ratio (M-H, Random, 95% CI) 1.12 [1.06, 1.18]
8 Pain at injection site 3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Bivalent vaccine (10- to 18-year-
olds)
1 268 Risk Ratio (M-H, Random, 95% CI) 1.99 [1.57, 2.53]
8.2 Quadrivalent vaccine (16- to 26-
year olds)
2 5162 Risk Ratio (M-H, Random, 95% CI) 1.13 [1.07, 1.19]
9 Swelling at injection site 3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Bivalent vaccine (10- to 18-year-
olds)
1 268 Risk Ratio (M-H, Random, 95% CI) 2.51 [1.17, 5.42]
9.2 Quadrivalent vaccine (16- to 26-
year olds)
2 5162 Risk Ratio (M-H, Random, 95% CI) 1.29 [1.04, 1.60]
10 Redness at injection site 3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Bivalent vaccine (10- to 18-year-
olds)
1 268 Risk Ratio (M-H, Random, 95% CI) 1.66 [0.99, 2.79]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
10.2 Quadrivalent vaccine (16- to 26-
year olds)
2 5162 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.99, 1.27]
11 Overall systemic events and gener-
al symptoms
2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Quadrivalent vaccine (16- to 26-
year olds)
2 5008 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.90, 1.08]
12 Serious adverse events (overall) 3   Odds Ratio (M-H, Random, 95% CI) Subtotals only
12.1 Bivalent vaccine (10- to 18-year-
olds)
1 270 Odds Ratio (M-H, Random, 95% CI) 1.48 [0.15, 14.46]
12.2 Quadrivalent vaccine (16- to 26-
year olds)
2 5162 Odds Ratio (M-H, Random, 95% CI) 0.69 [0.29, 1.66]
13 Deaths 3   Odds Ratio (M-H, Random, 95% CI) Subtotals only
13.1 Bivalent vaccine (10- to 18-year-
olds)
1 270 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Quadrivalent vaccine (16- to 26-
year olds)
2 5173 Odds Ratio (M-H, Random, 95% CI) 0.30 [0.09, 1.01]
 
 
Analysis 4.1.   Comparison 4 HPV vaccine versus control in males, Outcome 1 External genital lesions (any type).
Study or subgroup Quadriva-
lent vaccine
Control log[Rate
Ratio]
Rate Ratio Weight Rate Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
4.1.1 Quadrivalent vaccine (16- to 26-year olds)  
Giuliano 2011 0 0 -1.8 (0.441) 100% 0.16[0.07,0.38]
Subtotal (95% CI)       100% 0.16[0.07,0.38]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=4.13(P<0.0001)  
Favours quadrivalent 10000.001 100.1 1 Favours control
 
 
Analysis 4.2.   Comparison 4 HPV vaccine versus control in
males, Outcome 2 External genital lesions (HPV 6, 11, 16, or 18).
Study or subgroup Quadriva-
lent vaccine
Control log[Rate
Ratio]
Rate Ratio Weight Rate Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
4.2.1 Quadrivalent vaccine (16- to 26-year olds)  
Giuliano 2011 0 0 -2.3 (0.594) 100% 0.1[0.03,0.31]
Subtotal (95% CI)       100% 0.1[0.03,0.31]
Heterogeneity: Not applicable  
Favours quadrivalent 1000.01 100.1 1 Favours control
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Study or subgroup Quadriva-
lent vaccine
Control log[Rate
Ratio]
Rate Ratio Weight Rate Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Test for overall effect: Z=3.94(P<0.0001)  
Favours quadrivalent 1000.01 100.1 1 Favours control
 
 
Analysis 4.3.   Comparison 4 HPV vaccine versus control in males, Outcome 3 Anogenital warts.
Study or subgroup Quadriva-
lent vaccine
Control log[Rate
Ratio]
Rate Ratio Weight Rate Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
4.3.1 Quadrivalent vaccine (16- to 26-year olds)  
Giuliano 2011 0 0 -2.2 (0.646) 100% 0.11[0.03,0.38]
Subtotal (95% CI)       100% 0.11[0.03,0.38]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.46(P=0)  
Favours quadrivalent 1000.01 100.1 1 Favours control
 
 
Analysis 4.4.   Comparison 4 HPV vaccine versus control in males, Outcome
4 All penile, perianal, or perineal intraepithelial neoplasia lesions.
Study or subgroup Quadriva-
lent vaccine
Control log[Rate
Ratio]
Rate Ratio Weight Rate Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
4.4.1 Quadrivalent vaccine (16- to 26-year olds)  
Giuliano 2011 0 0 -1.8 (1.52) 100% 0.17[0.01,3.27]
Subtotal (95% CI)       100% 0.17[0.01,3.27]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.18(P=0.24)  
Favours quadrivalent 10000.001 100.1 1 Favours control
 
 
Analysis 4.5.   Comparison 4 HPV vaccine versus control in males,
Outcome 5 Penile, perianal, or perineal intraepithelial neoplasia grade 1.
Study or subgroup Quadriva-
lent vaccine
Control log[Rate
Ratio]
Rate Ratio Weight Rate Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
4.5.1 Quadrivalent vaccine (16- to 26-year olds)  
Giuliano 2011 0 0 -1.4 (1.641) 100% 0.25[0.01,6.22]
Subtotal (95% CI)       100% 0.25[0.01,6.22]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.4)  
Favours quadrivalent 10000.001 100.1 1 Favours control
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Analysis 4.6.   Comparison 4 HPV vaccine versus control in males, Outcome
6 Penile, perianal, or perineal intraepithelial neoplasia grade 2 or 3.
Study or subgroup Quadriva-
lent vaccine
Control log[Rate
Ratio]
Rate Ratio Weight Rate Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
4.6.1 Quadrivalent vaccine (16- to 26-year olds)  
Giuliano 2011 0 0 -0.7 (1.73) 100% 0.5[0.02,14.8]
Subtotal (95% CI)       100% 0.5[0.02,14.8]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.4(P=0.69)  
Favours quadrivalent 10000.001 100.1 1 Favours control
 
 
Analysis 4.7.   Comparison 4 HPV vaccine versus control in
males, Outcome 7 Overall local/injection site adverse events.
Study or subgroup Quadriva-
lent vaccine
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.7.1 Quadrivalent vaccine (16- to 26-year olds)  
Giuliano 2011 1169/1945 1047/1950 100% 1.12[1.06,1.18]
Subtotal (95% CI) 1945 1950 100% 1.12[1.06,1.18]
Total events: 1169 (Quadrivalent vaccine), 1047 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=4.03(P<0.0001)  
Favours quadrivalent 1 Favours control
 
 
Analysis 4.8.   Comparison 4 HPV vaccine versus control in males, Outcome 8 Pain at injection site.
Study or subgroup HPV vaccine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.8.1 Bivalent vaccine (10- to 18-year-olds)  
Petaja 2009 159/180 39/88 100% 1.99[1.57,2.53]
Subtotal (95% CI) 180 88 100% 1.99[1.57,2.53]
Total events: 159 (HPV vaccine), 39 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=5.63(P<0.0001)  
   
4.8.2 Quadrivalent vaccine (16- to 26-year olds)  
Giuliano 2011 1116/2020 992/2029 78.7% 1.13[1.06,1.2]
NCT01862874 2018 304/554 271/559 21.3% 1.13[1.01,1.27]
Subtotal (95% CI) 2574 2588 100% 1.13[1.07,1.19]
Total events: 1420 (HPV vaccine), 1263 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%  
Test for overall effect: Z=4.56(P<0.0001)  
Test for subgroup differences: Chi2=20.45, df=1 (P<0.0001), I2=95.11%  
Favours HPV vaccine 100.1 50.2 20.5 1 Favours control
 
 
Comparison of dierent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females
and males (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
85
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Analysis 4.9.   Comparison 4 HPV vaccine versus control in males, Outcome 9 Swelling at injection site.
Study or subgroup HPV vaccine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.9.1 Bivalent vaccine (10- to 18-year-olds)  
Petaja 2009 36/180 7/88 100% 2.51[1.17,5.42]
Subtotal (95% CI) 180 88 100% 2.51[1.17,5.42]
Total events: 36 (HPV vaccine), 7 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.35(P=0.02)  
   
4.9.2 Quadrivalent vaccine (16- to 26-year olds)  
Giuliano 2011 219/2020 187/2029 58.35% 1.18[0.98,1.42]
NCT01862874 2018 118/554 81/559 41.65% 1.47[1.14,1.9]
Subtotal (95% CI) 2574 2588 100% 1.29[1.04,1.6]
Total events: 337 (HPV vaccine), 268 (Control)  
Heterogeneity: Tau2=0.01; Chi2=1.9, df=1(P=0.17); I2=47.38%  
Test for overall effect: Z=2.32(P=0.02)  
Test for subgroup differences: Chi2=2.68, df=1 (P=0.1), I2=62.71%  
Favours HPV vaccine 1000.01 100.1 1 Favours control
 
 
Analysis 4.10.   Comparison 4 HPV vaccine versus control in males, Outcome 10 Redness at injection site.
Study or subgroup HPV vaccine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.10.1 Bivalent vaccine (10- to 18-year-olds)  
Petaja 2009 51/180 15/88 100% 1.66[0.99,2.79]
Subtotal (95% CI) 180 88 100% 1.66[0.99,2.79]
Total events: 51 (HPV vaccine), 15 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.93(P=0.05)  
   
4.10.2 Quadrivalent vaccine (16- to 26-year olds)  
Giuliano 2011 304/2020 275/2029 66.94% 1.11[0.95,1.29]
NCT01862874 2018 136/554 121/559 33.06% 1.13[0.91,1.41]
Subtotal (95% CI) 2574 2588 100% 1.12[0.99,1.27]
Total events: 440 (HPV vaccine), 396 (Control)  
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.87); I2=0%  
Test for overall effect: Z=1.77(P=0.08)  
Test for subgroup differences: Chi2=2.14, df=1 (P=0.14), I2=53.35%  
Favours HPV vaccine 1000.01 100.1 1 Favours control
 
 
Analysis 4.11.   Comparison 4 HPV vaccine versus control in males,
Outcome 11 Overall systemic events and general symptoms.
Study or subgroup Quadriva-
lent vaccine
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.11.1 Quadrivalent vaccine (16- to 26-year olds)  
Favours quadrivalent 20.5 1.50.7 1 Favours control
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Study or subgroup Quadriva-
lent vaccine
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Giuliano 2011 616/1945 622/1950 90.31% 0.99[0.91,1.09]
NCT01862874 2018 80/554 86/559 9.69% 0.94[0.71,1.24]
Subtotal (95% CI) 2499 2509 100% 0.99[0.9,1.08]
Total events: 696 (Quadrivalent vaccine), 708 (Control)  
Heterogeneity: Tau2=0; Chi2=0.14, df=1(P=0.71); I2=0%  
Test for overall effect: Z=0.28(P=0.78)  
Favours quadrivalent 20.5 1.50.7 1 Favours control
 
 
Analysis 4.12.   Comparison 4 HPV vaccine versus control in males, Outcome 12 Serious adverse events (overall).
Study or subgroup HPV vaccine Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.12.1 Bivalent vaccine (10- to 18-year-olds)  
Petaja 2009 3/181 1/89 100% 1.48[0.15,14.46]
Subtotal (95% CI) 181 89 100% 1.48[0.15,14.46]
Total events: 3 (HPV vaccine), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.34(P=0.73)  
   
4.12.2 Quadrivalent vaccine (16- to 26-year olds)  
Giuliano 2011 8/2020 11/2029 92.49% 0.73[0.29,1.82]
NCT01862874 2018 0/554 1/559 7.51% 0.34[0.01,8.26]
Subtotal (95% CI) 2574 2588 100% 0.69[0.29,1.66]
Total events: 8 (HPV vaccine), 12 (Control)  
Heterogeneity: Tau2=0; Chi2=0.21, df=1(P=0.65); I2=0%  
Test for overall effect: Z=0.83(P=0.4)  
Test for subgroup differences: Chi2=0.38, df=1 (P=0.54), I2=0%  
Favours HPV vaccine 1000.01 100.1 1 Favours control
 
 
Analysis 4.13.   Comparison 4 HPV vaccine versus control in males, Outcome 13 Deaths.
Study or subgroup HPV vaccine Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.13.1 Bivalent vaccine (10- to 18-year-olds)  
Petaja 2009 0/181 0/89   Not estimable
Subtotal (95% CI) 181 89 Not estimable
Total events: 0 (HPV vaccine), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.13.2 Quadrivalent vaccine (16- to 26-year olds)  
Giuliano 2011 3/2020 10/2029 86.01% 0.3[0.08,1.09]
NCT01862874 2018 0/562 1/562 13.99% 0.33[0.01,8.19]
Subtotal (95% CI) 2582 2591 100% 0.3[0.09,1.01]
Total events: 3 (HPV vaccine), 11 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%  
Favours HPV vaccine 1000.01 100.1 1 Favours control
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Study or subgroup HPV vaccine Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=1.94(P=0.05)  
Test for subgroup differences: Not applicable  
Favours HPV vaccine 1000.01 100.1 1 Favours control
 
 
Comparison 5.   Nonavalent HPV vaccine versus quadrivalent HPV vaccine in 9- to 26-year-olds
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 High-grade cervical epithelial neo-
plasia, adenocarcinoma in situ, and
cervical cancer
1 13753 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.85, 1.16]
2 High-grade cervical, vulval, and
vaginal disease
1 14054 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.85, 1.15]
3 High-grade cervical disease related
to HPV 6, 11, 16, or 18
1 11656 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.06, 16.01]
4 High-grade vulval and vaginal dis-
ease related to HPV 6, 11, 16, or 18
1 11769 Odds Ratio (M-H, Random, 95% CI) 0.14 [0.01, 2.77]
5 High-grade cervical disease related
to HPV 31, 33, 45, 52, or 58
1 11892 Odds Ratio (M-H, Random, 95% CI) 0.03 [0.00, 0.21]
6 High-grade vulval and vaginal dis-
ease related to HPV 31, 33, 45, 52, or
58
1 12021 Odds Ratio (M-H, Random, 95% CI) 0.14 [0.01, 2.77]
7 Cervical intraepithelial neoplasia 2
related to HPV 6, 11, 16, or 18
1 11656 Odds Ratio (M-H, Random, 95% CI) 3.00 [0.12, 73.77]
8 Cervical intraepithelial neoplasia 2
related to HPV 31, 33, 45, 52, or 58
1 11892 Odds Ratio (M-H, Random, 95% CI) 0.03 [0.00, 0.23]
9 Cervical intraepithelial neoplasia 3,
adenocarcinoma in situ, and cervical
cancer related to HPV 6, 11, 16, or 18
1 11656 Odds Ratio (M-H, Random, 95% CI) 0.33 [0.01, 8.19]
10 Cervical intraepithelial neoplasia
3, adenocarcinoma in situ, and cervi-
cal cancer related to HPV 31, 33, 45,
52, or 58
1 11892 Odds Ratio (M-H, Random, 95% CI) 0.07 [0.00, 1.16]
11 Overall local/injection site adverse
events
3 15863 Risk Ratio (M-H, Random, 95% CI) 1.07 [1.05, 1.08]
11.1 9- to 15-year-old females 1 599 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.98, 1.09]
11.2 16- to 26-year-old females 1 14764 Risk Ratio (M-H, Random, 95% CI) 1.07 [1.05, 1.08]
11.3 16- to 26-year-old males 1 500 Risk Ratio (M-H, Random, 95% CI) 1.10 [1.00, 1.22]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
12 Pain at injection site 3 15863 Risk Ratio (M-H, Random, 95% CI) 1.06 [1.02, 1.11]
12.1 9- to 15-year-old females 1 599 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.96, 1.07]
12.2 16- to 26-year-old females 1 14764 Risk Ratio (M-H, Random, 95% CI) 1.07 [1.06, 1.09]
12.3 16- to 26-year-old males 1 500 Risk Ratio (M-H, Random, 95% CI) 1.12 [1.01, 1.24]
13 Swelling at injection site 3 15863 Risk Ratio (M-H, Random, 95% CI) 1.37 [1.31, 1.44]
13.1 9- to 15-year-old females 1 599 Risk Ratio (M-H, Random, 95% CI) 1.33 [1.10, 1.60]
13.2 16- to 26-year-old females 1 14764 Risk Ratio (M-H, Random, 95% CI) 1.38 [1.31, 1.44]
13.3 16- to 26-year-old males 1 500 Risk Ratio (M-H, Random, 95% CI) 1.58 [0.96, 2.58]
14 Redness at injection site 3 15863 Risk Ratio (M-H, Random, 95% CI) 1.20 [1.00, 1.44]
14.1 9- to 15-year-old females 1 599 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.92, 1.47]
14.2 16- to 26-year-old females 1 14764 Risk Ratio (M-H, Random, 95% CI) 1.32 [1.26, 1.39]
14.3 16- to 26-year-old males 1 500 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.60, 1.33]
15 Overall systemic events and gener-
al symptoms
3 15863 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.98, 1.04]
15.1 9- to 15-year-old females 1 599 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.07]
15.2 16- to 26-year-old females 1 14764 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.98, 1.04]
15.3 16- to 26-year-old males 1 500 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.82, 1.26]
16 Serious adverse events (overall) 3 15863 Odds Ratio (M-H, Random, 95% CI) 0.60 [0.14, 2.61]
16.1 9- to 15-year-old females 1 599 Odds Ratio (M-H, Random, 95% CI) 0.5 [0.05, 5.54]
16.2 16- to 26-year-old females 1 14764 Odds Ratio (M-H, Random, 95% CI) 1.22 [1.00, 1.48]
16.3 16- to 26-year-old males 1 500 Odds Ratio (M-H, Random, 95% CI) 0.08 [0.00, 1.35]
17 Deaths 3 15248 Odds Ratio (M-H, Random, 95% CI) 1.20 [0.37, 3.94]
17.1 9- to 15-year old females 1 599 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 16- to 26-year-old females 1 14149 Odds Ratio (M-H, Random, 95% CI) 1.20 [0.37, 3.94]
17.3 16- to 26-year-old males 1 500 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 5.1.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent HPV vaccine in 9- to 26-year-
olds, Outcome 1 High-grade cervical epithelial neoplasia, adenocarcinoma in situ, and cervical cancer.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Joura 2015 325/6882 326/6871 100% 1[0.85,1.16]
   
Total (95% CI) 6882 6871 100% 1[0.85,1.16]
Total events: 325 (Nonavalent vaccine), 326 (Quadrivalent vaccine)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.06(P=0.95)  
Favours nonavalent 1000.01 100.1 1 Favours quadrivalent
 
 
Analysis 5.2.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent HPV vaccine
in 9- to 26-year-olds, Outcome 2 High-grade cervical, vulval, and vaginal disease.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Joura 2015 340/7027 344/7027 100% 0.99[0.85,1.15]
   
Total (95% CI) 7027 7027 100% 0.99[0.85,1.15]
Total events: 340 (Nonavalent vaccine), 344 (Quadrivalent vaccine)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.16(P=0.88)  
Favours nonavalent 1000.01 100.1 1 Favours quadrivalent
 
 
Analysis 5.3.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent HPV vaccine in
9- to 26-year-olds, Outcome 3 High-grade cervical disease related to HPV 6, 11, 16, or 18.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Joura 2015 1/5824 1/5832 100% 1[0.06,16.01]
   
Total (95% CI) 5824 5832 100% 1[0.06,16.01]
Total events: 1 (Nonavalent vaccine), 1 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0(P=1)  
Favours nonavalent 1000.01 100.1 1 Favours quadrivalent
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Analysis 5.4.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent HPV vaccine in 9- to
26-year-olds, Outcome 4 High-grade vulval and vaginal disease related to HPV 6, 11, 16, or 18.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Joura 2015 0/5876 3/5893 100% 0.14[0.01,2.77]
   
Total (95% CI) 5876 5893 100% 0.14[0.01,2.77]
Total events: 0 (Nonavalent vaccine), 3 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.29(P=0.2)  
Favours nonavalent 1000.01 100.1 1 Favours quadrivalent
 
 
Analysis 5.5.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent HPV vaccine in 9-
to 26-year-olds, Outcome 5 High-grade cervical disease related to HPV 31, 33, 45, 52, or 58.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Joura 2015 1/5949 35/5943 100% 0.03[0,0.21]
   
Total (95% CI) 5949 5943 100% 0.03[0,0.21]
Total events: 1 (Nonavalent vaccine), 35 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.51(P=0)  
Favours nonavalent 1000.01 100.1 1 Favours quadrivalent
 
 
Analysis 5.6.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent HPV vaccine in 9- to 26-
year-olds, Outcome 6 High-grade vulval and vaginal disease related to HPV 31, 33, 45, 52, or 58.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Joura 2015 0/6009 3/6012 100% 0.14[0.01,2.77]
   
Total (95% CI) 6009 6012 100% 0.14[0.01,2.77]
Total events: 0 (Nonavalent vaccine), 3 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.29(P=0.2)  
Favours nonavalent 1000.01 100.1 1 Favours quadrivalent
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Analysis 5.7.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent HPV vaccine in 9-
to 26-year-olds, Outcome 7 Cervical intraepithelial neoplasia 2 related to HPV 6, 11, 16, or 18.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Joura 2015 1/5824 0/5832 100% 3[0.12,73.77]
   
Total (95% CI) 5824 5832 100% 3[0.12,73.77]
Total events: 1 (Nonavalent vaccine), 0 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.67(P=0.5)  
Favours nonavalent 1000.01 100.1 1 Favours quadrivalent
 
 
Analysis 5.8.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent HPV vaccine in 9- to
26-year-olds, Outcome 8 Cervical intraepithelial neoplasia 2 related to HPV 31, 33, 45, 52, or 58.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Joura 2015 1/5949 32/5943 100% 0.03[0,0.23]
   
Total (95% CI) 5949 5943 100% 0.03[0,0.23]
Total events: 1 (Nonavalent vaccine), 32 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.42(P=0)  
Favours nonavalent 1000.01 100.1 1 Favours quadrivalent
 
 
Analysis 5.9.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent HPV vaccine in 9- to 26-year-olds, Outcome
9 Cervical intraepithelial neoplasia 3, adenocarcinoma in situ, and cervical cancer related to HPV 6, 11, 16, or 18.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Joura 2015 0/5824 1/5832 100% 0.33[0.01,8.19]
   
Total (95% CI) 5824 5832 100% 0.33[0.01,8.19]
Total events: 0 (Nonavalent vaccine), 1 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.67(P=0.5)  
Favours nonavalent 1000.01 100.1 1 Favours quadrivalent
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Analysis 5.10.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent HPV
vaccine in 9- to 26-year-olds, Outcome 10 Cervical intraepithelial neoplasia 3,
adenocarcinoma in situ, and cervical cancer related to HPV 31, 33, 45, 52, or 58.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Joura 2015 0/5949 7/5943 100% 0.07[0,1.16]
   
Total (95% CI) 5949 5943 100% 0.07[0,1.16]
Total events: 0 (Nonavalent vaccine), 7 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.86(P=0.06)  
Favours nonavalent 1000.01 100.1 1 Favours quadrivalent
 
 
Analysis 5.11.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent HPV
vaccine in 9- to 26-year-olds, Outcome 11 Overall local/injection site adverse events.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.11.1 9- to 15-year-old females  
Vesikari 2015 274/299 265/300 4.87% 1.04[0.98,1.09]
Subtotal (95% CI) 299 300 4.87% 1.04[0.98,1.09]
Total events: 274 (Nonavalent vaccine), 265 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.35(P=0.18)  
   
5.11.2 16- to 26-year-old females  
Joura 2015 6961/7686 6009/7078 93.78% 1.07[1.05,1.08]
Subtotal (95% CI) 7686 7078 93.78% 1.07[1.05,1.08]
Total events: 6961 (Nonavalent vaccine), 6009 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=10.4(P<0.0001)  
   
5.11.3 16- to 26-year-old males  
van Damme 2016 196/249 179/251 1.35% 1.1[1,1.22]
Subtotal (95% CI) 249 251 1.35% 1.1[1,1.22]
Total events: 196 (Nonavalent vaccine), 179 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.9(P=0.06)  
   
Total (95% CI) 8234 7629 100% 1.07[1.05,1.08]
Total events: 7431 (Nonavalent vaccine), 6453 (Quadrivalent vaccine)  
Heterogeneity: Tau2=0; Chi2=1.47, df=2(P=0.48); I2=0%  
Test for overall effect: Z=10.59(P<0.0001)  
Test for subgroup differences: Chi2=1.46, df=1 (P=0.48), I2=0%  
Favours nonavalent 1 Favours quadrivalent
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Analysis 5.12.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent
HPV vaccine in 9- to 26-year-olds, Outcome 12 Pain at injection site.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.12.1 9- to 15-year-old females  
Vesikari 2015 269/299 266/300 30.53% 1.01[0.96,1.07]
Subtotal (95% CI) 299 300 30.53% 1.01[0.96,1.07]
Total events: 269 (Nonavalent vaccine), 266 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.51(P=0.61)  
   
5.12.2 16- to 26-year-old females  
Joura 2015 6900/7686 5911/7078 56.1% 1.07[1.06,1.09]
Subtotal (95% CI) 7686 7078 56.1% 1.07[1.06,1.09]
Total events: 6900 (Nonavalent vaccine), 5911 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=11.06(P<0.0001)  
   
5.12.3 16- to 26-year-old males  
van Damme 2016 193/249 174/251 13.37% 1.12[1.01,1.24]
Subtotal (95% CI) 249 251 13.37% 1.12[1.01,1.24]
Total events: 193 (Nonavalent vaccine), 174 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.06(P=0.04)  
   
Total (95% CI) 8234 7629 100% 1.06[1.02,1.11]
Total events: 7362 (Nonavalent vaccine), 6351 (Quadrivalent vaccine)  
Heterogeneity: Tau2=0; Chi2=4.6, df=2(P=0.1); I2=56.48%  
Test for overall effect: Z=2.66(P=0.01)  
Test for subgroup differences: Chi2=4.56, df=1 (P=0.1), I2=56.17%  
Favours nonavalent 1 Favours quadrivalent
 
 
Analysis 5.13.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent
HPV vaccine in 9- to 26-year-olds, Outcome 13 Swelling at injection site.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.13.1 9- to 15-year-old females  
Vesikari 2015 144/299 109/300 5.45% 1.33[1.1,1.6]
Subtotal (95% CI) 299 300 5.45% 1.33[1.1,1.6]
Total events: 144 (Nonavalent vaccine), 109 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.9(P=0)  
   
5.13.2 16- to 26-year-old females  
Joura 2015 3039/7686 2035/7078 93.73% 1.38[1.31,1.44]
Subtotal (95% CI) 7686 7078 93.73% 1.38[1.31,1.44]
Total events: 3039 (Nonavalent vaccine), 2035 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Favours nonavalent 1 Favours quadrivalent
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Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=13.6(P<0.0001)  
   
5.13.3 16- to 26-year-old males  
van Damme 2016 36/249 23/251 0.81% 1.58[0.96,2.58]
Subtotal (95% CI) 249 251 0.81% 1.58[0.96,2.58]
Total events: 36 (Nonavalent vaccine), 23 (Quadrivalent vaccine)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.81(P=0.07)  
   
Total (95% CI) 8234 7629 100% 1.37[1.31,1.44]
Total events: 3219 (Nonavalent vaccine), 2167 (Quadrivalent vaccine)  
Heterogeneity: Tau2=0; Chi2=0.44, df=2(P=0.8); I2=0%  
Test for overall effect: Z=14.01(P<0.0001)  
Test for subgroup differences: Chi2=0.44, df=1 (P=0.8), I2=0%  
Favours nonavalent 1 Favours quadrivalent
 
 
Analysis 5.14.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent
HPV vaccine in 9- to 26-year-olds, Outcome 14 Redness at injection site.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.14.1 9- to 15-year-old females  
Vesikari 2015 102/299 88/300 29.52% 1.16[0.92,1.47]
Subtotal (95% CI) 299 300 29.52% 1.16[0.92,1.47]
Total events: 102 (Nonavalent vaccine), 88 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.25(P=0.21)  
   
5.14.2 16- to 26-year-old females  
Joura 2015 2602/7686 1810/7078 55.01% 1.32[1.26,1.39]
Subtotal (95% CI) 7686 7078 55.01% 1.32[1.26,1.39]
Total events: 2602 (Nonavalent vaccine), 1810 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=10.88(P<0.0001)  
   
5.14.3 16- to 26-year-old males  
van Damme 2016 38/249 43/251 15.47% 0.89[0.6,1.33]
Subtotal (95% CI) 249 251 15.47% 0.89[0.6,1.33]
Total events: 38 (Nonavalent vaccine), 43 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
   
Total (95% CI) 8234 7629 100% 1.2[1,1.44]
Total events: 2742 (Nonavalent vaccine), 1941 (Quadrivalent vaccine)  
Heterogeneity: Tau2=0.02; Chi2=4.72, df=2(P=0.09); I2=57.64%  
Test for overall effect: Z=1.93(P=0.05)  
Test for subgroup differences: Chi2=4.72, df=1 (P=0.09), I2=57.63%  
Favours nonavalent 1 Favours quadrivalent
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Analysis 5.15.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent HPV vaccine
in 9- to 26-year-olds, Outcome 15 Overall systemic events and general symptoms.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.15.1 9- to 15-year-old females  
Vesikari 2015 142/299 156/300 3.09% 0.91[0.78,1.07]
Subtotal (95% CI) 299 300 3.09% 0.91[0.78,1.07]
Total events: 142 (Nonavalent vaccine), 156 (Quadrivalent vaccine)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.1(P=0.27)  
   
5.15.2 16- to 26-year-old females  
Joura 2015 4268/7686 3886/7078 95.15% 1.01[0.98,1.04]
Subtotal (95% CI) 7686 7078 95.15% 1.01[0.98,1.04]
Total events: 4268 (Nonavalent vaccine), 3886 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.77(P=0.44)  
   
5.15.3 16- to 26-year-old males  
van Damme 2016 101/249 100/251 1.76% 1.02[0.82,1.26]
Subtotal (95% CI) 249 251 1.76% 1.02[0.82,1.26]
Total events: 101 (Nonavalent vaccine), 100 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.16(P=0.87)  
   
Total (95% CI) 8234 7629 100% 1.01[0.98,1.04]
Total events: 4511 (Nonavalent vaccine), 4142 (Quadrivalent vaccine)  
Heterogeneity: Tau2=0; Chi2=1.5, df=2(P=0.47); I2=0%  
Test for overall effect: Z=0.57(P=0.57)  
Test for subgroup differences: Chi2=1.5, df=1 (P=0.47), I2=0%  
Favours nonavalent 1 Favours quadrivalent
 
 
Analysis 5.16.   Comparison 5 Nonavalent HPV vaccine versus quadrivalent HPV
vaccine in 9- to 26-year-olds, Outcome 16 Serious adverse events (overall).
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.16.1 9- to 15-year-old females  
Vesikari 2015 1/299 2/300 22.92% 0.5[0.05,5.54]
Subtotal (95% CI) 299 300 22.92% 0.5[0.05,5.54]
Total events: 1 (Nonavalent vaccine), 2 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.56(P=0.57)  
   
5.16.2 16- to 26-year-old females  
Joura 2015 242/7686 184/7078 59% 1.22[1,1.48]
Subtotal (95% CI) 7686 7078 59% 1.22[1,1.48]
Favours nonavalent 1000.01 100.1 1 Favours quadrivalent
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Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 242 (Nonavalent vaccine), 184 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.99(P=0.05)  
   
5.16.3 16- to 26-year-old males  
van Damme 2016 0/249 6/251 18.08% 0.08[0,1.35]
Subtotal (95% CI) 249 251 18.08% 0.08[0,1.35]
Total events: 0 (Nonavalent vaccine), 6 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.76(P=0.08)  
   
Total (95% CI) 8234 7629 100% 0.6[0.14,2.61]
Total events: 243 (Nonavalent vaccine), 192 (Quadrivalent vaccine)  
Heterogeneity: Tau2=0.94; Chi2=4.1, df=2(P=0.13); I2=51.25%  
Test for overall effect: Z=0.68(P=0.5)  
Test for subgroup differences: Chi2=4.06, df=1 (P=0.13), I2=50.77%  
Favours nonavalent 1000.01 100.1 1 Favours quadrivalent
 
 
Analysis 5.17.   Comparison 5 Nonavalent HPV vaccine versus
quadrivalent HPV vaccine in 9- to 26-year-olds, Outcome 17 Deaths.
Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.17.1 9- to 15-year old females  
Vesikari 2015 0/299 0/300   Not estimable
Subtotal (95% CI) 299 300 Not estimable
Total events: 0 (Nonavalent vaccine), 0 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.17.2 16- to 26-year-old females  
Joura 2015 6/7071 5/7078 100% 1.2[0.37,3.94]
Subtotal (95% CI) 7071 7078 100% 1.2[0.37,3.94]
Total events: 6 (Nonavalent vaccine), 5 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.3(P=0.76)  
   
5.17.3 16- to 26-year-old males  
van Damme 2016 0/249 0/251   Not estimable
Subtotal (95% CI) 249 251 Not estimable
Total events: 0 (Nonavalent vaccine), 0 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 7619 7629 100% 1.2[0.37,3.94]
Total events: 6 (Nonavalent vaccine), 5 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.3(P=0.76)  
Favours nonavalent 1000.01 100.1 1 Favours quadrivalent
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Study or subgroup Nonava-
lent vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for subgroup differences: Not applicable  
Favours nonavalent 1000.01 100.1 1 Favours quadrivalent
 
 
Comparison 6.   Quadrivalent HPV vaccine versus control in people living with HIV
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 High-grade anal intraepithelial
neoplasia
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 ≥ 27-year-old females and
males with HIV
1 574 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.70, 1.48]
2 Recurrence of anogenital warts 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 18- to 65-year-old females and
males with HIV treated for anogen-
ital warts
1 12 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.06, 8.90]
3 Abnormal anal cytology 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 ≥ 27-year-old females and
males with HIV
1 262 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.64, 1.05]
4 Overall local/injection site ad-
verse events
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 7- to 12-year-old children with
HIV
1 126 Risk Ratio (M-H, Random, 95% CI) 2.19 [0.70, 6.83]
5 Overall systemic event and gen-
eral symptoms
1   Odds Ratio (M-H, Random, 95% CI) Subtotals only
5.1 7- to 12-year-old children with
HIV
1 126 Odds Ratio (M-H, Random, 95% CI) 0.62 [0.05, 7.05]
6 Serious adverse events (overall) 2   Odds Ratio (M-H, Random, 95% CI) Subtotals only
6.1 ≥ 27 year old females and
males with HIV
1 575 Odds Ratio (M-H, Random, 95% CI) 0.68 [0.42, 1.10]
6.2 ≥ 18-year-old MSM with HIV 1 129 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Deaths 2   Odds Ratio (M-H, Random, 95% CI) Subtotals only
7.1 ≥ 27-year-old females and
males with HIV
1 575 Odds Ratio (M-H, Random, 95% CI) 0.49 [0.12, 1.99]
7.2 ≥ 18-year-old MSM with HIV 1 129 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 6.1.   Comparison 6 Quadrivalent HPV vaccine versus control in
people living with HIV, Outcome 1 High-grade anal intraepithelial neoplasia.
Study or subgroup Quadriva-
lent vaccine
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.1.1 ≥ 27-year-old females and males with HIV  
Wilkin 2018 46/288 45/286 100% 1.02[0.7,1.48]
Subtotal (95% CI) 288 286 100% 1.02[0.7,1.48]
Total events: 46 (Quadrivalent vaccine), 45 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.08(P=0.94)  
Favours quadrivalent 20.5 1.50.7 1 Favours control
 
 
Analysis 6.2.   Comparison 6 Quadrivalent HPV vaccine versus control
in people living with HIV, Outcome 2 Recurrence of anogenital warts.
Study or subgroup Quadriva-
lent vaccine
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.2.1 18- to 65-year-old females and males with HIV treated for
anogenital warts
 
NCT00941889 2016 1/7 1/5 100% 0.71[0.06,8.9]
Subtotal (95% CI) 7 5 100% 0.71[0.06,8.9]
Total events: 1 (Quadrivalent vaccine), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.26(P=0.79)  
Favours quadrivalent 1000.01 100.1 1 Favours control
 
 
Analysis 6.3.   Comparison 6 Quadrivalent HPV vaccine versus
control in people living with HIV, Outcome 3 Abnormal anal cytology.
Study or subgroup Quadriva-
lent vaccine
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.3.1 ≥ 27-year-old females and males with HIV  
Wilkin 2018 58/130 72/132 100% 0.82[0.64,1.05]
Subtotal (95% CI) 130 132 100% 0.82[0.64,1.05]
Total events: 58 (Quadrivalent vaccine), 72 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.6(P=0.11)  
Favours quadrivalent 1000.01 100.1 1 Favours control
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Analysis 6.4.   Comparison 6 Quadrivalent HPV vaccine versus control in
people living with HIV, Outcome 4 Overall local/injection site adverse events.
Study or subgroup Quadriva-
lent vaccine
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.4.1 7- to 12-year-old children with HIV  
Levin 2010 21/96 3/30 100% 2.19[0.7,6.83]
Subtotal (95% CI) 96 30 100% 2.19[0.7,6.83]
Total events: 21 (Quadrivalent vaccine), 3 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.35(P=0.18)  
Favours quadrivalent 1000.01 100.1 1 Favours control
 
 
Analysis 6.5.   Comparison 6 Quadrivalent HPV vaccine versus control in people
living with HIV, Outcome 5 Overall systemic event and general symptoms.
Study or subgroup Quadriva-
lent vaccine
Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.5.1 7- to 12-year-old children with HIV  
Levin 2010 2/96 1/30 100% 0.62[0.05,7.05]
Subtotal (95% CI) 96 30 100% 0.62[0.05,7.05]
Total events: 2 (Quadrivalent vaccine), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.39(P=0.7)  
Favours quadrivalent 1000.01 100.1 1 Favours control
 
 
Analysis 6.6.   Comparison 6 Quadrivalent HPV vaccine versus control
in people living with HIV, Outcome 6 Serious adverse events (overall).
Study or subgroup Quadriva-
lent vaccine
Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.6.1 ≥ 27 year old females and males with HIV  
Wilkin 2018 33/288 46/287 100% 0.68[0.42,1.1]
Subtotal (95% CI) 288 287 100% 0.68[0.42,1.1]
Total events: 33 (Quadrivalent vaccine), 46 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.58(P=0.11)  
   
6.6.2 ≥ 18-year-old MSM with HIV  
Hidalgo-Tenorio 2017 0/66 0/63   Not estimable
Subtotal (95% CI) 66 63 Not estimable
Total events: 0 (Quadrivalent vaccine), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours quadrivalent 1000.01 100.1 1 Favours control
 
Comparison of dierent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females
and males (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
100
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
Analysis 6.7.   Comparison 6 Quadrivalent HPV vaccine versus control in people living with HIV, Outcome 7 Deaths.
Study or subgroup Quadriva-
lent vaccine
Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.7.1 ≥ 27-year-old females and males with HIV  
Wilkin 2018 3/288 6/287 100% 0.49[0.12,1.99]
Subtotal (95% CI) 288 287 100% 0.49[0.12,1.99]
Total events: 3 (Quadrivalent vaccine), 6 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.99(P=0.32)  
   
6.7.2 ≥ 18-year-old MSM with HIV  
Hidalgo-Tenorio 2017 0/66 0/63   Not estimable
Subtotal (95% CI) 66 63 Not estimable
Total events: 0 (Quadrivalent vaccine), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours quadrivalent 1000.01 100.1 1 Favours control
 
 
Comparison 7.   Bivalent HPV vaccine versus control in 18- to 25-year-old females with HIV
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain at injection site 1 120 Risk Ratio (M-H, Random, 95% CI) 1.86 [1.38, 2.51]
2 Swelling at injection site 1 120 Risk Ratio (M-H, Random, 95% CI) 9.19 [2.24, 37.73]
3 Serious adverse events (overall) 1 120 Odds Ratio (M-H, Random, 95% CI) 1.47 [0.24, 9.15]
4 Deaths 1 120 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 7.1.   Comparison 7 Bivalent HPV vaccine versus control in
18- to 25-year-old females with HIV, Outcome 1 Pain at injection site.
Study or subgroup Bivalent
vaccine
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Denny 2013 52/61 27/59 100% 1.86[1.38,2.51]
   
Total (95% CI) 61 59 100% 1.86[1.38,2.51]
Total events: 52 (Bivalent vaccine), 27 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=4.11(P<0.0001)  
Favours bivalent 1000.01 100.1 1 Favours control
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Analysis 7.2.   Comparison 7 Bivalent HPV vaccine versus control in 18-
to 25-year-old females with HIV, Outcome 2 Swelling at injection site.
Study or subgroup Bivalent
vaccine
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Denny 2013 19/61 2/59 100% 9.19[2.24,37.73]
   
Total (95% CI) 61 59 100% 9.19[2.24,37.73]
Total events: 19 (Bivalent vaccine), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.08(P=0)  
Favours bivalent 1000.01 100.1 1 Favours control
 
 
Analysis 7.3.   Comparison 7 Bivalent HPV vaccine versus control in 18- to 25-
year-old females with HIV, Outcome 3 Serious adverse events (overall).
Study or subgroup Bivalent
vaccine
Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Denny 2013 3/61 2/59 100% 1.47[0.24,9.15]
   
Total (95% CI) 61 59 100% 1.47[0.24,9.15]
Total events: 3 (Bivalent vaccine), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.42(P=0.68)  
Favours bivalent 1000.01 100.1 1 Favours control
 
 
Analysis 7.4.   Comparison 7 Bivalent HPV vaccine versus control
in 18- to 25-year-old females with HIV, Outcome 4 Deaths.
Study or subgroup Bivalent
vaccine
Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Denny 2013 0/61 0/59   Not estimable
   
Total (95% CI) 61 59 Not estimable
Total events: 0 (Bivalent vaccine), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours bivalent 1000.01 100.1 1 Favours control
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Comparison 8.   Bivalent HPV vaccine versus quadrivalent HPV vaccine in people living with HIV
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Overall local/injection site adverse
events
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 ≥ 18-year-old females and males
with HIV
1 92 Risk Ratio (M-H, Random, 95% CI) 1.31 [1.06, 1.62]
2 Serious adverse events (overall) 2   Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 ≥ 18-year-old females and males
with HIV
1 92 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 15- to 25-year-old females with HIV 1 332 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.38, 2.55]
 
 
Analysis 8.1.   Comparison 8 Bivalent HPV vaccine versus quadrivalent HPV vaccine
in people living with HIV, Outcome 1 Overall local/injection site adverse events.
Study or subgroup Bivalent
vaccine
Quadriva-
lent vaccine
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.1.1 ≥ 18-year-old females and males with HIV  
ToM 2014 42/46 32/46 100% 1.31[1.06,1.62]
Subtotal (95% CI) 46 46 100% 1.31[1.06,1.62]
Total events: 42 (Bivalent vaccine), 32 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.53(P=0.01)  
Favours bivalent 1000.01 100.1 1 Favours quadrivalent
 
 
Analysis 8.2.   Comparison 8 Bivalent HPV vaccine versus quadrivalent HPV
vaccine in people living with HIV, Outcome 2 Serious adverse events (overall).
Study or subgroup Bivalent
vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.2.1 ≥ 18-year-old females and males with HIV  
ToM 2014 0/46 0/46   Not estimable
Subtotal (95% CI) 46 46 Not estimable
Total events: 0 (Bivalent vaccine), 0 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
8.2.2 15- to 25-year-old females with HIV  
NCT01031069 2017 9/167 9/165 100% 0.99[0.38,2.55]
Subtotal (95% CI) 167 165 100% 0.99[0.38,2.55]
Total events: 9 (Bivalent vaccine), 9 (Quadrivalent vaccine)  
Heterogeneity: Not applicable  
Favours bivalent 1000.01 100.1 1 Favours quadrivalent
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Study or subgroup Bivalent
vaccine
Quadriva-
lent vaccine
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.03(P=0.98)  
Test for subgroup differences: Not applicable  
Favours bivalent 1000.01 100.1 1 Favours quadrivalent
 
 
A D D I T I O N A L   T A B L E S
 
  Bivalent vaccine Quadrivalent vaccine Nonavalent vaccine
Manufactur-
er
GlaxoSmithKline (GSK, Rixen-
sart, Belgium)
Merck, Sharp & Dome (Merck & Co,
Whitehouse Station, NJ, USA)
Merck, Sharp & Dome (Merck & Co, White-
house Station, NJ, USA)
Antigens L1 VLPs of HPV16 (20 μg) and
HPV18 (20 μg)
L1 VLPs of HPV6 (20 μg), HPV11 (40
μg), HPV16 (40 μg) and HPV18 (20
mg)
L1 VLPs of HPV6 (30 μg), HPV11 (40 μg),
HPV16 (60 μg), HPV18 (40 mg),HPV31 (20
μg), HPV33 (20 μg), HPV45 (20 μg), HPV52
(20 μg)and HPV58 (20 μg)
Vaccination
schedule
3 doses: at day 1, month 1, and
month 6
3 doses: at day 1, month 2, and
month 6
3 doses: at day 1, month 2, and month 6
Adjuvant AS04: 500 μg aluminium hy-
droxide, 50 μg 3-deacylated
monophosphoryl lipid A (MPL)
225 μg amorphous aluminium hy-
droxyl-phosphate sulphate
500 μg amorphous aluminium hydrox-
yl-phosphate sulphate
Trade name Cervarix Gardasil, Silgard Gardasil-9
Produced
by recombi-
nant tech-
nology us-
ing
Baculovirus in Trichoplusia in in-
sect cells
Saccharomyces cerevisae (Baker’s
yeast)
Saccharomyces cerevisae (Baker’s yeast)
Table 1.   Characteristic of licensed prophylactic HPV vaccines 
Abbreviations
HPV: human papillomavirus
MPL: monophosphoryl lipid
VLP: virus-like particle
 
 
Study Group Number of
participants
with seri-
ous adverse
events
Details of serious adverse events*
Vaccine (bi-
valent)
3/61 Gastroenteritis, bacterial pneumonia, migraineDenny 2013
Control 2/59 Lobar pneumonia, skull fracture
Table 2.   Serious adverse events 
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Vaccine
(quadriva-
lent; 2-dose)
0/259  Dobson 2013
Vaccine
(quadriva-
lent; 3-dose)
0/261  
Vaccine
(quadriva-
lent)
8/2020 8 participants with 12 events: cardiac arrest, non-cardiac chest pain, hypersensitiv-
ity, appendicitis, cellulitis, varicella infection, cervical vertebral fracture, gunshot
wound, road traffic accident, traumatic brain injury, traumatic intracranial haemor-
rhage, convulsion
Giuliano
2011
Control 11/2033 11 participants with 13 events: myocardial ischaemia, pericardial haemorrhage, ac-
cidental overdose, chemical poisoning, contusion, gunshot wound (3), head injury,
multiple drug overdose, road traffic accident, completed suicide (2)
Vaccine (bi-
valent)
9/167 9 participants with 10 events: immune thrombocytopenic purpura, gastritis, menin-
gitis tuberculous, pneumonia, pneumonia mycoplasmal, tonsillitis, viral infection,
road traffic accident, miscarriage, renal failure
NCT01031069
2017
Vaccine
(quadriva-
lent)
9/165 9 participants with 10 events: appendicitis (2), pneumonia bacterial, pulmonary tu-
berculosis, tonsillitis, urinary tract infection, monoarthritis, abortion spontaneous
complete, pre-eclampsia, suicide attempt
Vaccine
(quadriva-
lent)
0/554  NCT01862874
2018
Control 1/559 Completed suicide
Vaccine
(quadriva-
lent)
0/66  Hidal-
go-Tenorio
2017
Control 0/63  
Vaccine
(nonavalent;
2-dose, 6-
month in-
terval in fe-
males)
6/301 6 participants with 7 events: abdominal pain (2), appendicitis, dengue fever, pharyn-
gitis, foreign body injury, ovarian cyst
Vaccine
(nonavalent;
2-dose, 6-
month inter-
val in males)
9/301 9 participants with 10 events: Wol+-Parkinson-White syndrome, diarrhoea, animal
bite, appendicitis, rotavirus gastroenteritis, Chikungunya virus infection, bacterial
meningitis, pneumonia, concussion, epilepsy
Iversen 2016
Vaccine
(nonavalent;
2-dose, 12-
month inter-
val in males
and females)
3(6)/301 1 female participant with atopic dermatitis
2 male participants with appendicitis, forearm fracture
At 37 month follow-up there were 3 additional serious adverse events: gastritis, oral
herpes, radiculopathy (disaggregated data by sex were not available)
Table 2.   Serious adverse events  (Continued)
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Vaccine
(nonavalent;
3-dose in fe-
males)
6/301 6 participants with 8 events: cardiac arrest, appendicitis, subcutaneous abscess,
papillary thyroid cancer, encephalitis autoimmune, status epilepticus, depression,
ovarian cyst
Vaccine
(nonavalent)
242/7686 242 participants with 269 events: Anaemia, aortic valve incompetence, postur-
al orthostatic tachycardia syndrome, vertigo positional, anal fistula, coeliac dis-
ease, Crohn's disease, diarrhoea, gastritis, haemorrhoids, inguinal hernia, irrita-
ble bowel syndrome, pyrexia, sudden death, cholangitis, cholecystitis, cholelithia-
sis, allergy to vaccine, anaphylactic reaction, hypersensitivity, sarcoidosis, jaw ab-
scess, appendicitis (10), cholecystitis infective, chronic tonsillitis, dengue fever, in-
fectious enteritis (2), gastroenteritis, viral gastroenteritis, haemorrhagic fever, in-
fectious mononucleosis, influenza, pharyngitis, pyelonephritis (2), pyelonephritis
acute, septic shock, tonsillitis, tonsillitis streptococcal, urinary tract infection (3),
urosepsis, wound infection, bladder injury, burns second degree, craniocerebral in-
jury, femur fracture, humerus fracture (2), ligament rupture, lower limb fracture,
multiple injuries (2), pubis fracture, road traffic accident, spinal compression frac-
ture, hyperglycaemia, myalgia, osteoarthritis, acute lymphocytic leukaemia, acute
promyelocytic leukaemia, adenocarcinoma of the cervix, brain neoplasm, ependy-
moma, leukaemic infiltration brain, malignant melanoma (2), malignant melanoma
in situ, nasal cavity cancer, ovarian neoplasm, diabetic coma, epilepsy, hypersom-
nia, Intracranial venous sinus thrombosis, migraine, multiple sclerosis (2), presyn-
cope, sciatica, sensory disturbance, syncope (2), tension headache, abortion spon-
taneous (40), abortion spontaneous incomplete, blighted ovum, cephalo-pelvic
disproportion (4), cervix dystocia, false labour, foetal death (2), foetal distress syn-
drome (5), labour complication, pre-eclampsia (2), premature labour, premature
rupture of membranes (4), prolonged labour (2), uterine contractions during preg-
nancy, anorexia and bulimia syndrome, bipolar disorder (3), completed suicide, ma-
jor depression, calculus ureteric, calculus urinary, nephrolithiasis, renal failure (2),
bartholinitis, cervical dysplasia (5), cervix haemorrhage uterine, endometriosis (2),
ovarian cyst, pelvic pain, asthmatic crisis, pneumonia aspiration, pneumothorax,
respiratory failure, vocal cord polyp, abortion induced (79), deep vein thrombosis,
hypovolaemic shock (2)
Joura 2015
Vaccine
(quadriva-
lent)
184/7078 184 participants with 197 events: Anaemia, cleM lip and palate, Meckel's divertic-
ulum, abdominal pain (2), abdominal pain lower, colitis ulcerative, enterocolitis,
gastritis, inguinal hernia, omental infarction, cholecystitis , cholelithiasis (2), ap-
pendicitis (16), bronchitis (2), cellulitis, conjunctivitis, gastroenteritis (2), influenza,
pelvic inflammatory disease, post abortion infection, pyelonephritis, pyelonephri-
tis acute (2), urinary tract infection (2), viral pharyngitis, foreign body in eye, frac-
ture displacement, hand fracture, head injury, joint dislocation (2), neck injury,
poisoning, post procedural haemorrhage (2), spinal cord injury, spinal cord injury
cervical, fibromyalgia (2), adenocarcinoma gastric, malignant palate neoplasm,
pituitary tumour benign, respiratory papilloma, thyroid cancer, benign intracra-
nial hypertension, cerebral haemorrhage, epilepsy, facial paresis, headache, hy-
drocephalus, hypoesthesia, multiple sclerosis, neuritis, orthostatic intolerance,
spondylitic myelopathy, tension headache, abortion spontaneous (28), abortion
spontaneous complete (2), blighted ovum, cephalo-pelvic disproportion (6), cervix
dystocia, ectopic pregnancy, foetal distress syndrome, foetal malposition, foetal
malpresentation, gestational diabetes, oligohydramnios, pre-eclampsia, premature
labour, premature rupture of membranes (2), prolonged labour, anorexia nervosa,
bipolar disorder, depression, cystitis haemorrhagic, renal failure acute, cervical dys-
plasia (3), dysmenorrhoea, endometriosis, fallopian tube cyst, ovarian cyst (2), dys-
pnoea, nasal polyps, abortion induced (53), axillary vein thrombosis
Lehtinen
2018
Vaccine
(quadriva-
lent)
58/2436 58 participants with 62 events: Splenomegaly, vitello-intestinal duct remnant, ab-
dominal pain (2), colitis ulcerative, constipation, food poisoning, chest pain, pyrex-
ia, cholesystitis, appendicitis (5), appendicitis perforated, infectious mononucleosis
(4), peritonsillar abscess, pneumonia (2), pneumonia bacterial, salmonellosis, ton-
sillitis (4), alcohol poisoning (3), cervical vertebral fracture, concussion (4), contu-
Table 2.   Serious adverse events  (Continued)
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sion (2), forearm fracture, hand fracture (2), limb injury, lower limb fracture, muscle
rupture, neck injury, radius fracture (2), upper limb fracture (2), type 1 diabetes mel-
litus, exostosis, juvenile idiopathic arthritis, syncope (2), anxiety, disturbance in so-
cial behaviour, emotional disorder of childhood, psychotic disorder, testicular tor-
sion, acne, dermatitis
Vaccine
(control,
HBV)
25/1267 25 participants with 25 events: Appendicitis (3), appendicitis perforated, bronchitis,
gastroenteritis bacterial, infectious mononucleosis, peritonsillar abscess, sinusitis,
sinusitis bacterial, alcohol poisoning, foot fracture (2), forearm fracture, hand frac-
ture, joint dislocation, splenic rupture, tibia fracture, traumatic renal injury, type 1
diabetes mellitus, astrocytoma low grade, depression, panic disorder, suicide at-
tempt, dyspnoea
Vaccine (bi-
valent; 2-
dose)
11/358 11 participants with 13 events: Abdominal pain lower, mouth cyst, appendicitis,
gastroenteritis viral, lung abscess, peritonitis, viral infection, joint dislocation, ter-
atoma, epilepsy, seizure, asthma, eczema
Leung 2015
Vaccine (bi-
valent; 3-
dose)
14/358 14 participants with 16 events: Lymphadenitis, vertigo positional, abdominal pain,
anaphylactic shock, upper respiratory tract infection, pneumonia, influenza, vulval
ulceration, ankle fracture, overdose, tendon injury, presyncope, tension headache,
abortion spontaneous incomplete, completed suicide, depression, menorrhagia
Vaccine
(quadriva-
lent)
0/96  Levin 2010
Control 0/30  
Vaccine
(quadriva-
lent; 10-
month inter-
val)
0/111  Lin 2014
Vaccine
(quadri-
valent; 4-
month inter-
val)
0/109  
Vaccine
(quadriva-
lent)
Not reported Not reportedNCT00941889
2016
Control Not reported Not reported
Vaccine
(quadriva-
lent)
33/288 33 participants with 40 events: Pericardial effusion, abdominal mass, abdominal
pain, anal fistula, colitis, chest pain (2), death, appendicitis, cellulitis, chlamydial
infection, gastroenteritis viral, influenza (2), meningitis viral, peritonsillar abscess,
pneumonia, pneumonia pneumococcal, pseudomembranous colitis, sepsis, low-
er limb fracture, multiple injuries, stab wound, anal cancer, basal cell carcinoma,
Hodgkin's disease, prostate cancer, transitional cell carcinoma, cerebrovascular ac-
cident, seizure, acute psychosis, alcohol withdrawal syndrome, depression, suicide
attempt, acute respiratory failure, alveolitis allergic, asthma, pleural effusion, inter-
vertebral disc operation
Wilkin 2018
Control 46/287 46 participants with 79 events: Acute myocardial infarction (2), coronary artery dis-
ease, myocardial infarction, abdominal pain, gastrointestinal haemorrhage, large
intestine perforation, pancreatitis, pancreatitis acute (2), pancreatitis chronic, small
Table 2.   Serious adverse events  (Continued)
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intestinal obstruction (3), chest pain (5), pyrexia, cholelithiasis, bronchitis (2), diver-
ticulitis (2), gastroenteritis (2), gastroenteritis viral, influenza (2), orchitis, perirectal
abscess, pneumonia (3), pneumonia streptococcal, primary syphilis, pyelonephritis,
scrotal abscess, sepsis (3), viral infection, fall, foot fracture, overdose, radius frac-
ture, road traffic accident, weight decreased, dehydration, osteoarthritis, anal can-
cer, anal squamous cell carcinoma, B-cell lymphoma, basal cell carcinoma, follicle
centre lymphoma diffuse small cell lymphoma, oesophageal adenocarcinoma, pan-
creatic carcinoma metastatic, prostate cancer, renal cell carcinoma, squamous cell
carcinoma of head and neck, haemorrhagic stroke, syncope (2), alcohol withdraw-
al syndrome, completed suicide, mental status changes, psychotic disorder, sub-
stance abuse, suicide attempt, genital ulceration, chronic obstructive pulmonary
disease (4), dyspnoea, pleural effusion, pulmonary hypertension, hypotension
Vaccine (bi-
valent)
3/181 Crohn’s disease, appendicitis, epilepsyPetaja 2009
Control
(HBV)
1/89 Osteochondrosis
Vaccine (bi-
valent; 2-
dose, 6-
month inter-
val)
20/550 20 participants with 34 events: Lymphadenitis, autoimmune thyroiditis, strabismus,
abdominal strangulated hernia, abdominal pain, anal haemorrhage, gastritis, nau-
sea, chronic gastritis, anaphylactic reaction, cholelithiasis, infections and infesta-
tions (13), injury, poisoning and procedural complications (4), type 1 diabetes melli-
tus, cholesteatoma, convulsion, seizure, IgA nephropathy, respiratory disorder
Vaccine (bi-
valent; 2-
dose, 12-
month inter-
val)
24/415 24 participants with 38 events: Lymphadenitis, supraventricular tachycardia, ab-
dominal pain lower, constipation, dyspepsia, faecaloma, drug hypersensitivity, in-
fections and infestations (25), injury, poisoning and procedural complications, hy-
povolaemia, systemic lupus erythematosus, VIIth nerve paralysis, tonsillar hypertro-
phy, circulatory collapse
Puthanakit
2016
Vaccine (bi-
valent; 3-
dose)
28/482 28 participants with 53 events: Infections and infestations (32), injury, poisoning
and procedural complications (3), hypovolaemia (2), synovial cyst, medulloblas-
toma, synovial sarcoma, uterine leiomyoma, hyperemesis gravidarum, premature
baby, abortion threatened, postpartum haemorrhage, stillbirth, schizoaffective dis-
order (3), psychotic disorder, ovarian cyst ruptured, transient tachypnoea of the
newborn, ectopic pregnancy termination
Vaccine (bi-
valent; 3-
dose)
15/239 15 participants with 20 events: Basedow’s disease, abdominal pain, appendix disor-
der, gastroenteritis, appendicitis, pharyngitis streptococcal, tonsillitis (2), urinary
tract infection, ligament rupture, multiple injuries, ligament laxity, polyarthritis, mi-
graine with aura, abortion spontaneous incomplete, abnormal behaviour, depres-
sion, renal colic, renal disorder, erythema multiforme
Vaccine (bi-
valent; 2-
dose)
16/241 16 participants with 26 events: Abdominal pain, umbilical hernia (2), obstructive
vomiting, gastroenteritis viral, cholecystitis acute, acute tonsillitis, appendicitis (2),
endometritis decidual, vestibular neuronitis, tibia fracture, contusion, fall, fibroma,
fibrosarcoma, pre-eclampsia, premature baby, abortion missed, depression, major
depression, psychotic disorder, suicide attempt, cystitis haemorrhagic, hyperventi-
lation, circulatory collapse
Romanowski
2011
Vaccine (bi-
valent; 2-
dose, 6-
month inter-
val)
19/240 19 participants with 23 events: Atrial septal defect, spina bifida, bile duct stone, ap-
pendicitis (4), tonsillitis bacterial, humerus fracture, road traffic accident, tibia frac-
ture, upper limb fracture, malignant melanoma stage IV, basilar artery thrombosis,
cerebrovascular accident, abortion spontaneous, abortion spontaneous incomplete
(2), foetal distress syndrome, anorexia nervosa, bulimia nervosa, depression, circu-
latory collapse
Table 2.   Serious adverse events  (Continued)
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Vaccine (bi-
valent; 2-
dose, 2-
month inter-
val)
14/240 14 participants with 16 events: Abdominal pain (3), hepatomegaly, pilonidal cyst,
urinary tract infection, vestibular neuronitis, concussion, stab wound, coccydynia,
uterine leiomyoma, benign hydatidiform mole, abortion spontaneous, ectopic preg-
nancy, adenomyosis, ovarian cyst
Vaccine (bi-
valent)
0/46  ToM 2014
Vaccine
(quadriva-
lent)
0/46  
Vaccine
(nonavalent)
0/249  van Damme
2016
Vaccine
(quadriva-
lent)
6/251 Joint dislocation, ligament injury, ligament rupture, foot fracture, concussion, cy-
tomegalovirus infection
Vaccine
(nonavalent)
1/299 One participant with two events: Anaemia and pulmonary vasculitisVesikari 2015
Vaccine
(quadriva-
lent)
2/300 Complex partial seizures, Henoch-Schonlein purpura
Table 2.   Serious adverse events  (Continued)
Abbreviations
*For each event, n = 1 unless otherwise stated.
HBV: hepatitis B vaccine
 
 
Quadrivalent HPV vaccine compared with control in children, adults, and MSM with HIV
Patient or population: children (7 to 12 years old) with HIV, adults (≥ 18 years old) with HIV, and MSM (≥ 18 years old) with HIV
Settings: Brazil, Puerto Rico, Spain, the USA
Intervention: quadrivalent HPV vaccine (3 doses at 0, 2, and 6 months)
Comparison: control (3 doses at 0, 2 and 6 months; not specified whether placebo contained vaccine adjuvant)
Anticipated absolute effects*
(95% CI)
Outcomes Population
Risk with
control
Risk with
quadrivalent
HPV vaccine
Relative effect
(95% CI)
No of Par-
ticipants
(studies)
Quality of
the evi-
dence
(GRADE)
High-grade anal in-
traepithelial neoplasia
at 4-year follow-up
Females and males with
HIV (≥ 27 years)
157 per
1000
160 per 1000
(110 to 233)
RR 1.02
(0.70 to 1.48)
574
(1 study)
⊕⊝⊝⊝
VERY
LOW1,2
Table 3.   Summary of findings: Quadrivalent HPV vaccine compared with control in children, adults, and MSM with
HIV 
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Recurrence of anogen-
ital warts at 18-month
follow-up
Females and males with
HIV treated for anogeni-
tal warts (18-65 years)
200 per
1000
143 per 1000
(7 to 778)
RR 0.71
(0.06 to 8.90)
12
(1 study)
⊕⊝⊝⊝
VERY
LOW2,3
Abnormal anal cytology
at 4-year follow-up
Females and males with
HIV (≥ 27 years)
545 per
1000
447 per 1000
(349 to 573)
RR 0.82
(0.64 to 1.05)
262
(1 study)
⊕⊝⊝⊝
VERY
LOW1,4
Overall local/injection
site adverse events
at 15-day follow-up
Children with HIV (7-12
years)
100 per
1000
219 per 1000
(70 to 683)
RR 2.19
(0.70 to 6.83)
126
(1 study)
⊕⊝⊝⊝
VERY
LOW1,2
Overall systemic events
and general symptoms
at 15-day follow-up
Children with HIV (7-12
years)
33 per
1000
21 per 1000
(2 to 235)
RR 0.62
(0.05 to 7.05)
126
(1 study)
⊕⊝⊝⊝
VERY
LOW1,2,6
Females and males with
HIV (≥ 27 years)
160 per
1000
115 per 1000
(74 to 174)
OR 0.68
(0.42 to 1.10)
575
(1 study)
⊕⊝⊝⊝
VERY
LOW1,4,6,7
Serious adverse events
at 4-year follow-up
(adults) or 7-month fol-
low-up (MSM) MSM with HIV (≥ 18
years)
0 per 1000 0 per 1000
(0 to 0)
Not estimable,
no events were
reported
129
(1 study)
⊕⊝⊝⊝
VERY
LOW5,6,7
Females and males with
HIV (≥ 27 years)
21 per
1000
10 per 1000
(3 to 41)
OR 0.49
(0.12 to 1.99)
575
(1 study)
⊕⊝⊝⊝
VERY
LOW1,2
Mortality
at 4-year follow-up
(adults) or 7-month fol-
low-up (MSM) MSM with HIV (≥ 18
years)
0 per 1000 0 per 1000
(0 to 0)
Not estimable,
no events were
reported
129
(1 study)
⊕⊕⊝⊝
LOW5
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: confidence interval; HIV: human immunodeficiency virus; HPV: human papillomavirus; MSM: men who have sex with men; OR:
odds ratio; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Table 3.   Summary of findings: Quadrivalent HPV vaccine compared with control in children, adults, and MSM with
HIV  (Continued)
1Downgraded one level for risk of bias: details about how randomisation sequence was generated or how blinding was achieved were
not reported.
2Downgraded two levels for serious imprecision: few events and a wide 95% confidence interval that incorporated a potentially beneficial
effect and a potentially harmful effect.
3Downgraded two levels for serious risk of bias: data for 62.5% (20/32) of the participants enrolled were missing due to lack of follow-up.
In addition, details about how randomisation, allocation concealment, and blinding were achieved were not reported.
4Downgraded two levels for imprecision: few events and wide 95% confidence interval that incorporated a potential beneficial effect and
no effect.
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5Downgraded two levels for serious imprecision: no events reported, the study was not powered to detect a difference in serious adverse
events or mortality.
6Downgraded one level for indirectness: This outcome is a composite measure of events which may or may not be clinically relevant, may
or may not be related to the vaccine and may occur outside a biologically plausible time frame relative to vaccine exposure. This outcome
is considered to provide indirect evidence about vaccine safety.
7See Table 2 for details of each serious event.
 
 
Bivalent HPV vaccine compared with control in 18- to 25-year-old females with HIV
Patient or population: 18- to 25-year-old females with HIV
Settings: South Africa
Intervention: bivalent HPV vaccine (3 doses at 0, 1, and 6 months)
Comparison: control (vaccine adjuvant-containing placebo) (3 doses at 0, 1 and 6 months)
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
control
Risk with biva-
lent HPV vaccine
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
High-grade cervical epithelial neo-
plasia, adenocarcinoma in situ, and
cervical cancer
No studies were identified that reported on this outcome.
High-grade cervical, vulval, and
vaginal disease
No studies were identified that reported on this outcome.
Overall local/injection site adverse
events
No studies were identified that reported on this outcome. Data for specific local adverse
events (pain and swelling at injection site) are presented in the Data and analyses and Effects
of interventions sections.
Overall systemic events and general
symptoms
No studies were identified that reported on this outcome.
Serious adverse events at 12-month
follow-up
34 per 1000 49 per 1000
(8 to 243)
OR 1.47
(0.24 to 9.15)
120
(1 study)
⊕⊝⊝⊝
VERY LOW1,3,4
Mortality at 12-month follow-up 0 per 1000 0 per 1000
(0 to 0)
Not estimable, no
events were re-
ported
120
(1 study)
⊕⊕⊝⊝
LOW2
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: confidence interval; HIV: human immunodeficiency virus; HPV: human papillomavirus; OR: odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Table 4.   Summary of findings: Bivalent HPV vaccine compared with control in 18- to 25-year-old females with HIV 
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1Downgraded two levels for serious imprecision: few events and a wide 95% confidence interval that incorporated a potentially large
beneficial effect and a potentially large harmful effect.
2Downgraded two levels for serious imprecision: no events reported, the study was not powered to detect a difference in mortality.
3Downgraded one level for indirectness: This outcome is a composite measure of events which may or may not be clinically relevant, may
or may not be related to the vaccine and may occur outside a biologically plausible time frame relative to vaccine exposure. This outcome
is considered to provide indirect evidence about vaccine safety.
4See Table 2 for details of each serious event.
 
 
Bivalent HPV vaccine compared with quadrivalent HPV vaccine in adults with HIV
Patient or population: adults and adolescents (combined male and female) with HIV, ≥ 15 years old
Settings: Brazil, Denmark, Estonia, India, and Thailand
Intervention: bivalent HPV vaccine (3 doses at 0, 1.5, and 6 months)
Comparison: quadrivalent HPV vaccine (3 doses at 0, 1.5, and 6 months)
Anticipated absolute effects*
(95% CI)
Outcomes Population
Risk with
quadriva-
lent HPV
vaccine
Risk with biva-
lent HPV vaccine
Relative effect
(95% CI)
No of Par-
ticipants
(studies)
Quality of
the evi-
dence
(GRADE)
High-grade neoplasia, cancer No studies were identified that reported on this outcome.
Overall local/injection
site adverse events at 4-
day
follow-up
Females and
males with HIV (≥
18 years)
696 per 1000 911 per 1000
(737 to 1000)
RR 1.31
(1.06 to 1.62)
92
(1 study)
⊕⊕⊝⊝
LOW1
Overall systemic events and general symptoms No studies were identified that reported on this outcome.
Females and
males with HIV (≥
18 years)
0 per 1000 0 per 1000
(0 to 0)
Not estimable,
no events were
reported
92
(1 study)
⊕⊝⊝⊝
VERY
LOW2,5,6
Serious adverse events
at 6-month follow-up
(adults) and 7-month fol-
low-up (females)
Females with HIV
(15-25 years)
55 per 1000 54 per 1000
(21 to 128)
OR 0.99
(0.38 to 2.55)
332
(1 study)
⊕⊝⊝⊝
VERY
LOW3,4,5,6
Mortality No studies were identified that reported on this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: confidence interval; HIV: human immunodeficiency virus; HPV: human papillomavirus; OR: odds ratio; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Table 5.   Summary of findings: Bivalent HPV vaccine compared with quadrivalent HPV vaccine in adults with HIV 
Comparison of dierent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females
and males (Review)
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Very low quality: We are very uncertain about the estimate.
Table 5.   Summary of findings: Bivalent HPV vaccine compared with quadrivalent HPV vaccine in adults with
HIV  (Continued)
1Downgraded two levels for serious imprecision: few events reported.
2Downgraded two levels for serious imprecision: no events reported, the study was not powered to detect a difference in serious adverse
events or mortality.
3Downgraded one level for risk of bias: details on how randomisation, allocation concealment, and blinding was achieved was not report-
ed.
4Downgraded two levels for serious imprecision: few events and a wide 95% confidence interval that incorporate a potentially large ben-
eficial effect and a potentially large harmful effect.
5Downgraded one level for indirectness: This outcome is a composite measure of events which may or may not be clinically relevant, may
or may not be related to the vaccine and may occur outside a biologically plausible time frame relative to vaccine exposure. This outcome
is considered to provide indirect evidence about vaccine safety.
6See Table 2 for details of each serious event.
 
 
A P P E N D I C E S
Appendix 1. Ovid MEDLINE search strategy
1. exp Papillomavirus Infections/
2. exp PAPILLOMAVIRIDAE/
3. (human papilloma virus or human papillomavirus).tw.
4. 1 or 2 or 3
5. exp Immunization/
6. (vaccin* or immuni*).tw.
7. 5 or 6
8. 4 and 7
9. exp Papillomavirus Vaccines/
10. (human papilloma virus adj (vaccin* or immuni*)).tw.
11. (human papillomavirus adj (vaccin* or immuni*)).tw.
12. HPV vaccin*.tw.
13. (cervarix or gardasil).tw.
14. 9 or 10 or 11 or 12 or 13
15. 8 or 14
16. randomised controlled trial.pt.
17. controlled clinical trial.pt.
18. randomized.ab.
19. placebo.ab.
20. clinical trials as topic.sh.
21. randomly.ab.
22. trial.ti.
23. 16 or 17 or 18 or 19 or 20 or 21 or 22
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24. (animals not (humans and animals)).sh.
25. 23 not 24
26. 15 and 25
Appendix 2. Ovid Embase search strategy
1. exp papillomavirus infection/
2. exp Papillomaviridae/
3. (human papilloma virus or human papillomavirus).tw.
4. 1 or 2 or 3
5. exp immunization/
6. (vaccin* or immuni*).tw.
7. 5 or 6
8. 4 and 7
9. exp Wart virus vaccine/
10. (human papilloma virus adj (vaccin* or immuni*)).tw.
11. (human papillomavirus adj (vaccin* or immuni*)).tw.
12. HPV vaccin*.tw.
13. (cervarix or gardasil).tw.
14. 9 or 10 or 11 or 12 or 13
15. 8 or 14
16. crossover procedure/
17. double-blind procedure/
18. randomised controlled trial/
19. single-blind procedure/
20. random*.mp.
21. factorial*.mp.
22. (crossover* or cross over* or cross-over*).mp.
23. placebo*.mp.
24. (double* adj blind*).mp.
25. (singl* adj blind*).mp.
26. assign*.mp.
27. allocat*.mp.
28. volunteer*.mp.
29. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. 15 and 29
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Appendix 3. The Cochrane Library search strategy
#1 MeSH descriptor: [Papillomavirus Infections] explode all trees
#2 MeSH descriptor: [Papillomaviridae] explode all trees
#3 ("human papilloma virus" or "human papillomavirus").ti,ab,kw
#4 #1 or #2 or #3
#5 MeSH descriptor: [Immunization] explode all trees
#6 (vaccin* or immuni*):ti,ab,kw
#7 #5 or #6
#8 #4 and #7
#9 MeSH descriptor: [Papillomavirus Vaccines] explode all trees
#10 (human papilloma virus NEAR (vaccin* or immuni*)):ti,ab,kw
#11 (human papillomavirus NEAR (vaccin* or immuni*)):ti,ab,kw
#12 (HPV NEXT vaccin*):ti,ab,kw
#13 (cervarix or gardasil):ti,ab,kw
#14 {or #9-#13}
#15 #8 or #14
Appendix 4. Methods used to collect adverse event data
 
Study Mode of data collection Time frame Attribution methods Intensity of as-
certainment
Harms-
related
monitor-
ing and
stopping
rules
Frequen-
cy-based
filter
Denny
2013
Proactive: trained field
workers to visit subjects or
instruct subjects to come
back to a field station for
the recording of solicited
and unsolicited symptoms.
Case report forms were
used.
Time frame
was specified.
(Solicited AEs
were recorded
for 7 days af-
ter each vacci-
nation. Unso-
licited AEs were
recorded for 30
days after each
vaccination.
SAEs, medical-
ly significant
AEs, new-on-
set chronic dis-
eases (NOCDs),
pregnancies
and their out-
come were
recorded up to
month 12).
Not reported Information rel-
ative to prema-
ture discontin-
uation of the
investigation-
al product was
documented.
The investiga-
tor was to doc-
ument whether
the decision
to discontin-
ue further vac-
cination was
made by the
subject or the
investigator
and which of
the following
possible rea-
sons was re-
sponsible for
Stopping
rules not
reported
No filter
used (“For
the analy-
sis of un-
solicit-
ed AEs/
SAEs/
Medical-
ly signifi-
cant con-
ditions/
NOCDs/
concomi-
tant med-
ication, all
vaccinat-
ed sub-
jects will
be con-
sidered
and sub-
jects who
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withdrawal:
SAE, non-seri-
ous AE, other
(specified). No
woman with-
drew from the
study due to
AEs, however
information
on how with-
drawals would
have been han-
dled in the
analysis was
not reported.
did not re-
port an
event will
be con-
sidered
as sub-
jects with-
out an
event”).
Dobson
2013
Passive: “information on
AEs was collected at the
next visit or if the partici-
pant called with concerns”
Time frame was
specified (“Be-
cause this was
a post-licen-
sure study, data
were only col-
lected on SAEs
occurring with-
in 30 days of
each vaccina-
tion”).
Not reported Not reported Stopping
rules not
reported
Unclear.
Results
were re-
ported
narrative-
ly only
(“Sched-
uled vac-
cine doses
were re-
ceived by
98.6% of
study par-
ticipants
with no
SAEs re-
ported").
Giuliano
2011
Proactive and passive: sub-
jects recorded AEs on vac-
cination report cards. SAEs
were recorded by investiga-
tors, including all deaths.
Time frame was
specified ("any
AEs occurring
at the injection
site on days 1
through 5 after
receiving each
dose of vac-
cine or place-
bo"). They also
recorded sys-
temic AEs and
all SAEs that
occurred on
days 1 to 15 af-
ter receiving
each dose. All
SAEs that in-
vestigators be-
lieved to be as-
sociated with
the vaccine or
the study pro-
cedure and all
deaths were
recorded dur-
Attribution made by
investigators (“Vac-
cine-related AEs were
those determined by
the investigator to be
possibly, probably, or
definitely related to
the vaccine”).
Number of
withdrawals
were report-
ed, but without
reasons.
No information
on how with-
drawals were
handled pre-
sented in the
analysis.
Stopping
rules not
reported
Filter not
used. AEs
were re-
ported as
n/N. Study
also re-
ported
number
of partici-
pants with
no event,
and num-
ber with
at least
1 event,
but did
not dis-
tinguish
between
partici-
pants with
1 or multi-
ple AEs.
  (Continued)
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ing the entire
study period)
Hidal-
go-Teno-
rio 2017
Proactive for local reac-
tions: “Questionnaire that
included the most frequent
local reactions”
Rare occurrences were also
recorded, but mode of data
collection is unclear.
Time frame is
unclear (possi-
bly at 2 and 6
months).
Attribution and blind-
ing not reported.
Definition used was
provided (“Frequent
local reactions includ-
ed fever, nausea, vom-
iting, dizziness, syn-
cope, headache and
others such as allergic
reaction, pruritus, dif-
ficulty breathing and/
or wheezing. Rare oc-
currences included
lymphadenopathies,
chest and lower-limb
pain, confusion, chills,
muscle pain", but it is
unclear if they were
predefined. "The AEs
were graded on a
scale of 1–4”)
Reasons for dis-
continuation
were separated
by arm.
No information
on how with-
drawals were
handled in the
analysis.
Attribution was
not reported.
Moni-
toring
stopping
rules were
report-
ed (“In
case of AE
grade 4,
the blind
of the vial
adminis-
tered was
broken
and, if the
code iden-
tified the
vaccine,
the reac-
tion was
communi-
cated im-
mediate-
ly to the
relevant
drug-vigi-
lance au-
thorities”)
No filter
used
Iversen
2016
Proactive and passive: im-
mediate reactions were
proactively collected: “Par-
ticipants were observed for
30 mins after each injec-
tion for any immediate re-
action”.
Non-serious injection site
and systemic events “were
not actively solicited”.
Time frame
was specified
(“SAEs were to
be reported ir-
respective of
causality from
day 1 (month
0) through 6
months after
the last vacci-
nation”).
Attribution made by
investigators (“Inves-
tigators were instruct-
ed to assign causali-
ty to adverse events
on the basis of expo-
sure, time course, like-
ly cause, and consis-
tency with the vac-
cine’s known safety
profile”).
Blinding was not re-
ported.
No definition given
for non-serious AEs.
SAEs were predefined
(“those events that re-
sulted in death, were
deemed life-threaten-
ing, led to a persistent
or significant disabili-
ty, required hospital-
ization, or were asso-
ciated with a congen-
ital anomaly, cancer,
or other important
medical event”).
Reasons for dis-
continuation
were separated
by arm, and af-
ter each dose
administration.
Attribution was
not reported.
No information
on how with-
drawals were
handled in the
analysis.
Stopping
rules not
reported
No filter
used
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Joura
2015
Mode of data collection was
not reported.
Time frame
was speci-
fied (“Deaths
and serious
vaccine-re-
lated AEs
were report-
ed through-
out the study.
Other SAEs
were reported
from day 1 to
6 months fol-
lowing the last
vaccination;
events of fetal
loss were re-
ported as SAEs
for any preg-
nancy with a
last menstrual
period before 6
months follow-
ing the last vac-
cination”).
Attribution was made
by the investigator
(“were deemed by the
investigator”).
Blinding was not re-
ported.
SAEs were prede-
fined (“any AE that re-
sulted in death, were
deemed by the investi-
gator to be life-threat-
ening, resulted in a
persistent or signifi-
cant disability or in-
capacity, resulted in
or prolonged an exist-
ing inpatient hospital
stay, or were congen-
ital anomalies, can-
cers, or other so-called
important medical
events”).
Attribution was
made by the
safety moni-
toring commit-
tee (“The exter-
nal data and
safety mon-
itoring com-
mittee whose
members were
aware of the
group assign-
ments assessed
safety findings
throughout the
study”).
No information
on how with-
drawals were
handled in the
analysis.
Stopping
rules not
reported
No filter
used. AEs
were re-
ported as
n/N. Study
also re-
ported
number
of partici-
pants with
at least
1 event,
but did
not dis-
tinguish
between
partici-
pants with
1 or multi-
ple AEs.
Lehtinen
2018
Proactive and passive: for
active safety surveillance,
a small subset of male ado-
lescents receiving either
vaccine were selected to
use diary cards.
Serious adverse events
were actively monitored in
the diary card subset and
in other male participants
in one cluster (90% HPV,
10% HBV) from month 1 to
month 12.
Passive monitoring of SAEs
and new-onset autoim-
mune diseases continued
for all study participants
during the whole follow-up
period
by linkage to inpatient and
outpatient health care use
recorded in the Care Regis-
ter for Social Welfare and
Health Care.
Active surveil-
lance:
• to 30 min-
utes after
vaccination
for rash and
urticarial (di-
ary card sub-
set);• to 30 days
after vacci-
nation for
symptoms
(diary card
subset);• to month
12 for med-
ically signif-
icant condi-
tions (diary
card subset);• to month
12 for seri-
ous adverse
events (di-
ary card sub-
set and other
male partici-
pants in one
cluster).
Passive SAE
and new-onset
Attribution by investi-
gator, blinded to treat-
ment.
Active surveil-
lance of SAEs,
non-serious
AEs and other
events was only
conducted for
a small subset
of male partici-
pants. Reasons
for discontinu-
ation were sep-
arated by arm
and reported
for withdrawals
due to SAEs,
non-serious AEs
and other rea-
sons.
Stopping
rules not
reported
No filter
used
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autoimmune
disease surveil-
lance:
• for entire
study period
(to approx-
imately 4
years).
Leung
2015
Passive for solicited local
and general symptoms: “di-
ary cards”
Time frame
was specified
(“Solicited lo-
cal and general
symptoms were
recorded for 7
days after each
vaccination”;
“Unsolicited
symptoms were
recorded for 30
days after each
vaccination";
“SAEs, med-
ically signifi-
cant AEs, pIMDs
and pregnancy
were reported
throughout the
study”; “SAEs
up to month
36”)
Attribution and blind-
ing were not reported.
Only Grade 3 symp-
toms were defined
(“redness or swelling
> 50 mm in diameter,
fever > 39C”)
No information
on how with-
drawals would
have been han-
dled in the
analysis, how-
ever “no sub-
ject was with-
drawn from the
study due to an
AE”
Attribution was
not reported.
Stopping
rules not
reported
No filter
used. Re-
sults re-
ported
as per-
centage
of partici-
pants with
symp-
toms,
there-
fore did
not dis-
tinguish
between
partici-
pants with
1 or multi-
ple AEs.
Levin
2010
Proactive: “Subjects were
observed in clinic for 30
minutes post vaccination.
A report card of relevant
signs and symptoms was
maintained by the caregiv-
er for 15 days after each in-
jection. Body temperature
was recorded for 5 days be-
ginning after the injection.
Telephone contact with the
caregiver was made on the
third day after each injec-
tion to inquire about reac-
tions. The caregiver was
instructed to immediate-
ly report unusual injection
site reactions”; “Routine
hematologic and chemistry
screens were performed at
the study site's laboratory
at entry, 4 weeks after the
first dose, and just before
and 4 weeks after the next 2
doses. CD4% and CD4 num-
ber were determined at en-
try, 8 weeks after the first
dose, 4 weeks after the sec-
Time frame was
specified (see
methods of da-
ta collection).
Attribution was made
by the study co-ordi-
nator.
Blinding not reported.
The severity of AEs
was done using the
“Division of AIDS Table
for Grading the Severi-
ty of Adverse Events”.
No information
on how with-
drawals were
handled in the
analysis.
Unclear.
“A clinic
visit was
required
within
24 hours
whenever
the study
coordina-
tor con-
sidered
that a re-
action
might be
≥ grade 3”.
However,
clear rules
regard-
ing termi-
nation of
the study
were not
reported.
No filter
used
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ond dose, and just before
and 4 weeks after the third
dose”.
Lin 2014 Unclear: “Following each
vaccination visit, partici-
pants were screened for ad-
verse events”.
Time frame is
unclear.
Not reported Reasons for dis-
continuation
were separated
by arm, and af-
ter each dose
administration.
Attribution was
not reported.
No information
on how with-
drawals were
handled in the
analysis.
Stopping
rules not
reported
No fil-
ter used.
Howev-
er, results
were on-
ly report-
ed narra-
tively as
propor-
tions. P-
value only
reported
for over-
all occur-
rence of
AEs. Spe-
cific AEs
were not
reported
separately
by group.
NCT00941889
2016
Not applicable, serious and/
or other non-serious ad-
verse events were not col-
lected or assessed.
Not applicable Not applicable Not applicable Not ap-
plicable
Not ap-
plicable
NCT01031069
2017
Mode of data collection was
not reported.
Solicited lo-
cal and gener-
al symptoms
within 7 days
after each and
any vaccina-
tion; unsolicit-
ed symptoms
within 30 days
(days 0-29) af-
ter any vacci-
nation; SAEs,
medically sig-
nificant condi-
tions, pregnan-
cy outcomes,
clinically rele-
vant abnormal-
ities in haema-
tological and
biochemical
parameters up
to 30 days after
the last dose of
vaccine.
Attribution, blinding
or definitions were not
reported.
Reasons for dis-
continuation
were separated
by arm.
All vaccinat-
ed subjects for
whom data
were available
were included
in the analysis.
Attribution was
not reported.
Stopping
rules not
reported
No filter
used
NCT01862874
2018
Mode of data collection was
not reported, except that a
Serious and
other adverse
events fol-
Attribution, blinding
or definitions were not
reported.
Reasons for dis-
continuation
Stopping
rules not
reported
Thresh-
old above
which
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vaccination report card was
used.
lowed up for
36 months; in-
jection-site AEs
were reported
up to 5 days af-
ter any vaccina-
tion; systemic
AEs were re-
ported up to 15
days after any
vaccination.
were separated
by arm.
All vaccinat-
ed subjects for
whom data
were available
were included
in the analysis.
Attribution was
not reported.
other
adverse
events are
reported:
5%
Wilkin
2018
Mode of data collection was
not reported.
Grade 3 or 4 AEs
that were pos-
sibly, proba-
bly, or definite-
ly related to the
vaccine: to par-
ticipant's last
study visit, for
up to 4 years.
Attribution deter-
mined by the local in-
vestigator, blinding
not reported.
Grade 3 or 4 adverse
events were defined
using the DAIDS Table
for Grading the Sever-
ity of Adult and Pedi-
atric Adverse Events.
Reasons for dis-
continuation
were separated
by arm.
All vaccinat-
ed subjects for
whom data
were available
were included
in the analysis.
Attribution was
made by the lo-
cal investigator.
Stopping
rules not
reported
No filter
used
Petaja
2009
Proactive and passive:
“Participants used diary
cards to report solicited lo-
cal and general symptoms
during a 7-day follow-up
period after each vaccine
dose”;
“Unsolicited signs and
symptoms were reported
within 30 days after each
dose”.
Data collection forms avail-
able from GSK report.
Time frame was
specified: 7-day
follow-up for
local and gen-
eral symptoms;
30 days for un-
solicited signs
and symptoms;
SAEs, NOCDs
and other med-
ically signif-
icant condi-
tions (MSCs)
were reported
throughout the
study period
(up to month
12).
Attribution method
not explicitly de-
scribed in methods
section. However, it
seems it was done
by the investigator
“Neither of the SAEs
were fatal, and both
events were consid-
ered by the investiga-
tor to be unrelated to
study vaccination”;
“the determination of
whether a chronic dis-
ease is considered to
be of new onset will
be based on review of
the subject's pre-vac-
cination medical his-
tory”.
Blinding was not re-
ported.
Outcome definition:
• “Solicited local AEs
included pain, red-
ness, and swelling
at the injection
site”;• “Solicited gener-
al AEs included
Reasons for dis-
continuation
were separated
by arm.
Attribution was
not reported.
No information
on how with-
drawals were
handled in the
analysis.
Stopping
rules not
fully de-
scribed,
“Your par-
ticipa-
tion in
the study
may be
stopped
the study
doctor de-
cides it
is in the
best inter-
est of your
health
and wel-
fare to
discontin-
ue partic-
ipation in
the study”
Filter not
used. AEs
were re-
ported
as n/N.
GSK re-
port lists
all symp-
toms indi-
vidually.
Study did
not dis-
tinguish
between
partici-
pants with
1
or multi-
ple AEs.
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fever, headache, fa-
tigue, gastrointesti-
nal symptoms (i.e.
nausea, vomiting,
diarrhoea, abdom-
inal pain), arthral-
gia, myalgia, rash,
and urticaria”• “Grade 3 solicited
AEs were defined
as pain that pre-
vented normal ac-
tivity, redness or
swelling larger than
50 mm, fever high-
er than 39.0 °C
(axillary tempera-
ture), urticaria dis-
tributed on at
least four body ar-
eas, or events that
prevented normal,
everyday activities.
Urticaria or rash
that appeared with-
in 30 minutes of
each vaccine dose
was also document-
ed by the investiga-
tor”• “An SAE was de-
fined as any unto-
ward medical oc-
currence that re-
sulted in death, was
life-threatening, re-
quired hospitaliza-
tion, resulted in dis-
ability or incapaci-
ty, was an impor-
tant medical event
or was a congenital
anomaly/birth de-
fect in the offspring
of a study subject”• “MSCs were de-
fined as non-seri-
ous AEs prompting
either emergency
room or physician
visits not related to
either common dis-
eases or routine vis-
its for physical ex-
amination or vacci-
nation, or SAEs not
related to common
diseases”• “Common diseases
included upper res-
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piratory infections,
sinusitis, pharyngi-
tis, gastroenteritis,
urinary tract infec-
tions, and injury"
Puthanakit
2016
Proactive and passive:
“Solicited local and gener-
al symptoms were record-
ed on diary cards for 7 days
after each vaccination. Un-
solicited symptoms were
recorded for 30 days after
each vaccination. Pregnan-
cies and outcomes, seri-
ous adverse events, med-
ically significant adverse
events, and potential im-
mune-mediated diseases
were reported throughout
the study”.
Time frame was
specified (see
methods of da-
ta collection).
Attribution and blind-
ing not reported.
Grade 3 symptoms
were defined (“as red-
ness or swelling >50
mm in diameter, fever
>39°C, urticaria dis-
tributed on ≥4 body
areas, and, for oth-
er symptoms, as pre-
venting normal activi-
ty”).
Reasons for dis-
continuation
were separated
by arm, and af-
ter each dose
administration.
Attribution was
not reported.
No information
on how with-
drawals were
handled in the
analysis.
Stopping
rules not
reported
No fil-
ter used,
howev-
er, results
were pro-
vided as
number
of partici-
pants with
at least
1 event,
there-
fore did
not dis-
tinguish
between
partici-
pants with
1 or multi-
ple AEs.
Ro-
manowski
2011
Proactive and passive:
“Solicited local symptoms
(pain, redness or swelling at
injection site) and general
symptoms (fever, headache,
fatigue, gastrointestinal
symptoms, arthralgia, myal-
gia, rash or urticaria) occur-
ring within 7 d after each
vaccination were recorded
by the subject or her par-
ent/legally acceptable rep-
resentative using a diary
card. Investigators docu-
mented the presence or ab-
sence of urticaria/rash with-
in 30 min after each vac-
cine. dose. Unsolicited AEs
occurring within one month
of each vaccine dose were
documented by the investi-
gator.
"SAEs and other medically
significant conditions were
reported in all subjects re-
gardless of causal relation-
ship to vaccination and in-
tensity."
Time frame was
specified (see
methods of da-
ta collection).
Attribution and blind-
ing not reported.
Outcome definition
reported (“Medically
significant condition
= AE prompting emer-
gency room or physi-
cian visits that was not
related to common
diseases. New onset
autoimmune diseases
(which excluded al-
lergy-related events
or isolated signs and
symptoms) were iden-
tified by comparing
all reported AEs with
a pre-defined list of
potential chronic au-
toimmune events de-
rived from the Medical
Dictionary for Regula-
tory Activities”).
Attribution was
not reported.
No information
on how with-
drawals would
have been han-
dled in the
analysis, how-
ever “no sub-
ject was with-
drawn from the
study due to an
AE or a SAE”
Stopping
rules not
reported
No fil-
ter used.
However,
for many
of the AEs,
results
were pro-
vided as
number
of partici-
pants with
at least
1 event,
there-
fore did
not dis-
tinguish
between
partici-
pants with
1 or multi-
ple AEs.
ToM 2014 Proactive and passive: “Par-
ticipants were observed for
30 minutes after each im-
munization to evaluate im-
Time frame was
specified (see
methods of da-
ta collection).
Attribution was un-
clear (see below).
Withdrawals
were not re-
ported by
group. No infor-
Stopping
rules not
reported
Filter not
used.
Solicit-
ed AEs re-
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mediate AEs. Solicited AEs
occurring during the first
4 days after each immu-
nization (injection site pain,
swelling, erythema, fever,
headache, nausea, myal-
gia, arthralgia and rash) and
other signs of illness and/or
changes in medication oc-
curring within 15 days after
immunization were record-
ed on diary cards”.
Blinding was not re-
ported.
Outcome definition
was reported (“Solicit-
ed and unsolicited
AEs, as well as labora-
tory tests, were grad-
ed according to the
common toxicity cri-
teria version 2.0. All
solicited local (injec-
tion site) and influen-
za-like (fever, arthral-
gia, chills, and fatigue)
reactions were consid-
ered causally related
to vaccination. Other
AEs were evaluated by
the primary investiga-
tor and graded as “un-
likely” or “probably”
related to the study
vaccines”).
mation on how
withdrawals
were handled
in the analysis
was provided.
Attribution was
not reported.
ported as
n/N. Study
also re-
ported
number
of partici-
pants with
at least
1 event,
but did
not dis-
tinguish
between
partici-
pants with
1 or multi-
ple AEs.
van
Damme
2016
Proactive and passive: “Fol-
lowing each vaccination,
participants were observed
for 30 min for any untoward
effects, including allergic re-
actions. All participants re-
ceived a vaccination report
card (VRC) at each vaccina-
tion visit. They were asked
to record their oral temper-
ature on the VRC from day
1 to day 5 after each vac-
cination (starting on the
evening after vaccination),
and any injection-site and
systemic AEs) for a total of
15 days including the day
of vaccination … SAEs were
collected for the entire du-
ration of the study irrespec-
tive of cause”.
Time frame was
specified (see
methods of da-
ta collection).
Attribution was made
by investigators based
on the information
provided by the pa-
tients (“The study site
personnel reviewed
the VRC for complete-
ness and could not al-
ter the original infor-
mation recorded by
the participants on
the VRC. The investi-
gator determined the
causality of systemic
AEs reported on the
VRC, and classified
each AE reported on
the VRC as a serious or
non-serious AE”).
Blinding was not re-
ported.
Outcome definition
was reported (“An oral
temperature 37.8 C
during the follow-up
period was consid-
ered an elevated tem-
perature (fever). For
each AE, participants
were asked to rate
the symptom as mild
(awareness of signor
symptom but easily
tolerated), moderate
Reasons for dis-
continuation
were separated
by arm.
Attribution was
not reported.
No informa-
tion provid-
ed about how
withdrawals
were handled
in the analysis.
Stopping
rules not
reported
Filter not
used. AEs
were re-
ported as
n/N. Study
also re-
ported
number
of partici-
pants with
no event,
and num-
ber with
at least
1 event,
but did
not dis-
tinguish
between
partici-
pants with
1 or multi-
ple AEs.
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(discomfort enough
to cause interference
with usual activities),
or severe (incapaci-
tating with inability to
work or do usual ac-
tivity); injection-site
AEs of swelling and
erythema were rat-
ed by size. Investiga-
tors were instructed
to assign causality to
AEs on the basis of ex-
posure, time course,
likely cause, and con-
sistency with the vac-
cine’s known profile.
Serious AEs (SAEs)
were predefined as
any AE that resulted
in death, deemed by
the investigator to be
life-threatening, or
that resulted in a per-
sistent or significant
disability or incapaci-
ty, resulted in or pro-
longed an existing in-
patient hospitaliza-
tion, or was a congeni-
tal anomaly, a cancer,
or an ‘other important
medical event").
Vesikari
2015
Proactive and passive: “Par-
ticipants were observed for
30 mins after each vaccina-
tion for any immediate re-
action. All subjects received
a vaccination report card
at the day 1, month 2 and
month 6 study vaccination
visits. Oral temperature was
reported from day 1 to day
5 after any vaccination, and
injection-site reactions and
systemic AEs were recorded
on the vaccination report
card from day 1 to day 15
after any vaccination. SAEs
were monitored through-
out the study regardless of
cause”.
Time frame was
specified (see
methods of da-
ta collection).
Attribution was made
by the investigator
(“Investigators as-
signed causality to
AEs based on expo-
sure, time course, like-
ly cause and consis-
tency with the vac-
cine’s known profile.
Vaccine-related AEs
were determined by
the investigator to be
possibly, probably or
definitely vaccine-re-
lated”).
Blinding was not re-
ported.
Outcome definition
was reported (“An el-
evated temperature
(fever) was defined as
maximum tempera-
ture ≥37.8°C. For each
AE, participants rat-
ed the symptom as
Reasons for dis-
continuation
were separated
by arm, and af-
ter each dose
administration.
Attribution was
not reported.
No informa-
tion provid-
ed about how
withdrawals
were handled
in the analysis.
Stopping
rules not
reported
Filter not
used. AEs
were re-
ported as
n/N. Study
also re-
ported
number
of partici-
pants with
no event,
and num-
ber with
at least
1 event,
but did
not dis-
tinguish
between
partici-
pants with
1 or multi-
ple AEs.
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mild (awareness of
symptom but easily
tolerated), moderate
(discomfort enough
to cause interference
with usual activities)
or severe (incapaci-
tating with inability to
work or do usual ac-
tivity); injection-site
AEs of swelling and
erythema were rat-
ed by size. SAEs were
predefined as any AE
that resulted in death,
were deemed by the
investigator to be life-
threatening, resulted
in a persistent or sig-
nificant disability or
incapacity, resulted
in or prolonged an ex-
isting in-patient hos-
pitalization or was a
congenital anomaly,
a cancer or an “oth-
er important medical
event”.
  (Continued)
 
Abbreviations
AE: adverse event
HBV: hepatitis B vaccine
HPV: human papillomavirus
NOCD: new onset chronic disease
pIMD: potentially immune mediated diseases
SAE: serious adverse event
VRC: vaccination report card
Appendix 5. Two versus three doses of HPV vaccine in 9- to 15-year old females - immunogenicity outcomes
 
Outcome or subgroup* Follow-up Studies Partici-
pants
Statistical
method
Effect estimate (95%
CI)
Certainty
of the ev-
idence
(GRADE)
1.1 GMT of HPV 6 (mMU/
mL)
1 month after last
dose
2 (Dobson
2013; Iversen
2016)
1001 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 1.13
(0.99 to 1.29)
⊕⊕⊕⊕
HIGH
1.1.1 Quadrivalent vac-
cine
1 month after last
dose
1 (Dobson
2013)
489 Ratio of
GMTs (IV,
random-ef-
Ratio of GMTs 1.18
(0.93 to 1.49)
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fects, 95%
CI)
1.1.2 Nonavalent vac-
cine
1 month after last
dose
1 (Iversen
2016)
512 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 1.11
(0.94 to 1.30)
 
1.2 GMT of HPV 11
(mMU/mL)
1 month after last
dose
2 (Dobson
2013; Iversen
2016)
1006 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 1.09
(0.97 to 1.22)
⊕⊕⊕⊕
HIGH
1.2.1 Quadrivalent vac-
cine
1 month after last
dose
1 (Dobson
2013)
494 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 1.12
(0.95 to 1.32)
 
1.2.2 Nonavalent vac-
cine
1 month after last
dose
1 (Iversen
2016)
512 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 1.06
(0.91 to 1.25)
 
1.3 GMT of HPV 16           Not
pooled
due to
consider-
able het-
erogene-
ity across
studies (I2
= 89%)
1.3.1 Bivalent vaccine 1 month after last
dose
1 (Romanows-
ki 2011)
132 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.50
(0.38 to 0.66)
⊕⊕⊕⊝
MODER-
ATE1,4
1.3.2 Quadrivalent vac-
cine
1 month after last
dose
2 (Dobson
2013; Leung
2015)
1143 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 1.03
(0.92 to 1.15)
⊕⊕⊕⊕
HIGH
1.3.3 Nonavalent vac-
cine
1 month after last
dose
1 (Iversen
2016)
541 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 1.14
(0.98 to 1.34)
⊕⊕⊕⊕
HIGH
1.4 GMT of HPV 18 1 month after last
dose
4 (Romanows-
ki 2011; Dob-
son 2013;
1833 Ratio of
GMTs (IV,
random-ef-
Ratio of GMTs 0.77
(0.69 to 0.87)
⊕⊕⊕⊝
MODER-
ATE2
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Iversen 2016;
Leung 2015)
fects, 95%
CI)
1.4.1 Bivalent vaccine 1 month after last
dose
1 (Romanows-
ki 2011)
132 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.74
(0.57 to 0.97)
 
1.4.2 Quadrivalent vac-
cine
1 month after last
dose
2 (Dobson
2013; Leung
2015)
1159 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.72
(0.64 to 0.81)
 
1.4.3 Nonavalent vac-
cine
1 month after last
dose
1 (Iversen
2016)
542 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.91
(0.76 to 1.09)
 
1.5 GMT of HPV 31
(mMU/mL)
1 month after last
dose
1 (Iversen
2016)
543 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.82
(0.69 to 0.98)
⊕⊕⊕⊕
HIGH
1.6 GMT of HPV 33
(mMU/mL)
1 month after last
dose
1 (Iversen
2016)
548 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 1.29
(1.10 to 1.52)
⊕⊕⊕⊕
HIGH
1.7 GMT of HPV 45
(mMU/mL)
1 month after last
dose
1 (Iversen
2016)
549 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.54
(0.45 to 0.65)
⊕⊕⊕⊕
HIGH
1.8 GMT of HPV 52
(mMU/mL)
1 month after last
dose
1 (Iversen
2016)
547 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.64
(0.55 to 0.74)
⊕⊕⊕⊕
HIGH
1.9 GMT of HPV 58
(mMU/mL)
1 month after last
dose
1 (Iversen
2016)
543 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 1.02
(0.87 to 1.19)
⊕⊕⊕⊕
HIGH
             
1.10 Seroconversion to
HPV 6
1 month after last
dose
2 (Dobson
2013; Iversen
2016)
1001 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.99 to 1.01) ⊕⊕⊕⊕
HIGH
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1.10.1 Quadrivalent
vaccine
1 month after last
dose
1 (Dobson
2013)
489 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.99 to 1.01)  
1.10.2 Nonavalent vac-
cine
1 month after last
dose
1 (Iversen
2016)
512 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.99 to 1.02)  
1.11 Seroconversion to
HPV 11
1 month after last
dose
2 (Dobson
2013; Iversen
2016)
1006 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.99 to 1.01) ⊕⊕⊕⊕
HIGH
1.11.1 Quadrivalent
vaccine
1 month after last
dose
1 (Dobson
2013)
494 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.99 to 1.01)  
1.11.2 Nonavalent vac-
cine
1 month after last
dose
1 (Iversen
2016)
512 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.99 to 1.01)  
1.12 Seroconversion to
HPV 16
1 month after last
dose
4 (Romanows-
ki 2011; Dob-
son 2013;
Iversen 2016;
Leung 2015)
1816 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (1.00 to 1.00) ⊕⊕⊕⊕
HIGH
1.12.1 Bivalent vaccine 1 month after last
dose
1 (Romanows-
ki 2011)
132 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.97 to 1.03)  
1.12.2 Quadrivalent
vaccine
1 month after last
dose
2 (Dobson
2013; Leung
2015)
1143 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (1.00 to 1.00)  
1.12.3 Nonavalent vac-
cine
1 month after last
dose
1 (Iversen
2016)
541 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.99 to 1.01)  
1.13 Seroconversion to
HPV 18
1 month after last
dose
4 (Romanows-
ki 2011; Dob-
son 2013;
Iversen 2016;
Leung 2015)
1833 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (1.00 to 1.00) ⊕⊕⊕⊕
HIGH
1.13.1 Bivalent vaccine 1 month after last
dose
1 (Romanows-
ki 2011)
132 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.97 to 1.03)  
1.13.2 Quadrivalent
vaccine
1 month after last
dose
2 (Dobson
2013; Leung
2015)
1159 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (1.00 to 1.00)  
1.13.3 Nonavalent vac-
cine
1 month after last
dose
1 (Iversen
2016)
542 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.99 to 1.01)  
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1.14 Seroconversion to
HPV 31
1 month after last
dose
1 (Iversen
2016)
543 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.99 to 1.01) ⊕⊕⊕⊕
HIGH
1.15 Seroconversion to
HPV 33
1 month after last
dose
1 (Iversen
2016)
548 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.99 to 1.01) ⊕⊕⊕⊕
HIGH
1.16 Seroconversion to
HPV 45
1 month after last
dose
1 (Iversen
2016)
549 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.99 to 1.01) ⊕⊕⊕⊕
HIGH
1.17 Seroconversion to
HPV 52
1 month after last
dose
1 (Iversen
2016)
547 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.99 to 1.01) ⊕⊕⊕⊕
HIGH
1.18 Seroconversion to
HPV 58
1 month after last
dose
1 (Iversen
2016)
543 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.99 to 1.01) ⊕⊕⊕⊕
HIGH
             
1.19 GMT of HPV 6
(mMU/mL)
           
1.19.1 Quadrivalent
vaccine
60 months after
first dose
1 (Dobson
2013)
101 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.73
(0.50 to 1.06)
⊕⊕⊝⊝
LOW3,4
1.19.2 Nonavalent vac-
cine
36 months after
first dose
1 (Iversen
2016)
476 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.90
(0.76 to 1.08)
⊕⊕⊕⊕
HIGH
1.20 GMT of HPV 11
(mMU/mL)
           
1.20.1 Quadrivalent
vaccine
60 months after
first dose
1 (Dobson
2013)
101 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.99
(0.68 to 1.44)
⊕⊕⊝⊝
LOW2,3
1.20.2 Nonavalent vac-
cine
36 months after
first dose
1 (Iversen
2016)
476 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.84
(0.70 to 1.01)
⊕⊕⊕⊕
HIGH
1.21 GMT of HPV 16
(mMU/mL)
           
1.21.1 bivalent vaccine 60 months after
first dose
1 (Romanows-
ki 2011)
93 Ratio of
GMTs (IV,
random-ef-
Ratio of GMTs 0.51
(0.36 to 0.72)
⊕⊕⊝⊝
LOW3,4
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fects, 95%
CI)
1.21.2 Quadrivalent
vaccine
60 months after
first dose
1 (Dobson
2013)
101 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 1.14
(0.76 to 1.73)
⊕⊕⊝⊝
LOW3,4
1.21.3 Nonavalent vac-
cine
36 months after
first dose
1 (Iversen
2016)
503 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.85
(0.69 to 1.04)
⊕⊕⊕⊕
HIGH
1.22 GMT of HPV 18
(mMU/mL)
           
1.22 1 Bivalent vaccine 60 months after
first dose
1 (Romanows-
ki 2011)
92 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.69
(0.47 to 1.02)
⊕⊕⊝⊝
LOW3,4
1.22.2 Quadrivalent
vaccine
60 months after
first dose
1 (Dobson
2013)
101 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.57
(0.34 to 0.96)
⊕⊕⊝⊝
LOW3,4
1.22.3 Nonavalent vac-
cine
36 months after
first dose
1 (Iversen
2016)
504 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.77
(0.65 to 0.91)
⊕⊕⊕⊕
HIGH
1.23 GMT of HPV 31
(mMU/mL)
36 months after
first dose
1 (Iversen
2016)
506 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.62
(0.51 to 0.75)
⊕⊕⊕⊕
HIGH
1.24 GMT of HPV 33
(mMU/mL)
36 months after
first dose
1 (Iversen
2016)
510 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 1.11
(0.94 to 1.31)
⊕⊕⊕⊕
HIGH
1.25 GMT of HPV 45
(mMU/mL)
36 months after
first dose
1 (Iversen
2016)
511 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.46
(0.39 to 0.56)
⊕⊕⊕⊕
HIGH
1.26 GMT of HPV 52
(mMU/mL)
36 months after
first dose
1 (Iversen
2016)
509 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.57
(0.49 to 0.67)
⊕⊕⊕⊕
HIGH
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1.27 GMT of HPV 58
(mMU/mL)
36 months after
first dose
1 (Iversen
2016)
505 Ratio of
GMTs (IV,
random-ef-
fects, 95%
CI)
Ratio of GMTs 0.88
(0.74 to 1.05)
⊕⊕⊕⊕
HIGH
             
1.28 Seropositivity to
HPV 6
           
1.28.1 Quadrivalent
vaccine
60 months after
first dose
1 (Dobson
2013)
101 RR (M-H, ran-
dom-effects,
95% CI)
RR 0.98 (0.91 to 1.05) ⊕⊕⊝⊝
LOW3,4
1.28.2 Nonavalent vac-
cine
36 months after
first dose
1 (Iversen
2016)
476 RR (M-H, ran-
dom-effects,
95% CI)
RR 0.97 (0.94 to 1.01) ⊕⊕⊕⊕
HIGH
1.29 Seropositivity to
HPV 11
           
1.29.1 Quadrivalent
vaccine
60 months after
first dose
1 (Dobson
2013)
101 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (95% CI not
estimable, all partici-
pants were seroposi-
tive)
⊕⊕⊝⊝
LOW3,4
1.29.2 Nonavalent vac-
cine
36 months after
first dose
1 (Iversen
2016)
476 RR (M-H, ran-
dom-effects,
95% CI)
RR 0.95 (0.92 to 0.99) ⊕⊕⊕⊕
HIGH
1.30 Seropositivity to
HPV 16
           
1.30.1 Bivalent vaccine 60 months after
first dose
1 (Romanows-
ki 2011)
490 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (95% CI not
estimable, all partici-
pants were seroposi-
tive)
⊕⊕⊕⊕
HIGH
1.30.2 Quadrivalent
vaccine
60 months after
first dose
1 (Dobson
2013)
101 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (95% CI not
estimable, all partici-
pants were seroposi-
tive)
⊕⊕⊝⊝
LOW3,4
1.30.3 Nonavalent vac-
cine
36 months after
first dose
1 (Iversen
2016)
503 RR (M-H, ran-
dom-effects,
95% CI)
RR 0.98 (0.96 to 1.00) ⊕⊕⊕⊕
HIGH
1.31 Seropositivity to
HPV 18
           
1.31.1 Bivalent vaccine 60 months after
first dose
1 (Romanows-
ki 2011)
480 RR (M-H, ran-
dom-effects,
95% CI)
RR 1.00 (0.99 to 1.01) ⊕⊕⊕⊕
HIGH
1.31.2 Quadrivalent
vaccine
60 months after
first dose
1 (Dobson
2013)
101 RR (M-H, ran-
dom-effects,
95% CI)
RR 0.89 (0.78 to 1.03) ⊕⊕⊝⊝
LOW3,4
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1.31.3 Nonavalent vac-
cine
36 months after
first dose
1 (Iversen
2016)
504 RR (M-H, ran-
dom-effects,
95% CI)
RR 0.98 (0.95 to 1.02) ⊕⊕⊕⊕
HIGH
1.32 Seropositivity to
HPV 31
36 months after
first dose
1 (Iversen
2016)
506 RR (M-H, ran-
dom-effects,
95% CI)
RR 0.96 (0.93 to 1.00) ⊕⊕⊕⊕
HIGH
1.33 Seropositivity to
HPV 33
36 months after
first dose
1 (Iversen
2016)
510 RR (M-H, ran-
dom-effects,
95% CI)
RR 0.96 (0.92 to 0.99) ⊕⊕⊕⊕
HIGH
1.34 Seropositivity to
HPV 45
36 months after
first dose
1 (Iversen
2016)
511 RR (M-H, ran-
dom-effects,
95% CI)
RR 0.92 (0.86 to 0.98) ⊕⊕⊕⊕
HIGH
1.35 Seropositivity to
HPV 52
36 months after
first dose
1 (Iversen
2016)
509 RR (M-H, ran-
dom-effects,
95% CI)
RR 0.96 (0.92 to 0.99) ⊕⊕⊕⊕
HIGH
1.36 Seropositivity to
HPV 58
36 months after
first dose
1 (Iversen
2016)
505 RR (M-H, ran-
dom-effects,
95% CI)
RR 0.99 (0.97 to 1.01) ⊕⊕⊕⊕
HIGH
  (Continued)
 
*Results were stratified into subgroups by type of HPV vaccine and time point. GMTs and seropositivity to HPV 31, 33, 45, 52, and 58 are
only measured in nonavalent vaccine trials (Iversen 2016).
1GRADE rating applies to specific vaccine type and outcome
2Downgraded one level for inconsistency: moderate heterogeneity (I2 > 30%)
3Downgraded one level for risk of bias: high loss to follow up
4Downgraded one level for imprecision: small sample size
Abbreviations
CI: confidence interval
GMT: geometric mean titre
HPV: human papillomavirus
IV: inverse variance
M-H: Mantel-Haenszel
RR: risk ratio
SMD: standard mean difference
mMU: milli-Merck unit
Appendix 6. Two doses of HPV vaccine with longer interval versus two doses of HPV vaccine with shorter interval in
9- to 14-year old females and males - immunogenicity outcomes
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Outcome or sub-
group*
Population Follow-up Studies Partici-
pants
Statistical method Effect estimate (95%
CI)
Certainty
of the evi-
dence
(GRADE)
3.1 GMT of HPV 6
(mMU/mL)
             
3.1.1 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old females 1 month af-
ter last dose
1 (Iversen
2016)
381 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.62 (1.32
to 1.98)
⊕⊕⊕⊕
HIGH
3.1.2 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old males 1 month af-
ter last dose
1 (Iversen
2016)
397 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.72 (1.41
to 2.09)
⊕⊕⊕⊕
HIGH
3.2 GMT of HPV
11 (mMU/mL)
             
3.2.1 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old females 1 month af-
ter last dose
1 (Iversen
2016)
381 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 2.10 (1.82
to 2.40)
⊕⊕⊕⊕
HIGH
3.2.2 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old males 1 month af-
ter last dose
1 (Iversen
2016)
398 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 2.08 (1.71
to 2.53)
⊕⊕⊕⊕
HIGH
3.3 GMT of HPV
16 (EU/mL or
mMU/mL)
             
3.3.1 Bivalent
vaccine (0 and 2
months) vs (0 and
6 months
9- to 14-year-old females 1 month af-
ter last dose
1 (Ro-
manowski
2011)
136 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 2.06 (1.60
to 2.64)
⊕⊕⊕⊝
MODERATE1
3.3.2 Bivalent
vaccine (0 and 6
9- to 14-year-old females 1 month af-
ter last dose
1
(Puthanakit
2016)
835 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.22 (1.10
to 1.34)
⊕⊕⊕⊕
HIGH
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months) vs (0 and
12 months)
3.3.3 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old females 1 month af-
ter last dose
1 (Iversen
2016)
401 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.73 (1.42
to 2.10)
⊕⊕⊕⊕
HIGH
3.3.4 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old males 1 month af-
ter last dose
1 (Iversen
2016)
408 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.75 (1.44
to 2.12)
⊕⊕⊕⊕
HIGH
3.4 GMT of HPV
18 (EU/mL or
mMU/mL)
             
3.4.1 Bivalent
vaccine (0 and 2
months) vs (0 and
6 months
9- to 14-year-old females 1 month af-
ter last dose
1 (Ro-
manowski
2011)
132 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.60 (1.22
to 2.10)
⊕⊕⊕⊝
MODERATE1
3.4.2 Bivalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old females 1 month af-
ter last dose
1
(Puthanakit
2016)
854 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.12 (1.01
to 1.25)
⊕⊕⊕⊕
HIGH
3.4.3 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old females 1 month af-
ter last dose
1 (Iversen
2016)
401 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.44 (1.16
to 1.79)
⊕⊕⊕⊕
HIGH
3.4.4 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old males 1 month af-
ter last dose
1 (Iversen
2016)
409 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.57 (1.27
to 1.95)
⊕⊕⊕⊕
HIGH
3.5 GMT of HPV
31 (mMU/mL)
             
3.5.1 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old females 1 month af-
ter last dose
1 (Iversen
2016)
404 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.45 (1.18
to 1.79)
⊕⊕⊕⊕
HIGH
  (Continued)
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3.5.2 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old males 1 month af-
ter last dose
1 (Iversen
2016)
407 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.43 (1.17
to 1.76)
⊕⊕⊕⊕
HIGH
3.6 GMT of HPV
33 (mMU/mL)
             
3.6.1 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old females 1 month af-
ter last dose
1 (Iversen
2016)
405 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.98 (1.63
to 2.40)
⊕⊕⊕⊕
HIGH
3.6.2 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old males 1 month af-
ter last dose
1 (Iversen
2016)
408 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 2.27 (1.87
to 2.76)
⊕⊕⊕⊕
HIGH
3.7 GMT of HPV
45 (mMU/mL)
             
3.7.1 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old females 1 month af-
ter last dose
1 (Iversen
2016)
406 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.23 (0.98
to 1.54)
⊕⊕⊕⊕
HIGH
3.7.2 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old males 1 month af-
ter last dose
1 (Iversen
2016)
409 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.13 (0.90
to 1.41)
⊕⊕⊕⊕
HIGH
3.8 GMT of HPV
52 (mMU/mL)
             
3.8.1 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old females 1 month af-
ter last dose
1 (Iversen
2016)
403 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.77 (1.47
to 2.13)
⊕⊕⊕⊕
HIGH
3.8.2 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old males 1 month af-
ter last dose
1 (Iversen
2016)
410 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.91 (1.59
to 2.29)
⊕⊕⊕⊕
HIGH
  (Continued)
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3.9 GMT of HPV
58 (mMU/mL)
             
3.9.1 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old females 1 month af-
ter last dose
1 (Iversen
2016)
399 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.79 (1.48
to 2.17)
⊕⊕⊕⊕
HIGH
3.9.2 Nonavalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old males 1 month af-
ter last dose
1 (Iversen
2016)
406 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 2.00 (1.66
to 2.41)
⊕⊕⊕⊕
HIGH
               
3.10 Seroconver-
sion to HPV16
9- to 14-year-old females 1 month af-
ter last dose
1
(Puthanakit
2016)
835 RR (M-H, ran-
dom-effects, 95%
CI)
RR 1.00 (1.00 to 1.00)  
3.10.1 Bivalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old females 1 month af-
ter last dose
1
(Puthanakit
2016)
835 RR (M-H, ran-
dom-effects, 95%
CI)
RR 1.00 (1.00 to 1.00) ⊕⊕⊕⊕
HIGH
3.11 Seroconver-
sion to HPV 18
9- to 14-year-old females 1 month af-
ter last dose
1
(Puthanakit
2016)
854 RR (M-H, ran-
dom-effects, 95%
CI)
RR 1.00 (1.00 to 1.00)  
3.11.1 Bivalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old females 1 month af-
ter last dose
1
(Puthanakit
2016)
854 RR (M-H, ran-
dom-effects, 95%
CI)
RR 1.00 (1.00 to 1.00) ⊕⊕⊕⊕
HIGH
3.12 GMT of HPV
6 (mMU/mL)†
             
9- to 14-year-old males and females
long interval (0, 12 months)
246 Mean 401.2 (354.8 to
453.7)
 3.12.1 Nonava-
lent vaccine (0
and 6 months)
vs (0 and 12
months)
9- to 14-year-old females short inter-
val (0, 6 months)
36 months
after first
dose
1 (Iversen
2016)
236
Mean GMT (95% CI)
Mean 209.6 (184.9 to
237.6)
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9- to 14-year-old males short interval
(0, 6 months)
254 Mean 160.1 (141.9 to
180.7)
 
3.13 GMT of HPV
11 (mMU/mL)†
             
9- to 14-year-old males and females
long interval (0, 12 months)
246 Mean 308.2 (271.8 to
349.6)
 
9- to 14-year-old females short inter-
val (0, 6 months)
236 Mean 133.7 (117.6 to
152.1)
 
3.13.1 Nonava-
lent vaccine (0
and 6 months)
vs (0 and 12
months)
9- to 14-year-old males short interval
(0, 6 months)
36 months
after first
dose
1 (Iversen
2016)
255
Mean GMT (95% CI)
Mean 115.2 (101.8 to
130.3)
 
3.14 GMT of HPV
16 (mMU/mL)†
             
3.14.1 Bivalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old females 36 months
after first
dose
1
(Puthanakit
2016)
817 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.29 (1.15
to 1.44)
⊕⊕⊕⊕
HIGH
9- to 14-year-old males and females
long interval (0, 12 months)
253 Mean 1534.3 (1328.8 to
1771.5)
 
9- to 14-year-old females short inter-
val (0, 6 months)
263 Mean 673.8 (582.8 to
779.1)
 
3.14.3 Nonava-
lent vaccine (0
and 6 months)
vs (0 and 12
months)
9- to 14-year-old males short interval
(0, 6 months)
36 months
after first
dose
1 (Iversen
2016)
248
Mean GMT (95% CI)
Mean 592.6 (514.7 to
682.4)
 
3.15 GMT of HPV
18 (mMU/mL)†
             
3.15.1 Bivalent
vaccine (0 and 6
months) vs (0 and
12 months)
9- to 14-year-old females 36 months
after first
dose
1
(Puthanakit
2016)
794 Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 1.43 (1.26
to 1.62)
⊕⊕⊕⊕
HIGH
3.15.3 Nonava-
lent vaccine (0
and 6 months)
9-14 year old males and females long
interval (0, 12 months)
36 months
after first
dose
1 (Iversen
2016)
255 Mean GMT (95% CI) Mean 276.4 (245.3 to
311.6)
 
  (Continued)
Cochrane
Library
Trusted evidence.
Inform
ed decisions.
Better health.
  
Cochrane Database of System
atic Review
s
Com
parison of dierent hum
an papillom
avirus (H
PV) vaccine types and dose schedules for prevention of H
PV-related disease in fem
ales
and m
ales (Review
)
Copyright ©
 2019 The Authors. Cochrane Database of System
atic Review
s published by John W
iley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
139
9- to 14-year-old females short inter-
val (0, 6 months)
248 Mean 158.9 (140.8 to
179.4)
 vs (0 and 12months)
9- to 14-year-old males short interval
(0, 6 months)
262 Mean 141.7 (125.9 to
159.4)
 
3.16 GMT of HPV
31 (mMU/mL)†
             
9- to 14-year-old males and females
long interval (0, 12 months)
257 Mean 218.0 (190.6 to
249.4)
 
9- to 14-year-old females short inter-
val (0, 6 months)
248 Mean 127.8 (111.4 to
146.5)
 
3.16.1 Nonava-
lent vaccine (0
and 6 months)
vs (0 and 12
months)
9- to 14-year-old males short interval
(0, 6 months)
36 months
after first
dose
1 (Iversen
2016)
261
Mean GMT (95% CI)
Mean 106.9 (93.5 to
122.1)
 
3.17 GMT of HPV
33 (mMU/mL)†
             
9- to 14-year-old males and females
long interval (0, 12 months)
258 Mean 240.4 (213.8 to
270.3)
 
9- to 14-year-old females short inter-
val (0, 6 months)
249 Mean 106.0 (94.1 to
119.5)
 
3.17.1 Nonava-
lent vaccine (0
and 6 months)
vs (0 and 12
months)
9- to 14-year-old males short interval
(0, 6 months)
36 months
after first
dose
1 (Iversen
2016)
261
Mean GMT (95% CI)
Mean 95.7 (85.1 to 107.5)  
3.18 GMT of HPV
45 (mMU/mL)†
             
9- to 14-year-old males and females
long interval (0, 12 months)
257 Mean 43.6 (38.3 to 49.7)  
9- to 14-year-old females short inter-
val (0, 6 months)
250 Mean 30.6 (26.9 to 35.0)  
3.18.1 Nonava-
lent vaccine (0
and 6 months)
vs (0 and 12
months)
9- to 14-year-old males short interval
(0, 6 months)
36 months
after first
dose
1 (Iversen
2016)
263
Mean GMT (95% CI)
Mean 26.8 (23.6 to 30.4)  
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3.19 GMT of HPV
52 (mMU/mL)†
             
9- to 14-year-old males and females
long interval (0, 12 months)
257 Mean 143.2 (128.3 to
159.9)
 
9- to 14-year-old females short inter-
val (0, 6 months)
248 Mean 66.2 (59.1 to 74.0)  
3.19.1 Nonava-
lent vaccine (0
and 6 months)
vs (0 and 12
months)
9- to 14-year-old males short interval
(0, 6 months)
36 months
after first
dose
1 (Iversen
2016)
263
Mean GMT (95% CI)
Mean 63.4 (56.8 to 70.7)  
3.20 GMT of HPV
58 (mMU/mL)†
             
9- to 14-year-old males and females
long interval (0, 12 months)
255 Mean 265.3 (234.8 to
299.8)
 
9- to 14-year-old females short inter-
val (0, 6 months)
246 Mean 125.8 (111.1 to
142.5)
 
3.20.1 Nonava-
lent vaccine (0
and 6 months)
vs (0 and 12
months)
9- to 14-year-old males short interval
(0, 6 months)
36 months
after first
dose
1 (Iversen
2016)
261
Mean GMT (95% CI)
Mean 119.2 (105.6 to
134.5)
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*Results were stratified into subgroups by type of HPV vaccine, gender, schedule, and time point
†Data for nonavalent vaccine at 36 month follow-up (Iversen 2016) was not disaggregated for gender, therefore only mean values (95%
CI) are presented per group.
1Downgraded one level for imprecision: small sample size
Abbreviations
CI: confidence interval
EU: enzyme-linked immunosorbent assay (ELISA) unit
GMT: geometric mean titre
HPV: human papillomavirus
IV: inverse variance
M-H: Mantel-Haenszel
RR: risk ratio
mMU: milli-Merck unit
Appendix 7. Summary of findings: Longer interval versus shorter interval between second and third doses of
quadrivalent HPV vaccine in 18- to 25-year-old males
 
Patient or population: 18- to 25-year-old males
Settings: community health centres in the USA
Intervention: quadrivalent HPV vaccine (3 doses at 0, 2 and 6 months)
Comparison: quadrivalent HPV vaccine (3 doses at 0, 2 and 12 months)
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
longer interval
Risk with
shorter inter-
val
Relative effect
(95% CI)
No of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Invasive anal or penile cancer No studies were identified that reported on this outcome
Penile or anal intraepithelial neopla-
sia
No studies were identified that reported on this outcome
External genital lesions (any geno-
type)
No studies were identified that reported on this outcome
Overall local/injection site adverse
events
Adverse events data not reported separately for each arm
Overall systemic events and general
symptoms
Adverse events data not reported separately for each arm
Serious adverse events at 13-month
follow-up
0 per 1000 0 per 1000 Not estimable,
no events were
reported
220
(1 study)
⊕⊝⊝⊝
VERY LOW1,2,3
Mortality No studies were identified that reported on this outcome
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
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CI: confidence interval; HPV: human papillomavirus
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect
  (Continued)
 
Footnotes
1Downgraded one level for risk of bias: allocation concealment was not reported and the trial was open label.
2Downgraded two levels for serious imprecision: no events reported, the study was not powered to detect a difference in serious adverse
events.
3Downgraded one level for indirectness: This outcome is a composite measure of events which may or may not be clinically relevant, may
or may not be related to the vaccine and may occur outside a biologically plausible time frame relative to vaccine exposure. This outcome
is considered to provide indirect evidence about vaccine safety.
Appendix 8. Three doses of HPV vaccine with shorter interval versus three doses of HPV vaccine with longer interval
in 18- to 25-year-old males - immunogenicity outcomes
 
Outcome Follow-up Studies Partici-
pants
Statistical method Effect estimate (95% CI)
7.1 GMT of
HPV 6
1 month after last
dose
1 (Lin
2014)
170 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 1.31 (0.88 to 1.96)
7.2 GMT of
HPV 11
1 month after last
dose
1 (Lin
2014)
172 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 1.83 (1.18 to 2.84)
7.3 GMT of
HPV 16
1 month after last
dose
1 (Lin
2014)
173 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 1.32 (0.90 to 1.93)
7.4 GMT of
HPV 18
1 month after last
dose
1 (Lin
2014)
174 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 1.35 (0.65 to 2.78)
 
 
Abbreviations
CI: confidence interval
GMT: geometric mean titre
HPV: human papillomavirus
IV: inverse variance
Appendix 9. Quadrivalent HPV vaccine compared to control in 16- to 26-year old males - secondary outcomes
 
Outcome Studies Partici-
pants
Statistical method Effect estimate
(95% CI)
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4.1 Persistent infection of HPV 6, 11, 16, or 18 1 (Giu-
liano
2011)
2790 Rate ratio (IV, random-ef-
fects, 95% CI)
Rate ratio 0.14 (0.08
to 0.26)
4.2 Persistent infection of HPV 6, 11, 16, or 18 1
(NCT01862874
2018)
995 Rate ratio (IV, random-ef-
fects, 95% CI)
Rate ratio 0.14 (0.04
to 0.47)
4.3 Combined persistent HPV type 6-, 11-, 16-, or 18-
related infection or disease (HPV type 6, 11, 16, or
18-related condyloma acuminate, penile, perianal,
or perineal intraepithelial neoplasia or cancer)
1
(NCT01862874
2018)
996 Rate ratio (IV, random-ef-
fects, 95% CI)
Rate ratio 0.13 (0.04
to 0.45)
  (Continued)
 
Abbreviations
CI: confidence interval
HPV: human papillomavirus
IV: inverse variance
Appendix 10. Bivalent HPV vaccine versus control vaccine in 10- to 18-year-old males - immunogenicity outcomes
 
Outcome Follow-up Studies Participants Statistical method Effect estimate (95%
CI)
5.1 Seroconver-
sion to HPV 16
1 month after last
dose
1 (Petaja
2009)
10- to 18-year-old
males
RR (M-H, random-effects,
95% CI)
RR 55.83 (11.43 to
272.67)
5.2 Seroconver-
sion to HPV 18
1 month after last
dose
1 (Petaja
2009)
10- to 18-year-old
males
RR (M-H, random-effects,
95% CI)
RR 34.68 (10.22 to
117.68)
5.3 GMT of HPV
16
1 month after last
dose
1 (Petaja
2009)
10- to 18-year-old
males
SMD (IV, random-effects,
95% CI)
SMD 1.50 (1.21 to 1.79)
5.4 GMT of HPV
18
1 month after last
dose
1 (Petaja
2009)
10- to 18-year-old
males
SMD (IV, random-effects,
95% CI)
SMD 1.36 (1.07 to 1.64)
 
 
Abbreviations
CI: confidence interval
GMT: geometric mean titre
HPV: human papillomavirus
IV: inverse variance
M-H: Mantel-Haenszel
RR: risk ratio
SMD: standard mean difference
Appendix 11. Nonavalent HPV vaccine versus quadrivalent HPV vaccine in females - secondary outcomes
 
Outcome or subgroup* Follow-up Studies Partici-
pants
Statistical method Effect estimate
(95% CI)
 
Comparison of dierent human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females
and males (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
143
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
2.1 GMT of HPV 6
(mMU/mL)
         
2.1.1 9- to 15-year olds 1 month after last
dose
1 (Vesikari
2015)
534 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 1.07
(0.93 to 1.24)
2.1.2 16- to 26-year olds 1 month after last
dose
1 (Joura
2015)
7968 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 1.02
(0.99 to 1.06)
2.2 GMT of HPV 11
(mMU/mL)
         
2.2.1 9- to 15-year olds 1 month after last
dose
1 (Vesikari
2015)
534 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 0.93
(0.80 to 1.08)
2.2.2 16- to 26-year olds 1 month after last
dose
1 (Joura
2015)
7977 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 0.80
(0.77 to 0.83)
2.3 GMT of HPV 16
(mMU/mL)
         
2.3.1 9- to 15-year olds 1 month after last
dose
1 (Vesikari
2015)
546 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 0.98
(0.85 to 1.12)
2.3.2 16- to 26-year olds 1 month after last
dose
1 (Joura
2015)
8094 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 0.99
(0.96 to 1.03)
2.4 GMT of HPV 18
(mMU/mL)
         
2.4.1 9- to 15-year olds 1 month after last
dose
1 (Vesikari
2015)
545 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 1.09
(0.91 to 1.31)
2.4.2 16- to 26-year olds 1 month after last
dose
1 (Joura
2015)
9080 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 1.19
(1.14 to 1.23)
           
2.5 Seroconversion to
HPV 6
1 month after last
dose
2 (Joura
2015;
Vesikari
2015)
8502 RR (M-H, random-effects, 95%
CI)
RR 1.00 (1.00 to 1.00)
2.5.1 9- to 15-year olds 1 month after last
dose
1 (Vesikari
2015)
534 RR (M-H, random-effects, 95%
CI)
RR 1.00 (0.99 to 1.01)
2.5.2 16- to 26-year olds 1 month after last
dose
1 (Joura
2015)
7968 RR (M-H, random-effects, 95%
CI)
RR 1.00 (1.00 to 1.00)
2.6 Seroconversion to
HPV 11
1 month after last
dose
2 (Joura
2015;
Vesikari
2015)
8511 RR (M-H, random-effects, 95%
CI)
RR 1.00 (1.00 to 1.00)
2.6.1 9- to 15-year olds 1 month after last
dose
1 (Vesikari
2015)
534 RR (M-H, random-effects, 95%
CI)
RR 1.00 (0.99 to 1.01)
  (Continued)
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2.6.2 16- to 26-year olds 1 month after last
dose
1 (Joura
2015)
7977 RR (M-H, random-effects, 95%
CI)
RR 1.00 (1.00 to 1.00)
2.7 Seroconversion to
HPV 16
1 month after last
dose
2 (Joura
2015;
Vesikari
2015)
8640 RR (M-H, random-effects, 95%
CI)
RR 1.00 (1.00 to 1.00)
2.7.1 9- to 15-year olds 1 month after last
dose
1 (Vesikari
2015)
546 RR (M-H, random-effects, 95%
CI)
RR 1.00 (0.99 to 1.01)
2.7.2 16- to 26-year olds 1 month after last
dose
1 (Joura
2015)
8094 RR (M-H, random-effects, 95%
CI)
RR 1.00 (1.00 to 1.00)
2.8 Seroconversion to
HPV 18
1 month after last
dose
2 (Vesikari
2015; Joura
2015)
9625 RR (M-H, random-effects, 95%
CI)
RR 1.00 (1.00 to 1.00)
2.8.1 9- to 15-year olds 1 month after last
dose
1 (Vesikari
2015)
545 RR (M-H, random-effects, 95%
CI)
RR 1.00 (0.99 to 1.01)
2.8.2 16- to 26-year olds 1 month after last
dose
1 (Joura
2015)
9080 RR (M-H, random-effects, 95%
CI)
RR 1.00 (1.00 to 1.00)
           
2.9 GMT of HPV 6
(mMU/mL)
         
2.9.1 16- to 26-year olds 42 months after
first dose
1 (Joura
2015)
1367 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 1.02
(0.92 to 1.13)
2.10 GMT of HPV 11
(mMU/mL)
         
2.10.1 16- to 26-year
olds
42 months after
first dose
1 (Joura
2015)
1367 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 0.82
(0.74 to 0.90)
2.11 GMT of HPV 16
(mMU/mL)
         
2.11.1 16- to 26-year
olds
42 months after
first dose
1 (Joura
2015)
1399 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 0.96
(0.85 to 1.07)
2.12 GMT of HPV 18
(mMU/mL)
         
2.12.1 16- to 26-year
olds
42 months after
first dose
1 (Joura
2015)
1576 Ratio of GMTs (IV, random-ef-
fects, 95% CI)
Ratio of GMTs 1.17
(1.03 to 1.33)
2.13 Seropositivity to
HPV 6
         
2.13.1 16- to 26-year
olds
24 months after
first dose
1 (Joura
2015)
1404 RR (M-H, random-effects, 95%
CI)
RR 1.01 (0.99 to 1.02)
  (Continued)
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2.14 Seropositivity to
HPV 11
         
2.14.1 16- to 26-year
olds
24 months after
first dose
1 (Joura
2015)
1497 RR (M-H, random-effects, 95%
CI)
RR 1.00 (0.99 to 1.01)
2.15 Seropositivity to
HPV 16
         
2.15.1 16- to 26-year
olds
24 months after
first dose
1 (Joura
2015)
1536 RR (M-H, random-effects, 95%
CI)
RR 1.01 (1.00 to 1.01)
2.16 Seropositivity to
HPV 18
         
2.16.1 16- to 26-year
olds
24 months after
first dose
1 (Joura
2015)
1732 RR (M-H, random-effects, 95%
CI)
RR 1.07 (1.02 to 1.11)
           
2.17 6 months' persis-
tent infection of HPV 6,
11, 16, or 18
median 4 years 1 (Joura
2015)
11,642 RR (M-H, random-effects, 95%
CI)
RR 0.72 (0.53 to 0.98)
2.18 6 months' persis-
tent infection of HPV 31,
33, 45, 52, or 58
median 4 years 1 (Joura
2015)
11,896 RR (M-H, random-effects, 95%
CI)
RR 0.04 (0.03 to 0.06)
2.19 12 months' persis-
tent infection of HPV 6,
11, 16, or 18
median 4 years 1 (Joura
2015)
11,642 RR (M-H, random-effects, 95%
CI)
RR 0.72 (0.43 to 1.20)
2.20 12 months' persis-
tent infection of HPV 31,
33, 45, 52, or 58
median 4 years 1 (Joura
2015)
11,896 RR (M-H, random-effects, 95%
CI)
RR 0.04 (0.02 to 0.05)
  (Continued)
 
*Results were stratified into subgroups by age group
Abbreviations
CI: confidence interval
GMT: geometric mean titre
HPV: human papillomavirus
IV: inverse variance
M-H: Mantel-Haenszel
RR: risk ratio
mMU: milli-Merck unit
Appendix 12. Nonavalent HPV vaccine versus quadrivalent HPV vaccine in males - secondary outcomes
 
Outcome Follow-up Studies Partici-
pants
Statistical method Effect estimate (95% CI)
6.1 GMT of HPV 6 1 month after last
dose
1 (van Damme
2016)
454 Ratio of GMTs (IV, ran-
dom-effects, 95% CI)
Ratio of GMTs 1.23 (1.03 to
1.45)
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6.2 GMT of HPV 11 1 month after last
dose
1 (van Damme
2016)
454 Ratio of GMTs (IV, ran-
dom-effects, 95% CI)
Ratio of GMTs 0.89 (0.75 to
1.04)
6.3 GMT of HPV 16 1 month after last
dose
1 (van Damme
2016)
471 Ratio of GMTs (IV, ran-
dom-effects, 95% CI)
Ratio of GMTs 1.04 (0.88 to
1.21)
6.4 GMT of HPV 18 1 month after last
dose
1 (van Damme
2016)
470 Ratio of GMTs (IV, ran-
dom-effects, 95% CI)
Ratio of GMTs 1.12 (0.91 to
1.37)
6.5 GMT of HPV 31 1 month after last
dose
1 (van Damme
2016)
471 Ratio of GMTs (IV, ran-
dom-effects, 95% CI)
Ratio of GMTs 52.96 (42.69
to 65.71)
6.6 GMT of HPV 33 1 month after last
dose
1 (van Damme
2016)
472 Ratio of GMTs (IV, ran-
dom-effects, 95% CI)
Ratio of GMTs 135.44
(117.18 to 156.54)
6.7 GMT of HPV 45 1 month after last
dose
1 (van Damme
2016)
468 Ratio of GMTs (IV, ran-
dom-effects, 95% CI)
Ratio of GMTs 105.16
(887.87 to 125.85)
6.8 GMT of HPV 52 1 month after last
dose
1 (van Damme
2016)
471 Ratio of GMTs (IV, ran-
dom-effects, 95% CI)
Ratio of GMTs 226.68
(194.71 to 263.90)
6.9 GMT of HPV 58 1 month after last
dose
1 (van Damme
2016)
465 Ratio of GMTs (IV, ran-
dom-effects, 95% CI)
Ratio of GMTs 121.23
(101.71 to 144.49)
           
6.10 Seroconver-
sion to HPV 6
1 month after last
dose
1 (van Damme
2016)
454 RR (M-H, random-effects,
95% CI)
RR 1.00 (0.97 to 1.02)
6.11 Seroconver-
sion to HPV 11
1 month after last
dose
1 (van Damme
2016)
454 RR (M-H, random-effects,
95% CI)
RR 1.00 (0.99 to 1.01)
6.12 Seroconver-
sion to HPV 16
1 month after last
dose
1 (van Damme
2016)
471 RR (M-H, random-effects,
95% CI)
RR 1.00 (0.99 to 1.01)
6.13 Seroconver-
sion to HPV 18
1 month after last
dose
1 (van Damme
2016)
470 RR (M-H, random-effects,
95% CI)
RR 1.00 (0.99 to 1.01)
6.14 Seroconver-
sion to HPV 31
1 month after last
dose
1 (van Damme
2016)
471 RR (M-H, random-effects,
95% CI)
RR 1.62 (1.47 to 1.79)
6.15 Seroconver-
sion to HPV 33
1 month after last
dose
1 (van Damme
2016)
472 RR (M-H, random-effects,
95% CI)
RR 5.84 (4.41 to 7.73)
6.16 Seroconver-
sion to HPV 45
1 month after last
dose
1 (van Damme
2016)
468 RR (M-H, random-effects,
95% CI)
RR 10.51 (7.09 to 15.57)
6.17 Seroconver-
sion to HPV 52
1 month after last
dose
1 (van Damme
2016)
471 RR (M-H, random-effects,
95% CI)
RR 36.38 (17.05 to 77.66)
6.18 Seroconver-
sion to HPV 58
1 month after last
dose
1 (van Damme
2016)
465 RR (M-H, random-effects,
95% CI)
RR 2.76 (2.33 to 3.28)
  (Continued)
 
Abbreviations
CI: confidence interval
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GMT: geometric mean titre
HPV: human papillomavirus
IV: inverse variance
M-H: Mantel-Haenszel
RR: risk ratio
Appendix 13. HPV vaccines for people living with HIV - secondary outcomes
 
Outcome Follow-up Studies Participants Statistical method Effect estimate
(95% CI)
Certainty
of the ev-
idence
(GRADE)
1 month after
last dose
1 (Levin
2010)
quadriva-
lent
114 children with HIV (7
to 12 years old)
Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 123.8
(89.0 to 172.1)
8.1 GMT of
HPV 6
24 months after
first dose
1 (Levin
2010)
116 children with HIV (7
to 12 years old)
Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 50.44
(34.21 to 74.38)
⊕⊕⊝⊝
LOW1,2
1 month after
last dose
1 (Levin
2010)
117 children with HIV (7
to 12 years old)
Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 330.4
(261.6 to 417.2)
8.2 GMT of
HPV 11
24 months after
first dose
1 (Levin
2010)
116 children with HIV (7
to 12 years old)
Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 68.75
(49.33 to 95.81)
⊕⊕⊝⊝
LOW1,2
1 month after
last dose
1 (Levin
2010)
117 children with HIV (7
to 12 years old)
Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 935.8
(724.5 to
1208.7)
8.3 GMT of
HPV 16
24 months after
first dose
1 (Levin
2010)
116 children with HIV (7
to 12 years old)
Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 189.44
(129.29 to 277.59)
⊕⊕⊝⊝
LOW1,2
1 month after
last dose
1 (Levin
2010)
117 children with HIV (7
to 12 years old)
Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 189.2
(132.8 to 269.7)
8.4 GMT of
HPV 18
24 months after
first dose
1 (Levin
2010)
116 children with HIV (7
to 12 years old)
Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 29.57
(18.08 to 48.37)
⊕⊕⊝⊝
LOW1,2
8.5 Sero-
conversion
to HPV 6
1 month after
last dose
1 (Levin
2010)
114 children with HIV (7
to 12 years old)
RR (M-H, ran-
dom-effects, 95%
CI)
RR 55.7 (3.6 to 868.4) ⊕⊕⊝⊝
LOW1,2
8.6 Sero-
conversion
to HPV 11
1 month after
last dose
1 (Levin
2010)
117 children with HIV (7
to 12 years old)
RR (M-H, ran-
dom-effects, 95%
CI)
RR 55.7 (3.6 to 868.6) ⊕⊕⊝⊝
LOW1,2
8.7 Sero-
conversion
to HPV 16
1 month after
last dose
1 (Levin
2010)
117 children with HIV (7
to 12 years old)
RR (M-H, ran-
dom-effects, 95%
CI)
RR 18.6 (3.9 to 88.1) ⊕⊕⊝⊝
LOW1,2
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8.8 Sero-
conversion
to HPV 18
1 month after
last dose
1 (Levin
2010)
117 children with HIV (7
to 12 years old)
RR (M-H, ran-
dom-effects, 95%
CI)
RR 53.9 (3.5 to 840.0) ⊕⊕⊝⊝
LOW1,2
8.9
Seroposi-
tivity, HPV
6, 11, 16, 18
1 month after
last dose
1 (Hidal-
go-Teno-
rio 2017)
128 HIV-infected MSM (≥
18 years old)
RR (M-H, ran-
dom-effects, 95%
CI)
RR 2.47 (1.66 to 3.68) ⊕⊕⊕⊝
MODER-
ATE1
1 month after
last dose
1 (ToM
2014)
40 HIV-infected males
and females
Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 0.79
(0.25 to 2.52)
⊕⊕⊝⊝
LOW3
8.10 GMT of
HPV 16
6 months after
last dose
1 (ToM
2014)
40 HIV-infected males
and females
Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 0.67
(0.21 to 2.08)
⊕⊕⊝⊝
LOW3
1 month after
last dose
1 (ToM
2014)
39 HIV-infected males
and females
Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 0.13
(0.04 to 0.41)
⊕⊕⊕⊝
MODER-
ATE1
8.11 GMT of
HPV 18
six months af-
ter last dose
1 (ToM
2014)
39 HIV-infected males
and females
Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 0.52
(0.16 to 1.76)
⊕⊕⊝⊝
LOW3
8.12
Seroposi-
tivity at 12
months,
HPV 16
6 months after
last dose
1 (ToM
2014)
91 HIV-infected males
and females
RR (M-H, ran-
dom-effects, 95%
CI)
RR 0.96 (0.89 to 1.03) ⊕⊕⊕⊝
MODER-
ATE1
8.13
Seroposi-
tivity at 12
months,
HPV 18
6 months after
last dose
1 (ToM
2014)
91 HIV-infected males
and females
RR (M-H, ran-
dom-effects, 95%
CI)
RR 0.76 (0.63 to 0.90) ⊕⊕⊕⊝
MODER-
ATE1
8.14 Persis-
tent anal
infection
(HPV 6, 11,
16, 18)
1 month after
last dose
1 (Wilkin
2018)
575 HIV-positive males
and females
RR (M-H, ran-
dom-effects, 95%
CI)
RR 0.81 (0.41 to 1.62) ⊕⊕⊕⊝
MODER-
ATE4
1 month after
last dose
1 (Denny
2013)
82 HIV-positive females Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 131.73
(80.57 to 215.39)
8.16 GMT of
HPV 16
12 months after
first dose
1 (Denny
2013)
78 HIV-positive females Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 36.14
(21.42 to 60.97)
⊕⊕⊕⊝
MODER-
ATE1
1 month after
last dose
1 (Denny
2013)
83 HIV-positive females Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 134.63
(79.88 to 226.89)
8.17 GMT of
HPV 18
12 months after
first dose
1 (Denny
2013)
79 HIV-positive females Ratio of GMTs (IV,
random-effects,
95% CI)
Ratio of GMTs 26.39
(15.32 to 45.48)
⊕⊕⊕⊝
MODER-
ATE1
  (Continued)
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8.18 Sero-
conversion
to HPV 16
12 months after
first dose
1 (Denny
2013)
79 HIV-positive females RR (M-H, ran-
dom-effects, 95%
CI)
RR 1.29 (1.07 to 1.56) ⊕⊕⊕⊝
MODER-
ATE1
8.19 Sero-
conversion
to HPV 18
12 months after
first dose
1 (Denny
2013)
79 HIV-positive females RR (M-H, ran-
dom-effects, 95%
CI)
RR 1.53 (1.21 to 1.95) ⊕⊕⊕⊝
MODER-
ATE1
  (Continued)
 
*Results were stratified into subgroups by type of HPV vaccine and gender
1Downgraded one level for imprecision: small sample size.
2Downgraded one level for risk of bias: details about how randomisation sequence was generated or how blinding was achieved were
not reported.
3Downgraded two levels for imprecision: small sample size and very wide 95% confidence interval that incorporates a potential large
beneficial effect and a potential large harmful effect.
4Downgraded one level for imprecision: wide 95% confidence interval that incorporates a potential beneficial effect and a potential harm-
ful effect.
Abbreviations
CI: confidence interval
GMT: geometric mean titre
HPV: human papillomavirus
IV: inverse variance
M-H: Mantel-Haenszel
RR: risk ratio
Appendix 14. Sensitivity analysis using Peto odds ratio for outcomes with very rare events
 
Analysis number, outcome (subgroup) Studies Partici-
pants
Odds ratio (M-H, ran-
dom-effects model,
95% CI)
Peto odds ratio
(Peto, fixed-effect
model, 95% CI)
1.5.3 Deaths (nonavalent vaccine) 1 602 0.33 (0.01 to 8.19) 0.14 (0.00 to 6.82)
4.12 Serious adverse events (overall) 2 5162 0.69 (0.29 to 1.66) 0.67 (0.28 to 1.62)
4.13 Deaths 2 5173 0.30 (0.09 to 1.01) 0.32 (0.11 to 0.91)
6.2 High-grade cervical disease related to HPV 6 to 11,
16, or 18
1 11,656 1.00 (0.06 to 16.01) 1.00 (0.06 to 16.01)
6.3 High-grade vulval and vaginal disease related to
HPV 6, 11, 16, or 18
1 11,769 0.14 (0.01 to 2.77) 0.14 (0.01 to 1.30)
6.4 High-grade cervical disease related to HPV 31, 33,
45, 52, or 58
1 11,892 0.03 (0.00 to 0.21) 0.15 (0.08 to 0.29)
6.5 High-grade vulval and vaginal disease related to
HPV 31, 33, 45, 52, or 58
1 12,021 0.14 (0.01 to 2.77) 0.14 (0.01 to 1.30)
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6.7 Cervical intraepithelial neoplasia 2 related to HPV
6, 11, 16, or 18
1 11,656 3.00 (0.12 to 73.77) 7.40 (0.15 to 373.90)
6.8 Cervical intraepithelial neoplasia 2 related to HPV
31, 33, 45, 52, or 58
1 11,892 0.03 (0.00 to 0.23) 0.15 (0.08 to 0.30)
6.9 Cervical intraepithelial neoplasia 3, adenocarci-
noma in situ, and cervical cancer related to HPV 6, 11,
16, or 18
1 11,656 0.33 (0.01 to 8.19) 0.14 (0.00 to 6.83)
6.10 Cervical intraepithelial neoplasia 3, adenocarci-
noma in situ, and cervical cancer related to HPV 31,
33, 45, 52, or 58
1 11,892 0.07 (0.00 to 1.16) 0.14 (0.03 to 0.59)
6.17.2 Deaths (16- to 26- year olds) 1 14,149 1.00 (0.29 to 3.46) 1.00 (0.29 to 3.46)
8.2 Overall systemic events and general symptoms 1 126 0.62 (0.05 to 7.05) 0.59 (0.04 to 8.54)
  (Continued)
 
Abbreviations
CI: confidence interval
HPV: human papillomavirus
M-H: Mantel-Haenszel
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